PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 32978975-3 2021 We found that exposure to low oxygen concentration differentially regulates transporter expression in BeWo cells, including down-regulation of ENT1, OATP4A1, OCTN2, BCRP, MRP2/3/5, and up-regulation of CNT1, OAT4, OATP2B1, SERT, SOAT, and MRP1. Oxygen 30-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-147 33426680-1 2021 Equilibrative nucleoside transporters (ENTs) 1 and 2 reportedly accept fluorouracil as a substrate. Fluorouracil 71-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-52 33426680-2 2021 Here, we evaluated ENT1/2 expression at the mRNA, protein and functional levels in a panel of four triple-negative breast cancer (TNBC) cell lines, BT-549, Hs578T, MDA-MB-231, and MDA-MB-435, and we examined the relationship of the observed profiles to fluorouracil sensitivity. Fluorouracil 253-265 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-25 33426680-3 2021 Nitrobenzylthioinosine (NBMPR) at 0.1 muM inhibits only ENT1, while dipyridamole at 10 muM or NBMPR at 100 muM inhibits both ENT1 and ENT2. 4-nitrobenzylthioinosine 0-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 33426680-3 2021 Nitrobenzylthioinosine (NBMPR) at 0.1 muM inhibits only ENT1, while dipyridamole at 10 muM or NBMPR at 100 muM inhibits both ENT1 and ENT2. 4-nitrobenzylthioinosine 24-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 33426680-3 2021 Nitrobenzylthioinosine (NBMPR) at 0.1 muM inhibits only ENT1, while dipyridamole at 10 muM or NBMPR at 100 muM inhibits both ENT1 and ENT2. Dipyridamole 68-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 33426680-3 2021 Nitrobenzylthioinosine (NBMPR) at 0.1 muM inhibits only ENT1, while dipyridamole at 10 muM or NBMPR at 100 muM inhibits both ENT1 and ENT2. 4-nitrobenzylthioinosine 94-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 33426680-4 2021 We found that uptake of [3 H]uridine, a typical substrate of ENT1 and ENT2, was decreased to approximately 40% by 0.1 muM NBMPR. Uridine 29-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-65 33426680-4 2021 We found that uptake of [3 H]uridine, a typical substrate of ENT1 and ENT2, was decreased to approximately 40% by 0.1 muM NBMPR. 4-nitrobenzylthioinosine 122-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-65 33980604-4 2021 Substrate pharmacophores for ENT1 and ENT2 are distinct, with partial overlap of hydrogen bond donors, while the inhibitor pharmacophores predominantly feature hydrogen bond acceptors. Hydrogen 81-89 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 33980604-5 2021 Mizoribine and ribavirin mapped to the ENT1 substrate pharmacophore and proved to be substrates of the ENTs. mizoribine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-43 33980604-5 2021 Mizoribine and ribavirin mapped to the ENT1 substrate pharmacophore and proved to be substrates of the ENTs. Ribavirin 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-43 33980604-6 2021 The presence of the ENT-specific inhibitor, NBMPR, decreased mizoribine accumulation in ENT1 and ENT2 cells (ENT1, ~70% decrease, p = 0.0046; ENT2, ~50% decrease p = 0.0012). 4-nitrobenzylthioinosine 44-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 33980604-6 2021 The presence of the ENT-specific inhibitor, NBMPR, decreased mizoribine accumulation in ENT1 and ENT2 cells (ENT1, ~70% decrease, p = 0.0046; ENT2, ~50% decrease p = 0.0012). 4-nitrobenzylthioinosine 44-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-113 33980604-6 2021 The presence of the ENT-specific inhibitor, NBMPR, decreased mizoribine accumulation in ENT1 and ENT2 cells (ENT1, ~70% decrease, p = 0.0046; ENT2, ~50% decrease p = 0.0012). mizoribine 61-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 33980604-7 2021 NBMPR also decreased ribavirin accumulation in ENT1 and ENT2 cells (ENT1: ~50% decrease p = 0.0498; ENT2: ~30% decrease p = 0.0125). 4-nitrobenzylthioinosine 0-5 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-51 33980604-7 2021 NBMPR also decreased ribavirin accumulation in ENT1 and ENT2 cells (ENT1: ~50% decrease p = 0.0498; ENT2: ~30% decrease p = 0.0125). 4-nitrobenzylthioinosine 0-5 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 33980604-7 2021 NBMPR also decreased ribavirin accumulation in ENT1 and ENT2 cells (ENT1: ~50% decrease p = 0.0498; ENT2: ~30% decrease p = 0.0125). Ribavirin 21-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-51 33980604-8 2021 Darunavir mapped to the ENT1 inhibitor pharmacophore and NBMPR did not significantly influence darunavir accumulation in either ENT1 or ENT2 cells (ENT1: p = 0.28; ENT2: p = 0.53), indicating that darunavir"s interaction with the ENTs is limited to inhibition. Darunavir 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 33262250-9 2021 Clofarabine and cladribine were ENT1 and ENT2 substrates, while nevirapine and lexibulin were ENT1 and ENT2 non-transported inhibitors. Nevirapine 64-74 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-98 33262250-7 2021 Twenty-one compounds inhibited uridine uptake and abacavir, nevirapine, ticagrelor, and uridine triacetate had different IC50 values for ENT1 and ENT2. abacavir 50-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-141 33298588-0 2021 EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1. gemcitabine 12-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-126 33298588-2 2021 Here, we demonstrate a loss of gemcitabine chemosensitivity facilitated by human equilibrative nucleoside transporter 1 (ENT1) during EMT in pancreatic cancer and identify that cadherin switching from the epithelial (E) to neuronal (N) type, a hallmark of EMT, contributes to this loss. gemcitabine 31-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-119 33298588-2 2021 Here, we demonstrate a loss of gemcitabine chemosensitivity facilitated by human equilibrative nucleoside transporter 1 (ENT1) during EMT in pancreatic cancer and identify that cadherin switching from the epithelial (E) to neuronal (N) type, a hallmark of EMT, contributes to this loss. gemcitabine 31-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 121-125 33298588-8 2021 Together, our findings identify ENT1 as an inadvertent target of EMT signaling mediated by cadherin switching and provide a mechanism by which mesenchymal pancreatic cancer cells evade gemcitabine therapy during EMT. gemcitabine 185-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-36 33262250-7 2021 Twenty-one compounds inhibited uridine uptake and abacavir, nevirapine, ticagrelor, and uridine triacetate had different IC50 values for ENT1 and ENT2. Nevirapine 60-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-141 33287390-7 2020 In cancer cells, hENT1 inhibition significantly downregulated gemcitabine uptake and cytotoxicity, whereas DCK knockdown reduced cytotoxicity. gemcitabine 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-22 33262250-7 2021 Twenty-one compounds inhibited uridine uptake and abacavir, nevirapine, ticagrelor, and uridine triacetate had different IC50 values for ENT1 and ENT2. Ticagrelor 72-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-141 33262250-7 2021 Twenty-one compounds inhibited uridine uptake and abacavir, nevirapine, ticagrelor, and uridine triacetate had different IC50 values for ENT1 and ENT2. Uridine 88-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-141 33262250-7 2021 Twenty-one compounds inhibited uridine uptake and abacavir, nevirapine, ticagrelor, and uridine triacetate had different IC50 values for ENT1 and ENT2. 2',3',5'-tri-O-acetyladenosine 96-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-141 33262250-9 2021 Clofarabine and cladribine were ENT1 and ENT2 substrates, while nevirapine and lexibulin were ENT1 and ENT2 non-transported inhibitors. Clofarabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-36 33262250-9 2021 Clofarabine and cladribine were ENT1 and ENT2 substrates, while nevirapine and lexibulin were ENT1 and ENT2 non-transported inhibitors. Cladribine 16-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-36 33052430-3 2021 Extracellular adenosine level is controlled through the equilibrative nucleoside transporter 1 (ENT-1) and the enzyme adenosine deaminase (ADA). Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-94 33052430-3 2021 Extracellular adenosine level is controlled through the equilibrative nucleoside transporter 1 (ENT-1) and the enzyme adenosine deaminase (ADA). Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-101 33052430-4 2021 The aim of this study was to determine the control of adenosine blood level (ABL) via ENT-1 and ADA during apnoea-induced hypoxia in elite freedivers was similar to high-altitude adaptation. Adenosine 54-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 32513905-3 2020 Based on increased expression of thymidylate synthase (TYMS), thymidine kinase-1 (TK-1) and SLC29A1 (Equilibrative nucleoside transporter 1, ENT1) in HCC compared with liver tissue, we conducted a proof of concept study evaluating the efficacy of 18F-fluorothymidine (18F-FLT)-PET to assess response to TACE. 18f-fluorothymidine 247-266 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-145 32513905-3 2020 Based on increased expression of thymidylate synthase (TYMS), thymidine kinase-1 (TK-1) and SLC29A1 (Equilibrative nucleoside transporter 1, ENT1) in HCC compared with liver tissue, we conducted a proof of concept study evaluating the efficacy of 18F-fluorothymidine (18F-FLT)-PET to assess response to TACE. Fluorothymidine F-18 268-275 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-145 32513905-3 2020 Based on increased expression of thymidylate synthase (TYMS), thymidine kinase-1 (TK-1) and SLC29A1 (Equilibrative nucleoside transporter 1, ENT1) in HCC compared with liver tissue, we conducted a proof of concept study evaluating the efficacy of 18F-fluorothymidine (18F-FLT)-PET to assess response to TACE. Chlorotrianisene 303-307 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-145 33324223-3 2020 Adenosine and the key adenosine regulators adenosine deaminase (ADA), adenosine kinase (ADK), and equilibrative nucleoside transporter 1 may play a role in COVID-19 pathogenesis. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 33324223-3 2020 Adenosine and the key adenosine regulators adenosine deaminase (ADA), adenosine kinase (ADK), and equilibrative nucleoside transporter 1 may play a role in COVID-19 pathogenesis. Adenosine 22-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 33324223-5 2020 Depending on the stage of exposure to and infection by SARS-CoV-2, enhancing adenosine levels by targeting key adenosine regulators such as ADA, ADK and equilibrative nucleoside transporter 1 might find therapeutic use against COVID-19 and warrants further investigation. Adenosine 77-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-191 32671914-0 2020 Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma. gemcitabine 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Adenosine 24-33 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 33105674-8 2020 ENT1-mediated uptake of [3H] uridine was linear over 10 min and inhibited by NBMPR with an IC50 value of 1.35 +- 0.37 nM. [3h] uridine 24-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 33105674-8 2020 ENT1-mediated uptake of [3H] uridine was linear over 10 min and inhibited by NBMPR with an IC50 value of 1.35 +- 0.37 nM. 4-nitrobenzylthioinosine 77-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 32671914-2 2020 Investigation of human equilibrative nucleoside transporter-1 (HENT-1) and deoxycytidine kinase (DCK), genes involved in gemcitabine uptake and metabolism, can be beneficial in the selection of potential cancer patients who could be responding to the treatment. gemcitabine 121-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-61 33142664-1 2020 ": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer. gemcitabine 171-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-71 33142664-5 2020 As a hydrophilic nucleoside analogue, gemcitabine requires nucleoside transporters to permeate the plasma membrane, and a major role in the uptake of this drug is played by human equilibrative nucleoside transporter 1 (hENT-1). Nucleosides 17-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-217 33142664-5 2020 As a hydrophilic nucleoside analogue, gemcitabine requires nucleoside transporters to permeate the plasma membrane, and a major role in the uptake of this drug is played by human equilibrative nucleoside transporter 1 (hENT-1). gemcitabine 38-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-217 33142664-5 2020 As a hydrophilic nucleoside analogue, gemcitabine requires nucleoside transporters to permeate the plasma membrane, and a major role in the uptake of this drug is played by human equilibrative nucleoside transporter 1 (hENT-1). gemcitabine 38-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 219-225 33142664-6 2020 Several studies have proposed hENT-1 as a biomarker for gemcitabine efficacy in PDAC. gemcitabine 56-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-36 33142664-8 2020 High hENT-1 levels observed with this antibody were associated with prolonged disease-free status and overall-survival in patients receiving gemcitabine adjuvant chemotherapy. gemcitabine 141-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-11 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. 4-nitrobenzylthioinosine 162-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Dipyridamole 170-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 32858046-6 2020 The tonic activation of adenosine A2 receptors was dependent on the release of intracellular adenosine through equilibrative nucleoside transporters (ENT1/ENT2): NBTI or dipyridamole reduced (~25%) whereas, when ENTs were blocked, adenosine A2 receptor antagonists failed to reduce and A2 agonists increase parasitic burden. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-154 32858046-7 2020 Effects of adenosine A2 receptors antagonists and ENT1/2 inhibitor were prevented by L-NAME, indicating that nitric oxide production inhibition prevents adenosine from increasing parasitic burden. NG-Nitroarginine Methyl Ester 85-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-56 32858046-7 2020 Effects of adenosine A2 receptors antagonists and ENT1/2 inhibitor were prevented by L-NAME, indicating that nitric oxide production inhibition prevents adenosine from increasing parasitic burden. Nitric Oxide 109-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-56 32858046-7 2020 Effects of adenosine A2 receptors antagonists and ENT1/2 inhibitor were prevented by L-NAME, indicating that nitric oxide production inhibition prevents adenosine from increasing parasitic burden. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-56 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Hydroxychloroquine 80-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-191 32730777-3 2020 Here, proteomic investigation of a differentiated, HepaRG, and proliferating, HepG2 cell model was utilised to confirm the presence of the hENT1 transporter, thymidine kinase-1 and -2 (TK1, TK2) and thymidylate kinase, all essential in order to reproduce the cellular activation and disposition of fialuridine in the clinic. fialuridine 298-309 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 139-144 32878779-0 2020 New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. imidazo(2,1-b)(1,3,4)thiadiazole 4-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 169-207 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). lopinavir-ritonavir drug combination 220-239 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-191 32816368-7 2020 Mechanistic assessments revealed that overcoming GEM resistance by coadministration with BMJ was possibly due to modulation of GEM transport/metabolism pathway molecules (ribonucleotide reductase regulatory subunit M1, human equilibrative nucleoside transporter 1, and deoxycytidine kinase). gemcitabine 49-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 225-289 32878779-0 2020 New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. gemcitabine 125-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 169-207 32878779-6 2020 Interestingly, these compounds potentiated the antiproliferative activity of gemcitabine, and these results might be explained by the increase in the mRNA expression of the key gemcitabine transporter human equilibrative nucleoside transporter-1 (hENT-1). gemcitabine 77-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 207-245 32878779-6 2020 Interestingly, these compounds potentiated the antiproliferative activity of gemcitabine, and these results might be explained by the increase in the mRNA expression of the key gemcitabine transporter human equilibrative nucleoside transporter-1 (hENT-1). gemcitabine 77-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 247-253 32824670-0 2020 Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells. Adenosine 103-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 32824670-0 2020 Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells. Adenosine 103-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-54 32824670-10 2020 In conclusion, the lower expression and activity of the ENT1 transporter in mesenchymal GSCs contributes to the high level of extracellular adenosine that these GSCs present. Adenosine 140-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Chloroquine 87-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-191 32864162-6 2020 We found several drug-gene variant pairs that may alter the pharmacokinetics of hydroxychloroquine/chloroquine (CYP2C8, CYP2D6, SLCO1A2, and SLCO1B1); azithromycin (ABCB1); ribavirin (SLC29A1, SLC28A2, and SLC28A3); and lopinavir/ritonavir (SLCO1B1, ABCC2, CYP3A). Ribavirin 173-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-191 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 119-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-47 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 119-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 119-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-61 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 119-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-193 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Tritium 129-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Tritium 129-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-61 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Tritium 129-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-193 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 132-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-47 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 132-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 132-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-61 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Adenine 132-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-193 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Dipyridamole 223-235 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. Dipyridamole 223-235 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-61 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. 4-nitrobenzylthioinosine 239-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 32339528-6 2020 Although equilibrative nucleoside transporter 1 (ENT1/SLC29A1) and ENT2/SLC29A2 are also known to be able to transport adenine, [3H]adenine uptake in HepG2 cells was not inhibited by the ENT1/2-specific inhibitor of either dipyridamole or nitrobenzylthioinosine. 4-nitrobenzylthioinosine 239-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-61 32635975-6 2020 Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. Nucleosides 41-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. nucleobases 57-68 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. Nucleosides 41-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. nucleobase 57-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-9 2020 Of these, hENT1 and hENT2 transport both nucleosides and nucleobases into and out of cells, but their relative contributions to nucleoside and nucleobase homeostasis and, in particular, to adenosine signaling via purinoreceptors, are not known. Adenosine 189-198 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 32126230-11 2020 Results demonstrated that ENT1 was more important than ENT2 or CNT3 in determining plasma adenosine concentrations, indicated modest roles of ENT1 in the homeostasis of other nucleosides, and suggested that none of the transporters is a major participant in handling of nucleobases. Adenosine 90-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 32393653-4 2020 Inhibition of [3H]uridine uptake by NBMPR was biphasic, with IC50 values of 11.3 nM for ENT1 and 9.6 muM for ENT2. Tritium 15-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 32393653-4 2020 Inhibition of [3H]uridine uptake by NBMPR was biphasic, with IC50 values of 11.3 nM for ENT1 and 9.6 muM for ENT2. Uridine 18-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 32393653-4 2020 Inhibition of [3H]uridine uptake by NBMPR was biphasic, with IC50 values of 11.3 nM for ENT1 and 9.6 muM for ENT2. 4-nitrobenzylthioinosine 36-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 32393653-6 2020 The kinetics of ENT1- and ENT2-mediated [3H]uridine uptake revealed no difference in Jmax (16.53 and 30.40 pmol cm-2 min-1) and an eight-fold difference in Kt (13.6 and 108.9 muM). [3h]uridine 40-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-20 32393653-7 2020 The resulting five-fold difference in intrinsic clearance (Jmax/Kt) for ENT1- and ENT2 transport accounted for observed inhibition of [[3H]uridine uptake by 100 nM NBMPR. Tritium 136-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 32393653-7 2020 The resulting five-fold difference in intrinsic clearance (Jmax/Kt) for ENT1- and ENT2 transport accounted for observed inhibition of [[3H]uridine uptake by 100 nM NBMPR. Uridine 139-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 32393653-7 2020 The resulting five-fold difference in intrinsic clearance (Jmax/Kt) for ENT1- and ENT2 transport accounted for observed inhibition of [[3H]uridine uptake by 100 nM NBMPR. 4-nitrobenzylthioinosine 164-169 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 32313990-10 2020 This transporter may be ENT1 because NBMPR counteracted guanosine cytotoxicity in HuT-78 cells with nanomolar efficacy (IC50 of 25-30 nM). 4-nitrobenzylthioinosine 37-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 32313990-10 2020 This transporter may be ENT1 because NBMPR counteracted guanosine cytotoxicity in HuT-78 cells with nanomolar efficacy (IC50 of 25-30 nM). Guanosine 56-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 32635975-6 2020 Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 32635975-6 2020 Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. 4-nitrobenzylthioinosine 152-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-136 32635975-6 2020 Ribavirin uptake was inhibited by nucleosides such as adenosine and uridine, and by inhibitors of equilibrative nucleoside transporter 1 (ENT1) such as S-(4-nitrobenzyl)-6-thioinosine and dipyridamole in a concentration-dependent manner. Dipyridamole 188-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 32635975-8 2020 On the other hand, Na+-dependence of ribavirin uptake was not observed, suggesting the involvement of ENT1, but not Na+-dependent concentrative nucleoside transporters, in ribavirin uptake in K562 cells. Ribavirin 172-181 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-106 32635975-10 2020 These results suggest that ribavirin uptake into K562 cells is mainly mediated by ENT1, which may have a pivotal role in anticancer effect of ribavirin. Ribavirin 27-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 32635975-10 2020 These results suggest that ribavirin uptake into K562 cells is mainly mediated by ENT1, which may have a pivotal role in anticancer effect of ribavirin. Ribavirin 142-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 32200037-5 2020 We found that hENT1 reversed GEM-induced drug resistance by inhibiting glycolysis and altering glucose transport mediated by HIF-1alpha in pancreatic cancer. Glucose 95-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 32428837-1 2020 Nucleoside analogs are subject to resistance mechanisms including downregulation of equilibrative nucleoside transporter (ENT1) and deoxycytidine kinase (dCK). Nucleosides 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-126 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. ticagrelor 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 32523687-2 2020 We have previously demonstrated that sustained adenosine exposure by inhibition of adenosine degradation impairs lung endothelial barrier integrity and causes intrinsic apoptosis through equilibrative nucleoside transporter1/2-mediated intracellular adenosine signaling. Adenosine 47-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-226 32523687-2 2020 We have previously demonstrated that sustained adenosine exposure by inhibition of adenosine degradation impairs lung endothelial barrier integrity and causes intrinsic apoptosis through equilibrative nucleoside transporter1/2-mediated intracellular adenosine signaling. Adenosine 83-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-226 32523687-2 2020 We have previously demonstrated that sustained adenosine exposure by inhibition of adenosine degradation impairs lung endothelial barrier integrity and causes intrinsic apoptosis through equilibrative nucleoside transporter1/2-mediated intracellular adenosine signaling. Adenosine 83-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-226 32523687-3 2020 In this study, we further demonstrated that sustained adenosine exposure increased mitochondrial reactive oxygen species and reduced mitochondrial respiration via equilibrative nucleoside transporter1/2, but not via adenosine receptor-mediated signaling. Adenosine 54-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 163-202 32523687-8 2020 Our results suggest that inhibition of equilibrative nucleoside transporter1/2 and mitochondria-targeted antioxidants may be potential therapeutic approaches for lung diseases associated with sustained elevated adenosine. Adenosine 211-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-78 32141895-10 2020 Follow-up studies showed that erythrocyte equilibrative nucleoside transporter 1 (eENT1) is a key purinergic cellular component controlling plasma adenosine in humans at high altitude and mice under hypoxia and underlies the quicker and higher elevation of plasma adenosine upon re-ascent because of prior hypoxia-induced degradation of eENT1. Adenosine 147-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 32141895-10 2020 Follow-up studies showed that erythrocyte equilibrative nucleoside transporter 1 (eENT1) is a key purinergic cellular component controlling plasma adenosine in humans at high altitude and mice under hypoxia and underlies the quicker and higher elevation of plasma adenosine upon re-ascent because of prior hypoxia-induced degradation of eENT1. Adenosine 264-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 32457256-2 2020 Integral membrane transporter protein and intracellular enzymes including human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), ribonucleotide reductase (RR) M1, and M2 are known as important factors for chemosensitivity of gemcitabine. gemcitabine 252-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-118 31721163-0 2020 beta3 adrenoceptor-induced cholinergic bladder inhibition involves EPAC1 and PKC favoring ENT1-mediated adenosine outflow from the human and rat detrusor. Adenosine 104-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-94 32206108-12 2020 Hypoxia-mediated repression of human ENT1, which was markedly suppressed in RCC, resulted in a decrease in the cellular accumulation of DAC. Decitabine 136-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-41 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. ticagrelor 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 18-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 18-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 162-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 32066489-2 2020 Ticagrelor blocks adenosine reuptake through the inhibition of equilibrative nucleoside transporter 1 (ENT-1) on erythrocytes and platelets, thereby facilitating adenosine-induced physiological responses such as an increase in coronary blood flow velocity. Adenosine 162-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 32014934-1 2020 BACKGROUND/AIM: Tumoural transcriptional levels of RRM1, RRM2, CDA, dCK and hENT1 genes are potential biomarkers for gemcitabine"s efficacy in non-small cell lung cancer (NSCLC). gemcitabine 117-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 31601121-11 2019 Higher hENT1 expression in MDA-MB231 seems to drive nucleoside transport, whereas TK1 expression in MCF7 seems responsible for comparable [18F]FLT retention in ER+ tumors. Nucleosides 52-62 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 7-12 30660686-3 2020 These alterations are paralleled by lower maximal transport activity of the endogenous nucleoside adenosine via the human equilibrative nucleoside transporter 1 (hENT1) and activation of adenosine receptors. nucleoside adenosine 87-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-160 30660686-3 2020 These alterations are paralleled by lower maximal transport activity of the endogenous nucleoside adenosine via the human equilibrative nucleoside transporter 1 (hENT1) and activation of adenosine receptors. nucleoside adenosine 87-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-167 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. gemcitabine 211-222 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. gemcitabine 211-222 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. gemcitabine 224-227 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. gemcitabine 224-227 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. Fluorouracil 233-247 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. Fluorouracil 233-247 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. Fluorouracil 249-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 31778273-1 2020 The high expression of human equilibrative nucleoside transporter-1 (hENT1) and the low expression of dihydropyrimidine dehydrogenase (DPD) are reported to predict a favorable prognosis in patients treated with gemcitabine (GEM) and 5-fluorouracil (5FU) as the adjuvant setting, respectively. Fluorouracil 249-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 31711924-0 2020 ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin alpha3beta1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. gemcitabine 127-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-155 31711924-13 2020 Increased ITGA3 and ITGB1 expression and subsequent integrin alpha3beta1 signaling, via c-Jun-N-terminal kinase (JNK), inhibited expression of the gemcitabine transporter ENT1, which reduced gemcitabine uptake by pancreatic cancer cells. gemcitabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 31711924-13 2020 Increased ITGA3 and ITGB1 expression and subsequent integrin alpha3beta1 signaling, via c-Jun-N-terminal kinase (JNK), inhibited expression of the gemcitabine transporter ENT1, which reduced gemcitabine uptake by pancreatic cancer cells. gemcitabine 191-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 31711924-16 2020 The subsequent increase in integrin alpha3beta1 signaling, via JNK, inhibits expression of the gemcitabine transporter ENT1, so that cells take up smaller amounts of the drug. gemcitabine 95-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-123 31830468-0 2020 Affinity, binding kinetics and functional characterization of draflazine analogues for human Equilibrative Nucleoside Transporter 1 (SLC29A1). draflazine 62-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-131 31830468-0 2020 Affinity, binding kinetics and functional characterization of draflazine analogues for human Equilibrative Nucleoside Transporter 1 (SLC29A1). draflazine 62-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-140 31830468-3 2020 Currently, two non-selective ENT1 inhibitors (dilazep and dipyridamole) are on the market as vasodilators. Dipyridamole 58-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 31830468-6 2020 We developed a radioligand competition association assay to determine the binding kinetics of ENT1 inhibitors with four chemical scaffolds (including dilazep and dipyridamole). Dipyridamole 162-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-98 31964620-1 2020 Decitabine (DAC), a DNA methylation inhibitor, is transported into cancer cells mainly via equilibrative nucleoside transporter 1 (ENT1) and subsequently phosphorylated by deoxycytidine kinase (dCK). decitabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-129 31964620-1 2020 Decitabine (DAC), a DNA methylation inhibitor, is transported into cancer cells mainly via equilibrative nucleoside transporter 1 (ENT1) and subsequently phosphorylated by deoxycytidine kinase (dCK). decitabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 131-135 31201358-8 2020 RNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus. Cytarabine 75-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-155 31201358-8 2020 RNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus. Cytarabine 75-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 157-164 31201358-8 2020 RNA expression analysis and functional studies revealed that resistance to AraC was conferred by downregulation of the nucleoside membrane transporter ENT1 (SLC29A1) by reduced H3K27 acetylation at the ENT1 locus. Cytarabine 75-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 202-206 32312148-1 2020 Cellular uptake of clinically important deoxynucleoside analogs is mediated by nucleoside transporters including the human equilibrative nucleoside transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). deoxynucleoside 40-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-161 32312148-1 2020 Cellular uptake of clinically important deoxynucleoside analogs is mediated by nucleoside transporters including the human equilibrative nucleoside transporter 1 (hENT1) and the concentrative nucleoside transporter-1 (hCNT1). deoxynucleoside 40-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 163-168 31177538-6 2019 Similarly, UR supplementation increased (P < 0.05) expression of solute carriers SLC28A1 and SLC29A1 in the duodenum mucosa. Uridine 11-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-100 31335977-0 2019 High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia. nelarabine 100-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-9 31752123-3 2019 Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 31752123-3 2019 Gemcitabine uptake into tumor cells is mainly through the human equilibrative nucleoside transport 1 (hENT1). Nucleosides 78-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 31752123-8 2019 The 10D7G2 clone was the only hENT1 antibody whose high expression was associated with a prolonged progression free survival and overall survival in patients who received adjuvant gemcitabine. gemcitabine 180-191 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-35 31752123-9 2019 hENT1 mRNA level was also predictive of gemcitabine benefit. gemcitabine 40-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 31551431-0 2019 Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1. Nucleosides 120-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-100 31551431-4 2019 For this study, a prototypical SLC/GPCR pair was selected, i.e. the equilibrative nucleoside transporter-1 (SLC29A1/ENT1) and an adenosine receptor (AR), for which adenosine is the substrate/ligand. Adenosine 164-173 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-115 31166004-8 2019 CONCLUSIONS AND IMPLICATIONS: OAT2 and ENT1 are the main transporters involved in the hepatic uptake and anti-HBV efficacy of ETV. entecavir 126-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-43 31504065-11 2019 The results indicated that a low expression of the gemcitabine sensitive factor hENT-1 was significantly associated with the non-response group in vitro (p = 0.002). gemcitabine 51-62 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-86 30394160-4 2019 Enasidenib inhibited hENT1, hENT2, hENT3, and hENT4 in oocytes with IC50 values of 7, 63, 27, and 76 muM, respectively, but exhibited little inhibition of hCNT1-3. enasidenib 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-26 31505000-7 2019 Silencing the expression or activity of the human equilibrative nucleoside transporter 1 (ENT1), implicated in the mitochondrial transport of fialuridine, modestly protected PHH spheroids from fialuridine toxicity. fialuridine 193-204 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-94 31166004-0 2019 Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy. entecavir 129-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 41-79 31255992-9 2019 In the meta-analysis of patients treated with gemcitabine-based chemotherapy, high hENT1 expression was associated with longer OS (HR 0.43, 95% CI: 0.28 to 0.64) and DFS/PFS (HR 0.45, 95% CI: 0.33 to 0.61). gemcitabine 46-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-88 31255992-10 2019 CONCLUSION: hENT1 is a promising prognostic biomarker for gemcitabine-based chemotherapy in resected as well as in advanced BTC and should be further validated for the selection of patients for chemotherapy. gemcitabine 58-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 31505000-7 2019 Silencing the expression or activity of the human equilibrative nucleoside transporter 1 (ENT1), implicated in the mitochondrial transport of fialuridine, modestly protected PHH spheroids from fialuridine toxicity. fialuridine 142-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-88 31505000-7 2019 Silencing the expression or activity of the human equilibrative nucleoside transporter 1 (ENT1), implicated in the mitochondrial transport of fialuridine, modestly protected PHH spheroids from fialuridine toxicity. fialuridine 142-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-94 31505000-7 2019 Silencing the expression or activity of the human equilibrative nucleoside transporter 1 (ENT1), implicated in the mitochondrial transport of fialuridine, modestly protected PHH spheroids from fialuridine toxicity. fialuridine 193-204 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-88 31505000-8 2019 Interference with the phosphorylation of fialuridine into the active tri-phosphate metabolites by silencing of thymidine kinase 2 (TK2) provided substantial protection while simultaneous silencing of ENT1 and TK2 provided near complete protection. fialuridine 41-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 200-204 31505000-9 2019 Fialuridine-induced mitochondrial dysfunction was suggested by a decrease in the expression of mtDNA-encoded genes, which correlated with the onset of toxicity and was prevented under the simultaneous silencing of ENT1 and TK2. fialuridine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 214-218 30867652-18 2019 Conclusion: HNF4alpha is a prognostic marker for overall survival, is required for pancreatic cancer cell proliferation and promotes resistance to gemcitabine by downregulating hENT1. gemcitabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 177-182 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Adenosine 111-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Adenosine 111-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Nucleosides 151-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 31235912-1 2019 The human equilibrative nucleoside transporter 1 (hENT1), a member of the SLC29 family, plays crucial roles in adenosine signaling, cellular uptake of nucleoside for DNA and RNA synthesis, and nucleoside-derived anticancer and antiviral drug transport in humans. Nucleosides 151-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 31235912-3 2019 Despite its importance in human physiology and pharmacology, the molecular basis of hENT1-mediated adenosine transport and its inhibition by AdoRIs are limited, owing to the absence of structural information on hENT1. Adenosine 99-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 31235912-4 2019 Here, we present crystal structures of hENT1 in complex with two chemically distinct AdoRIs: dilazep and S-(4-nitrobenzyl)-6-thioinosine (NBMPR). Dilazep 93-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 31235912-4 2019 Here, we present crystal structures of hENT1 in complex with two chemically distinct AdoRIs: dilazep and S-(4-nitrobenzyl)-6-thioinosine (NBMPR). 4-nitrobenzylthioinosine 105-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 31235912-4 2019 Here, we present crystal structures of hENT1 in complex with two chemically distinct AdoRIs: dilazep and S-(4-nitrobenzyl)-6-thioinosine (NBMPR). 4-nitrobenzylthioinosine 138-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 31235912-5 2019 Combined with mutagenesis study, our structural analyses elucidate two distinct inhibitory mechanisms exhibited on hENT1 and provide insight into adenosine recognition and transport. Adenosine 146-155 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-120 31235912-6 2019 Our studies provide a platform for improved pharmacological intervention of adenosine and nucleoside analog drug transport by hENT1. Adenosine 76-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 126-131 31235912-6 2019 Our studies provide a platform for improved pharmacological intervention of adenosine and nucleoside analog drug transport by hENT1. Nucleosides 90-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 126-131 30022699-7 2019 Interestingly, of the six compounds that potently interacted with both ENT1 and ENT2 only nelarabine displayed selectivity. nelarabine 90-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-75 30726669-3 2019 Each of these was elaborated over 13 steps, including Suzuki-Miyaura cross-coupling, radical cyclization, and Pictet-Spengler reactions, into (-)- or (+)-crinane (1 or ent-1, respectively). (-)- or (+)-crinane 142-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-173 31113844-0 2019 Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Arginine 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 31113844-0 2019 Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Docetaxel 24-33 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 31113844-0 2019 Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. gemcitabine 91-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 31113844-7 2019 This resulted in an increase of hENT1 cell-surface expression and rendered the cells susceptible to GEM. gemcitabine 100-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 31113844-9 2019 CONCLUSIONS: The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. Docetaxel 54-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 31113844-9 2019 CONCLUSIONS: The priming of tumors with ADI-PEG20 and DTX results in the stabilization of c-MYC potentiating the effect of GEM treatment via an increase in hENT1 expression. gemcitabine 123-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 30716294-4 2019 Our data indicate that ENT1 participates in uptake of ribavirin by BeWo cells, fresh human placental villous fragments and microvillous plasma membrane (MVM) vesicles while activity of CNTs (probably CNT2) was only observed in BeWo cells. Ribavirin 54-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-27 30716294-7 2019 In summary, our data show that ribavirin placental pharmacokinetics are largely controlled by ENT1 activity and independent of ABCB1, ABCG2, and ABCC2 efflux pumps. Ribavirin 31-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-98 30557411-0 2018 Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 29987837-12 2019 Cladribine distribution across membranes is primarily facilitated by equilibrative nucleoside transporter (ENT) 1, concentrative nucleoside transporter (CNT) 3 and breast cancer resistance protein (BCRP), and there is no evidence of any cladribine-related effect on heart rate, atrioventricular conduction or cardiac repolarisation (QTc interval prolongation). Cladribine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-113 30528800-1 2019 Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. Nucleosides 129-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 30528800-1 2019 Human equilibrative nucleoside transporter 1 (hENT-1) is a membrane nucleoside transporter mediating the intracellular uptake of nucleosides and their analogues. Nucleosides 129-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-52 30528800-2 2019 hENT-1 was recently reported to have a predictive role in intrahepatic cholangiocarcinoma (iCC) patients receiving adjuvant gemcitabine-based chemotherapy, but its biological and clinical significance in iCC remains unsettled. gemcitabine 124-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-6 29851527-3 2019 Ticagrelor"s pleiotropic effects on reuptake of adenosine via inhibition of equilibrative nucleoside transporter 1 (ENT1) have been hypothesized to contribute to this. Adenosine 48-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-114 29851527-3 2019 Ticagrelor"s pleiotropic effects on reuptake of adenosine via inhibition of equilibrative nucleoside transporter 1 (ENT1) have been hypothesized to contribute to this. Adenosine 48-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-120 30557411-0 2018 Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 30557411-2 2018 Expression of human equilibrative nucleoside transporter 1 (hENT1) is regarded as a potential predictive biomarker for a gemcitabine response in some cancers. gemcitabine 121-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-58 30557411-2 2018 Expression of human equilibrative nucleoside transporter 1 (hENT1) is regarded as a potential predictive biomarker for a gemcitabine response in some cancers. gemcitabine 121-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 30557411-3 2018 This study was conducted to investigate the association between hENT1 expression and the effects of gemcitabine on BTC cell lines and on patients with advanced BTC receiving gemcitabine-based chemotherapy. gemcitabine 100-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 30557411-3 2018 This study was conducted to investigate the association between hENT1 expression and the effects of gemcitabine on BTC cell lines and on patients with advanced BTC receiving gemcitabine-based chemotherapy. gemcitabine 174-185 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 30557411-9 2018 Expression of hENT1 showed a linear correlation with the log value of the half-maximal inhibitory concentration of gemcitabine. gemcitabine 115-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 30557411-10 2018 During incubation with gemcitabine, pretreatment with hENT1-specific small interfering RNA (siRNA) resulted in higher cell viability than that in samples pretreated with control siRNA. gemcitabine 23-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 30557411-12 2018 In conclusion, this study showed that increased hENT1 expression is associated with a stronger toxic effect of gemcitabine on BTC cell lines. gemcitabine 111-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 30557411-13 2018 The clinical outcomes in this study suggest that increased intratumoral hENT1 immunohistochemical staining is a possible biomarker predicting better therapeutic effects of gemcitabine on patients with advanced BTC. gemcitabine 172-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 30501707-8 2018 Among 51 patients with therapeutic response, the expression level of hENT1 mRNA in CR group was higher than that in non-CR group [(2.58+-1.44 (2- Ct) vs 1.39 +-1.3 (2- Ct), P= 0.005)]. Chromium 83-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 30501707-8 2018 Among 51 patients with therapeutic response, the expression level of hENT1 mRNA in CR group was higher than that in non-CR group [(2.58+-1.44 (2- Ct) vs 1.39 +-1.3 (2- Ct), P= 0.005)]. Chromium 120-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 30501707-12 2018 Multivariate logistic regression model showed that the complex karyotype, Plt count doubling after 1 course treatment, TP53 mulation and high expression of hENT1 mRNA were the independent prognostic factors for predicting the CR after decitabine treatment. Decitabine 235-245 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 30501707-13 2018 CONCLUSION: IPSS staging, complex karyotype, Plt count doubling after 1 course treatment and hENT1 mRNA expression, TP53 gene mutation can be used to predict the tharapeutic efficacy of dectitabine for treatment of MDS. dectitabine 186-197 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 30469356-5 2018 ENT1 activity was, next, demonstrated to be the main uridine transport activity present in HepaRG cells, like in cultured human hepatocytes. Uridine 53-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 30469356-7 2018 Overall, these data suggest that HepaRG cells may be useful for analyzing cellular pharmacokinetics of nucleoside-like drugs in human hepatic cells, especially of those handled by ENT1. Nucleosides 103-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 180-184 30519105-0 2018 Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIalpha as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin. Cytarabine 129-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-24 30039191-0 2018 Correlation of 4"-[methyl-11C]-thiothymidine uptake with human equilibrative nucleoside transporter-1 and thymidine kinase-1 expressions in patients with newly diagnosed gliomas. 4'-thiothymidine 15-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 30039191-1 2018 OBJECTIVE: We examined expressions of human equilibrative nucleoside transporter-1 (hENT1) and thymidine kinase-1 (TK1), the key enzyme in 4"-[methyl-11C]-thiothymidine (4DST) phosphorylation, to elucidate the mechanism of 4DST uptake in patients with newly diagnosed gliomas. 4'-thiothymidine 139-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-82 30039191-1 2018 OBJECTIVE: We examined expressions of human equilibrative nucleoside transporter-1 (hENT1) and thymidine kinase-1 (TK1), the key enzyme in 4"-[methyl-11C]-thiothymidine (4DST) phosphorylation, to elucidate the mechanism of 4DST uptake in patients with newly diagnosed gliomas. 4'-thiothymidine 139-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 30254099-0 2018 Role of cysteine 416 in N-ethylmaleimide sensitivity of human equilibrative nucleoside transporter 1 (hENT1). Cysteine 8-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-100 30097436-4 2018 Using endogenous substrates of nucleoside transporters, [3H]-adenosine (ENTs, CNT2, and CNT3) and [3H]-thymidine (ENTs, CNT1, and CNT3), we showed significant activity of ENT1 and CNT2 in BeWo cells, whereas experiments in the villous fragments and MVM vesicles, representing a model of the apical membrane of a syncytiotrophoblast, revealed only ENT1 activity. [3h]-adenosine 56-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 30097436-4 2018 Using endogenous substrates of nucleoside transporters, [3H]-adenosine (ENTs, CNT2, and CNT3) and [3H]-thymidine (ENTs, CNT1, and CNT3), we showed significant activity of ENT1 and CNT2 in BeWo cells, whereas experiments in the villous fragments and MVM vesicles, representing a model of the apical membrane of a syncytiotrophoblast, revealed only ENT1 activity. [3h]-adenosine 56-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 347-351 30097436-5 2018 When testing [3H]-abacavir uptakes, we showed that of the nucleoside transporters, ENT1 plays the dominant role in abacavir uptake into placental tissues, whereas contribution of Na+-dependent transport, most likely mediated by CNTs, was observed only in BeWo cells. Tritium 14-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-87 30097436-5 2018 When testing [3H]-abacavir uptakes, we showed that of the nucleoside transporters, ENT1 plays the dominant role in abacavir uptake into placental tissues, whereas contribution of Na+-dependent transport, most likely mediated by CNTs, was observed only in BeWo cells. abacavir 18-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-87 30097436-5 2018 When testing [3H]-abacavir uptakes, we showed that of the nucleoside transporters, ENT1 plays the dominant role in abacavir uptake into placental tissues, whereas contribution of Na+-dependent transport, most likely mediated by CNTs, was observed only in BeWo cells. abacavir 115-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-87 30097436-9 2018 Therefore, drug-drug interactions and the effect of interindividual variability in placental ENT1 expression on abacavir disposition into fetal circulation should be further investigated to guarantee safe and effective abacavir-based combination therapies in pregnancy. abacavir 112-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-97 30254099-0 2018 Role of cysteine 416 in N-ethylmaleimide sensitivity of human equilibrative nucleoside transporter 1 (hENT1). Cysteine 8-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 30254099-0 2018 Role of cysteine 416 in N-ethylmaleimide sensitivity of human equilibrative nucleoside transporter 1 (hENT1). Ethylmaleimide 24-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-100 30254099-0 2018 Role of cysteine 416 in N-ethylmaleimide sensitivity of human equilibrative nucleoside transporter 1 (hENT1). Ethylmaleimide 24-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 30254099-1 2018 Human equilibrative nucleoside transporter 1 (hENT1), the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for cellular uptake of physiologic nucleosides and many antineoplastic and antiviral nucleoside drugs. Nucleosides 191-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 30254099-1 2018 Human equilibrative nucleoside transporter 1 (hENT1), the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for cellular uptake of physiologic nucleosides and many antineoplastic and antiviral nucleoside drugs. Nucleosides 191-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 30254099-1 2018 Human equilibrative nucleoside transporter 1 (hENT1), the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for cellular uptake of physiologic nucleosides and many antineoplastic and antiviral nucleoside drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 30254099-2 2018 hENT1, which is potently inhibited by nitrobenzylthioinosine (NBMPR), possesses 11 transmembrane helical domains with an intracellular N-terminus and an extracellular C-terminus. 4-nitrobenzylthioinosine 38-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 30254099-2 2018 hENT1, which is potently inhibited by nitrobenzylthioinosine (NBMPR), possesses 11 transmembrane helical domains with an intracellular N-terminus and an extracellular C-terminus. 4-nitrobenzylthioinosine 62-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 30254099-4 2018 To identify the residue(s) involved in NEM inhibition, we created a cysteine-less version of hENT1 (hENT1C-), with all 10 endogenous cysteine residues mutated to serine, and showed that it displays wild-type uridine transport and NBMPR-binding characteristics when produced in the Xenopus oocyte heterologous expression system, indicating that endogenous cysteine residues are not essential for hENT1 function. Cysteine 68-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 30254099-4 2018 To identify the residue(s) involved in NEM inhibition, we created a cysteine-less version of hENT1 (hENT1C-), with all 10 endogenous cysteine residues mutated to serine, and showed that it displays wild-type uridine transport and NBMPR-binding characteristics when produced in the Xenopus oocyte heterologous expression system, indicating that endogenous cysteine residues are not essential for hENT1 function. Uridine 208-215 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 30254099-7 2018 Kinetic experiments suggested that NEM modification of Cys416, which is located at the inner extremity of TM10, results in the inhibition of hENT1 uridine transport and NBMPR binding by constraining the protein in its inward-facing conformation. Uridine 147-154 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Adenosine 72-81 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-34 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Nitric Oxide 104-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-34 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Adenosine 264-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-34 29871907-8 2018 In vitro overexpression of SLC29A1 in human endothelial cells disrupted adenosine signaling and reduced nitric oxide levels that were further lowered upon bevacizumab exposure.Conclusions: The genomic region between SLC29A1 and HSP90AB1 and its role in regulating adenosine signaling are key targets for further investigation into the pathogenesis of bevacizumab-induced hypertension. Adenosine 264-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 216-223 30214194-0 2018 Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. gemcitabine 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-123 30143259-0 2018 GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through beta1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1. gemcitabine 35-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-161 30143259-1 2018 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-tumor drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 30143259-5 2018 Moreover, mechanistic investigations showed that silencing GnT-V caused dramatic decrease of beta1,6 GlcNAc structure on hENT1 leading to apparently decreased accumulation of hENT1 at plasma membrane, and therefore result in less uptake of gemcitabine in T24/shRNA cells. gemcitabine 240-251 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 121-126 30143259-6 2018 Together, our present study indicated that GnT-V enhances gemcitabine chemosensitivity via modulation of hENT1 N-glycosylation and transport activity in T24 cells, providing new insights into how N-glycosylation drives antitumor drug sensitivity during chemotherapy for patients with cancer. gemcitabine 58-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-110 30214194-0 2018 Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. gemcitabine 63-74 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-123 30214194-4 2018 In this study, we tested the antitumor effect of gemcitabine-loaded human serum albumin nanoparticle (GEM-HSA-NP) on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. gemcitabine 49-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 172-177 30214194-4 2018 In this study, we tested the antitumor effect of gemcitabine-loaded human serum albumin nanoparticle (GEM-HSA-NP) on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. gemcitabine 117-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 172-177 30214194-5 2018 Materials and methods: S-(4-nitrobenzyl)-6-thioinosine was utilized to inhibit the activity of hENT1 and simulate low hENT1 expression. 4-nitrobenzylthioinosine 23-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-100 30214194-5 2018 Materials and methods: S-(4-nitrobenzyl)-6-thioinosine was utilized to inhibit the activity of hENT1 and simulate low hENT1 expression. 4-nitrobenzylthioinosine 23-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-123 30214194-10 2018 In in vivo studies, GEM-HSA-NP was more effective than gemcitabine on inhibiting tumor growth whether the expression levels of hENT1 were high or low in PDX models. gem-hsa-np 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 127-132 30214194-12 2018 Conclusion: GEM-HSA-NP can overcome gemcitabine resistance induced by low hENT1 expression, which suggests its potential role for the clinical application. gemcitabine 36-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-79 29963262-2 2018 Many mechanisms are involved in gemcitabine resistance, such as reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) membrane transporter, deoxycytidine kinase deficiency, and changes in the signal transmission of mitogen-activity protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways. gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-134 29864673-3 2018 This activation occurred within hours after addition of the nucleosides and was primarily dependent on the ENT1 nucleoside transporter protein. Nucleosides 60-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 107-111 29891696-4 2018 Here we used CRISPR-Cas9 mutagenesis to show that phagocyte intoxication involves uptake of dAdo via the human equilibrative nucleoside transporter 1, dAdo conversion to dAMP by deoxycytidine kinase and adenosine kinase, and signaling via subsequent dATP formation to activate caspase-3-induced cell death. 2'-deoxyadenosine 92-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-149 29891696-4 2018 Here we used CRISPR-Cas9 mutagenesis to show that phagocyte intoxication involves uptake of dAdo via the human equilibrative nucleoside transporter 1, dAdo conversion to dAMP by deoxycytidine kinase and adenosine kinase, and signaling via subsequent dATP formation to activate caspase-3-induced cell death. 2'-deoxyadenosine triphosphate 250-254 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-149 29483661-8 2018 In pyramidal neurons, changes in ENT1 and ADA mRNA may suggest increased catabolism of adenosine. Adenosine 87-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-37 29963262-2 2018 Many mechanisms are involved in gemcitabine resistance, such as reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) membrane transporter, deoxycytidine kinase deficiency, and changes in the signal transmission of mitogen-activity protein kinase (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways. gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-141 29174536-1 2017 Decitabine (DAC), a nucleoside-related DNA methylation inhibitor, is taken up into cancer cells via equilibrative nucleoside transporter 1 (ENT1), and is then monophosphorylated by deoxycytidine kinase (dCK). Decitabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-138 29530865-6 2018 Transport analyses of hENT3-hENT1 chimeric constructs demonstrated that the N-terminal half of hENT3 is primarily responsible for the hENT3-3"-deoxy-nucleoside analog interaction. oxytocin, 1-desamino-(O-Et-Tyr)(2)- 143-148 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-33 29530865-6 2018 Transport analyses of hENT3-hENT1 chimeric constructs demonstrated that the N-terminal half of hENT3 is primarily responsible for the hENT3-3"-deoxy-nucleoside analog interaction. Nucleosides 149-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-33 29680437-0 2018 Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. Dipyridamole 100-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-84 29680437-2 2018 We hypothesized that an increase in extracellular adenosine induced by inhibitors of adenosine transporters, such as the non-selective ENT1/ENT2 inhibitor dipyridamole, would result in an improvement in RLS symptoms. Adenosine 50-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 135-139 29680437-2 2018 We hypothesized that an increase in extracellular adenosine induced by inhibitors of adenosine transporters, such as the non-selective ENT1/ENT2 inhibitor dipyridamole, would result in an improvement in RLS symptoms. Dipyridamole 155-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 135-139 29515256-1 2018 BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. pyrimidine 19-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 29515256-5 2018 High hENT1 tumour expression was associated with increased survival in gemcitabine treated (HR = 0.56 [0.38-0.82], p = 0.003) but not in 5FU/FA treated patients (HR = 1.19 [0.80-1.78], p = 0.390). gemcitabine 71-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 29323872-5 2018 Moreover, we show that transport via hENT1 is a limiting step in Ara-FA toxicity, while complexation with dendrimer allows Ara-FATP to kill cells even in the presence of a hENT1 inhibitor. ara-fa 65-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 29174536-1 2017 Decitabine (DAC), a nucleoside-related DNA methylation inhibitor, is taken up into cancer cells via equilibrative nucleoside transporter 1 (ENT1), and is then monophosphorylated by deoxycytidine kinase (dCK). Decitabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 140-144 29174536-6 2017 Simulations using simple kinetic models showed that apparent DAC uptake in dCK and ENT1 siRNA-treated cells was attributed to its conversion to monophosphates or a decrease in the cellular flux, respectively, and that the apparent uptake of DAC in dCK-knockdown and ENT1-knockdown cells was similar at longer times, but differed at a very short time. monophosphates 144-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-87 28992563-0 2017 Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. trifluridine tipiracil drug combination 91-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-61 29186204-14 2017 Mocetinostat reduced the expression of gemcitabine-resistance markers RRM1, RRM2, and increased the expression of gemcitabine-sensitivity marker, hENT1, in LMS cells. mocetinostat 0-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 28992563-9 2017 CONCLUSIONS: The combination of ENT1, MATE1 and OCT2 SNPs may serve as a predictive and prognostic marker in mCRC patients treated with TAS-102. trifluridine tipiracil drug combination 136-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-36 28765935-0 2017 FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. gemcitabine 66-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-106 29242850-1 2017 Stereoselective total syntheses of the four stereoisomeric forms of guaiacylglycerol 8-O-4"-coniferyl ether, viz., compounds 1, ent-1, 2, and ent-2, have been established. guaiacylglycerol 8-o-4"-coniferyl ether 68-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-133 29064388-5 2017 Human ENT1 (hENT1) is known to enable cellular uptake of gemcitabine while CDD deactivates gemcitabine. gemcitabine 57-68 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-10 29064388-5 2017 Human ENT1 (hENT1) is known to enable cellular uptake of gemcitabine while CDD deactivates gemcitabine. gemcitabine 57-68 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 29064388-5 2017 Human ENT1 (hENT1) is known to enable cellular uptake of gemcitabine while CDD deactivates gemcitabine. gemcitabine 91-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-10 29064388-5 2017 Human ENT1 (hENT1) is known to enable cellular uptake of gemcitabine while CDD deactivates gemcitabine. gemcitabine 91-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 29098031-6 2017 Furthermore, ASX acts through the hypoxia-inducible factor 1alpha/signal transducer and activator of transcription 3 signaling pathway to mediate TWIST1, ZEB1, hENT1, RRM1 and RRM2, regulating the gemcitabine-induced EMT phenotype and gemcitabine-induced cell death. astaxanthine 13-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 160-165 29057039-0 2017 Indolinone Inhibitors of ENT1 for the Treatment of Schizophrenia. Oxindoles 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-29 28765935-7 2017 Mechanistically, FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) at the protein level rather than the transcriptional level. gemcitabine 31-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-113 28765935-7 2017 Mechanistically, FBW7 promoted gemcitabine sensitivity via upregulation of equilibrative nucleoside transporter 1 (ENT1) at the protein level rather than the transcriptional level. gemcitabine 31-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-119 28765935-9 2017 Taken together, our results demonstrated that FBW7 could be a target for improving the therapeutic efficacy of gemcitabine by induction of ENT1. gemcitabine 111-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 139-143 28770102-0 2017 A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. gemcitabine 172-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-105 28641307-0 2017 Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. gemcitabine 80-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 28641307-1 2017 BACKGROUND: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-74 28641307-1 2017 BACKGROUND: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 28641307-1 2017 BACKGROUND: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. gemcitabine 201-212 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-74 28641307-1 2017 BACKGROUND: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. gemcitabine 201-212 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 28641307-2 2017 Since gemcitabine is widely used in the treatment of leiomyosarcoma and angiosarcoma, we investigated the correlation between hENT1 expression and gemcitabine efficacy in these sarcoma subtypes. gemcitabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 126-131 28729424-2 2017 Unlike the prototypic human ENT members hENT1 and hENT2, which mediate plasma membrane nucleoside transport at pH 7.4, hENT3 is an acidic pH-activated lysosomal transporter partially localized to mitochondria. Nucleosides 87-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 28641307-8 2017 In addition, hENT1 overexpression correlated with a significant improvement in PFS (9.3 vs 4.5 months; P=0.02) and OS (20.6 vs 10.8 months; P=0.001) in angiosarcoma patients treated with gemcitabine. gemcitabine 187-198 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-18 28641307-9 2017 CONCLUSIONS: Our study suggests that higher hENT1 expression are associated to gemcitabine efficacy both in patients with advanced leiomyosarcoma and angiosarcoma. gemcitabine 79-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28770102-0 2017 A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. gemcitabine 172-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 107-112 28770102-1 2017 Expression of human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma (PDAC) has been postulated to be a marker of sensitivity to gemcitabine. gemcitabine 163-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-58 28770102-1 2017 Expression of human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma (PDAC) has been postulated to be a marker of sensitivity to gemcitabine. gemcitabine 163-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 28770102-2 2017 However, heterogeneity in the studies attempting to quantify hENT1 expression in patients with PDAC treated with gemcitabine has yielded inconclusive results that impede the adoption of hENT1 expression as a predictive biomarker. pdac 95-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-66 28770102-2 2017 However, heterogeneity in the studies attempting to quantify hENT1 expression in patients with PDAC treated with gemcitabine has yielded inconclusive results that impede the adoption of hENT1 expression as a predictive biomarker. gemcitabine 113-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-66 28770102-8 2017 These data suggest that either antibody for hENT1 can be used to predict gemcitabine sensitivity in resected PDAC. gemcitabine 73-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28770102-8 2017 These data suggest that either antibody for hENT1 can be used to predict gemcitabine sensitivity in resected PDAC. pdac 109-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28365185-0 2017 Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. Curcumin 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-94 28693211-0 2017 Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy. gemcitabine 133-144 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-63 28693211-1 2017 The predictive roles of human equilibrative nucleoside transporter 1 (hENT-1) in patients who undergo curative resection and adjuvant chemotherapy with gemcitabine alone have not been established. gemcitabine 152-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-68 28693211-1 2017 The predictive roles of human equilibrative nucleoside transporter 1 (hENT-1) in patients who undergo curative resection and adjuvant chemotherapy with gemcitabine alone have not been established. gemcitabine 152-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-76 28693211-9 2017 hENT-1 status was one of the important predictive factors for OS and RFS in patients with pancreatic cancer who underwent curative resection followed by adjuvant chemotherapy with gemcitabine. gemcitabine 180-191 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-6 28365185-0 2017 Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. Curcumin 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-100 28365185-0 2017 Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. cyclohexanone 17-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-94 28365185-0 2017 Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells. cyclohexanone 17-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-100 28365185-3 2017 As curcumin is a promiscuous transporter inhibitor; we suspected that increased resistance occurred via inhibition of Equilibrative nucleoside transporter 1 (ENT1)-mediated gemcitabine uptake. Curcumin 3-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-156 28365185-3 2017 As curcumin is a promiscuous transporter inhibitor; we suspected that increased resistance occurred via inhibition of Equilibrative nucleoside transporter 1 (ENT1)-mediated gemcitabine uptake. Curcumin 3-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 158-162 28365185-3 2017 As curcumin is a promiscuous transporter inhibitor; we suspected that increased resistance occurred via inhibition of Equilibrative nucleoside transporter 1 (ENT1)-mediated gemcitabine uptake. gemcitabine 173-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-156 28365185-3 2017 As curcumin is a promiscuous transporter inhibitor; we suspected that increased resistance occurred via inhibition of Equilibrative nucleoside transporter 1 (ENT1)-mediated gemcitabine uptake. gemcitabine 173-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 158-162 28365185-4 2017 To test our hypothesis, we determined whether curcumin and a related analogue, 2,6-bis((3-methoxy-4-hydroxyphenyl)methylene)-cyclohexanone (or A13), inhibited ENT1-mediated accumulation of [3H]uridine and [3H]gemcitabine into pancreatic cancer cells. cyqualon 79-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 159-163 28365185-6 2017 We found that curcumin and A13 concentration-dependently inhibited the ENT1-mediated accumulation of both uridine and gemcitabine in MIA PaCa-2 and PANC-1 cells. Curcumin 14-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-75 28365185-6 2017 We found that curcumin and A13 concentration-dependently inhibited the ENT1-mediated accumulation of both uridine and gemcitabine in MIA PaCa-2 and PANC-1 cells. Uridine 106-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-75 28365185-6 2017 We found that curcumin and A13 concentration-dependently inhibited the ENT1-mediated accumulation of both uridine and gemcitabine in MIA PaCa-2 and PANC-1 cells. gemcitabine 118-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-75 28365185-10 2017 From these results, we concluded that curcumin and A13 are inhibitors of the ENT1 transporter, but only at high concentrations (2-20microM). Curcumin 38-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-81 28365185-11 2017 Curcumin is unlikely to inhibit gemcitabine uptake in tumours but may interfere with the oral absorption of ENT1 substrates due to high gut concentrations readily achievable from over-the-counter tablets/capsules. Curcumin 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-112 28259943-10 2017 In addition, sclareolide mediated the NOTCH 1 intracellular cytoplasmic domain (NICD)/glioma-associated oncogene 1 (Gli1) pathway, which triggered TWIST1/Slug-hENT1/RRM1 signaling and resensitized GR-HPCCs to gemcitabine. sclareolide 13-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 159-164 28476815-2 2017 The present study aimed to examine the relationship between intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) and the outcomes of NACRT with gemcitabine (GEM) combined with S-1 in patients with borderline-resectable pancreatic cancer (BRPC). nacrt 230-235 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-131 28476815-2 2017 The present study aimed to examine the relationship between intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) and the outcomes of NACRT with gemcitabine (GEM) combined with S-1 in patients with borderline-resectable pancreatic cancer (BRPC). nacrt 230-235 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-138 28476815-2 2017 The present study aimed to examine the relationship between intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) and the outcomes of NACRT with gemcitabine (GEM) combined with S-1 in patients with borderline-resectable pancreatic cancer (BRPC). gemcitabine 241-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-131 28476815-2 2017 The present study aimed to examine the relationship between intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) and the outcomes of NACRT with gemcitabine (GEM) combined with S-1 in patients with borderline-resectable pancreatic cancer (BRPC). gemcitabine 241-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-138 28476815-2 2017 The present study aimed to examine the relationship between intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) and the outcomes of NACRT with gemcitabine (GEM) combined with S-1 in patients with borderline-resectable pancreatic cancer (BRPC). gemcitabine 254-257 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-131 28476815-2 2017 The present study aimed to examine the relationship between intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) and the outcomes of NACRT with gemcitabine (GEM) combined with S-1 in patients with borderline-resectable pancreatic cancer (BRPC). gemcitabine 254-257 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-138 28476815-10 2017 CONCLUSION: Combined expression analyses of hENT1, TS, and DPD may predict long-term outcomes in patients with BRPC after NACRT. nacrt 122-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28196013-0 2017 Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy. gemcitabine 52-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-84 28259943-9 2017 Sclareolide upregulated hENT1, downregulated RRM1 and inhibited gemcitabine-induced EMT through the TWIST1/Slug pathway in the GR-HPCCs. sclareolide 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 28254415-0 2017 Functional reconstitution of human equilibrative nucleoside transporter-1 into styrene maleic acid co-polymer lipid particles. styrene maleic acid co-polymer 79-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-73 28254415-1 2017 The human equilibrative nucleoside transporter-1 (hENT1) is important for the entry of anti-cancer and anti-viral nucleoside analog therapeutics into the cell, and thus for their efficacy. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 28254415-2 2017 Understanding of hENT1 structure-function relationship could assist with development of nucleoside analogs with better cellular uptake properties. Nucleosides 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-22 28254415-4 2017 Here we report detergent-free reconstitution of the hENT1 transporter into styrene maleic acid co-polymer lipid particles (SMALPs) that form a native lipid disc. styrene maleic acid co-polymer 75-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 28254415-6 2017 hENT1-SMALPs purified using FLAG affinity M2 resin yielded ~0.4mg of active and homogenous protein per liter of culture as demonstrated by ligand binding, size-exclusion chromatography and SDS-PAGE analyses. Sodium Dodecyl Sulfate 189-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 28254415-7 2017 Electrospray ionization mass spectrometry (ESI-MS) analysis showed that each hENT1 lipid disc contains 16 phosphatidylcholine (PC) and 2 phosphatidylethanolamine (PE) lipid molecules. Phosphatidylcholines 106-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 28254415-7 2017 Electrospray ionization mass spectrometry (ESI-MS) analysis showed that each hENT1 lipid disc contains 16 phosphatidylcholine (PC) and 2 phosphatidylethanolamine (PE) lipid molecules. Phosphatidylcholines 127-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 28254415-7 2017 Electrospray ionization mass spectrometry (ESI-MS) analysis showed that each hENT1 lipid disc contains 16 phosphatidylcholine (PC) and 2 phosphatidylethanolamine (PE) lipid molecules. phosphatidylethanolamine 137-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 28254415-7 2017 Electrospray ionization mass spectrometry (ESI-MS) analysis showed that each hENT1 lipid disc contains 16 phosphatidylcholine (PC) and 2 phosphatidylethanolamine (PE) lipid molecules. phosphatidylethanolamine 163-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 28254415-8 2017 Polyunsaturated lipids are specifically excluded from the hENT1 lipid discs, possibly reflecting a functional requirement for a dynamic lipid environment. polyunsaturated lipids 0-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 28441348-5 2017 To directly test whether this block of replication was solely due to insufficient dNTP levels, we established a deoxy-nucleotide salvage pathway in fission yeast by expressing the human nucleoside transporter human equilibrative nucleoside transporter 1 (hENT1) and the Drosophila deoxynucleoside kinase. deoxy-nucleotide 112-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 255-260 27655645-6 2017 In NSCLC cells in vitro, we identified a burst in pemetrexed-mediated thymidine salvage pathway activity, assessed by 3H-thymidine assays, thymidine kinase 1 (TK1) expression, and equilibrative nucleoside transporter 1 (ENT1) mobilization to the cell membrane, that peaked at 2hrs. Pemetrexed 50-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-224 27655645-6 2017 In NSCLC cells in vitro, we identified a burst in pemetrexed-mediated thymidine salvage pathway activity, assessed by 3H-thymidine assays, thymidine kinase 1 (TK1) expression, and equilibrative nucleoside transporter 1 (ENT1) mobilization to the cell membrane, that peaked at 2hrs. Thymidine 70-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-224 28417642-0 2017 Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin. Ribavirin 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 28417642-3 2017 In vitro expression levels of equilibrative nucleoside transporter 1 (ENT1) has been shown to be a predictor of treatment response in patients receiving nucleoside-based chemotherapeutic agents. Nucleosides 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-74 28417642-9 2017 Results There was a strong direct correlation between expression of ENT1 in primary hepatocytes and ribavirin uptake at 24 hr. Ribavirin 100-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 28417642-12 2017 Conclusions In this study, we clearly demonstrate that ribavirin uptake in primary human hepatocytes is variable and correlates with ENT1 expression. Ribavirin 55-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-137 28417642-13 2017 This variation in ENT1 expression may account for differences in response rate in patients receiving ribavirin-based anti-hepatitis C virus therapy. Ribavirin 101-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-22 28396636-11 2017 In our hands, only the ENT1-3 uptake and ABCC2,3,4,5, and 10 efflux transporters displayed measurable transcripts in Panc1 cultures, along with a ribonucleoside reductase RRM1 known to affect gemcitabine toxicity. gemcitabine 192-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-27 27995448-5 2017 hENT1 transports the substrate adenosine with a Km of 215 +- 34 micromol/L and a Vmax of 578 +- 23.4 nmol mg-1 min-1. Adenosine 31-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Nitrobenzylmercaptopurine Ribonucleoside 56-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. 4-nitrobenzylthioinosine 98-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Nucleosides 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. deoxynucleosides 119-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-6 2017 Adenosine uptake by hENT1 is competitively inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), nucleosides, deoxynucleosides, and nucleoside-derived anti-cancer and anti-viral drugs. Nucleosides 86-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 27995448-7 2017 Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. Adenosine 20-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 11-16 27995448-7 2017 Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. 2'-deoxyadenosine 31-45 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 11-16 27995448-7 2017 Binding of hENT1 to adenosine, deoxyadenosine, and adenine by isothermal titration calorimetry is in general agreement with results of the competitive inhibition assays. Adenine 51-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 11-16 28292464-7 2017 RESULTS: Overall adenosine transport (i.e., hENT1+hENT2) was semisaturable and partially inhibited by 1 mumol/L, but abolished by 10 mumol/L NBTI in cells non-treated or treated with NH4Cl. 4-nitrobenzylthioinosine 141-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28292464-1 2017 INTRODUCTION: Adenosine is taken up via human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) at a physiological extracellular pH (pHo ~7.4) in human umbilical vein endothelial cells (HUVECs). Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-92 28199010-0 2017 Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy. gemcitabine 142-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 28199010-3 2017 The aim of this study was to see whether hENT1 expression, as determined by immunohistochemistry, was a suitable predictive marker for subsequent treatment with gemcitabine-based adjuvant chemotherapy. gemcitabine 161-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 41-46 28199010-11 2017 CONCLUSION: Expression of hENT1 is a suitable prognostic biomarker in patients undergoing adjuvant gemcitabine-based chemotherapy. gemcitabine 99-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 28062543-7 2017 The inhibition of ETV uptake in primary human trophoblast cells further confirmed that equilibrative nucleoside transporter (ENT) 1/2, CNT2/3, OCT3, and organic cation/carnitine transporter (OCTN) 2 might be involved in ETV transfer in human placenta. entecavir 18-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-133 28062543-7 2017 The inhibition of ETV uptake in primary human trophoblast cells further confirmed that equilibrative nucleoside transporter (ENT) 1/2, CNT2/3, OCT3, and organic cation/carnitine transporter (OCTN) 2 might be involved in ETV transfer in human placenta. entecavir 220-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-133 28062543-8 2017 Therefore, ETV uptake from maternal circulation to trophoblast cells was possibly transported by CNT2/3, ENT1/2, and OCTN2, whereas ETV efflux from trophoblast cells to fetal circulation was mediated by OCT3, and efflux from trophoblast cells to maternal circulation might be mediated by BCRP, multidrug resistance-associated protein 2, and P-glycoprotein. entecavir 11-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-111 28292464-7 2017 RESULTS: Overall adenosine transport (i.e., hENT1+hENT2) was semisaturable and partially inhibited by 1 mumol/L, but abolished by 10 mumol/L NBTI in cells non-treated or treated with NH4Cl. Adenosine 17-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28292464-7 2017 RESULTS: Overall adenosine transport (i.e., hENT1+hENT2) was semisaturable and partially inhibited by 1 mumol/L, but abolished by 10 mumol/L NBTI in cells non-treated or treated with NH4Cl. Ammonium Chloride 183-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 28218790-1 2017 Human equilibrative nucleoside transporters (hENT) 1 and 2, encoded by SLC29A1 and SLC29A2, permit the bidirectional passage of nucleoside analogues into cells and may correlate with clinical responses to chemotherapy in patients with colorectal cancer (CRC). Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-78 27694321-0 2016 Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Ticagrelor 105-115 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-46 28041785-2 2017 The equilibrative nucleoside transporter 1 (ENT1) terminates the action of adenosine by removal from the extracellular environment. Adenosine 75-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-42 28041785-2 2017 The equilibrative nucleoside transporter 1 (ENT1) terminates the action of adenosine by removal from the extracellular environment. Adenosine 75-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 28041785-3 2017 Therefore, it is proposed that inhibition of ENT1 in respiratory disease patients leads to increased adenosine concentrations, triggering bronchospasm and dyspnoea. Adenosine 101-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-49 28041785-6 2017 For each patient population, the relationship between in vitro ENT1 [3H]-NBTI binding affinity (Ki) and [3H]-adenosine uptake (IC50) to the incidence of: (1) bronchospasm/severe dyspnoea; (2) tolerated dyspnoea and; (3) no adverse effects, was evaluated. 3h]-nbti 69-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-67 28041785-6 2017 For each patient population, the relationship between in vitro ENT1 [3H]-NBTI binding affinity (Ki) and [3H]-adenosine uptake (IC50) to the incidence of: (1) bronchospasm/severe dyspnoea; (2) tolerated dyspnoea and; (3) no adverse effects, was evaluated. Tritium 69-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-67 28207300-2 2017 The equilibrative nucleoside transporter-1 codified by SLC29A1 gene has been associated with ribavirin uptake into hepatocytes and erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-62 28207300-3 2017 rs760370A>G single nucleotide polymorphism (SNP) at the SLC29A1 gene may have a role in ribavirin-based regimen treatment response. Ribavirin 91-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-66 27694321-4 2016 This additional effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors. Ticagrelor 26-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-158 27694321-4 2016 This additional effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors. Ticagrelor 26-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 160-164 27694321-4 2016 This additional effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors. Ticagrelor 94-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-158 27694321-4 2016 This additional effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors. Ticagrelor 94-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 160-164 27694321-4 2016 This additional effect of ticagrelor beyond P2Y12R antagonism was in part as a consequence of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to accumulation of extracellular adenosine and activation of Gs-coupled adenosine A2A receptors. Adenosine 221-230 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 160-164 27694321-11 2016 In summary, our studies describe 2 novel modes of action of ticagrelor, inhibition of platelet ENT1 and inverse agonism at the P2Y12R that contribute to its effective inhibition of platelet activation. Ticagrelor 60-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 27667754-7 2016 Secondly, enhanced uptake and cytotoxicity of Ara-CTP-dendrimers complexes toward 1301 cells with blocked human equilibrative nucleoside transporter - hENT1 suggested that this combination might be a versatile candidate for chemotherapy against resistant acute lymphoblastic leukemia cells with lower expression of hENT1. ara-ctp 46-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-156 27906634-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. Nucleosides 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 27906634-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. Nucleosides 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27906634-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) is a major route of entry of nucleosides and nucleoside analog drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27906634-3 2016 Immunofluorescence microscopy and fluorescence-activated cell sorting suggested that cytidine pre-treatment (40 muM, 6 h) promotes hENT1 internalization in a way that does not affect either hENT1-mediated nucleoside uptake or gemcitabine-induced cytotoxicity. Cytidine 85-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 131-136 27667754-7 2016 Secondly, enhanced uptake and cytotoxicity of Ara-CTP-dendrimers complexes toward 1301 cells with blocked human equilibrative nucleoside transporter - hENT1 suggested that this combination might be a versatile candidate for chemotherapy against resistant acute lymphoblastic leukemia cells with lower expression of hENT1. ara-ctp 46-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 315-320 27245475-10 2016 CONCLUSIONS: Because hENT1 and OAT2 are crucial for the uptake of gemcitabine and 5-fluorouracil, respectively, our results suggest that patients with AFP-producing GC could potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy. gemcitabine 66-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-26 27388143-5 2016 In the present study, we investigated the novel compound 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) as an inhibitor of ENT1 and ENT2. 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine 57-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 180-184 27388143-8 2016 Kinetic studies revealed that FPMINT reduced Vmax of [3H]uridine transport in ENT1 and ENT2 without affecting KM. [3h]uridine 53-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-82 27604902-2 2016 Although low expression of the nucleoside transporters hENT1 and hCNT3 that mediate cellular uptake of gemcitabine has been linked to gemcitabine resistance, the mechanisms regulating their expression in the PDAC tumor microenvironment are largely unknown. gemcitabine 103-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-60 27604902-2 2016 Although low expression of the nucleoside transporters hENT1 and hCNT3 that mediate cellular uptake of gemcitabine has been linked to gemcitabine resistance, the mechanisms regulating their expression in the PDAC tumor microenvironment are largely unknown. gemcitabine 134-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-60 27723310-1 2016 Total syntheses of ent-penicillones A (ent-1) and B (ent-2) from 3,5-dimethylcatechol (3) were accomplished in 10 and 9 synthetic steps, respectively. ent-penicillones 19-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-51 27723310-1 2016 Total syntheses of ent-penicillones A (ent-1) and B (ent-2) from 3,5-dimethylcatechol (3) were accomplished in 10 and 9 synthetic steps, respectively. 3,5-dimethylcatechol 65-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-51 27245475-10 2016 CONCLUSIONS: Because hENT1 and OAT2 are crucial for the uptake of gemcitabine and 5-fluorouracil, respectively, our results suggest that patients with AFP-producing GC could potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy. Fluorouracil 82-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-26 27245475-10 2016 CONCLUSIONS: Because hENT1 and OAT2 are crucial for the uptake of gemcitabine and 5-fluorouracil, respectively, our results suggest that patients with AFP-producing GC could potentially benefit from gemcitabine/fluoropyrimidine combination chemotherapy. gemcitabine 199-210 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-26 27432881-9 2016 In experiments with mutant hENT1, we showed for the first time interaction of Met(33) (involved in dipyridamole binding) with BCR-ABL inhibitors and reduced interaction with M33A mutant hENT1. Dipyridamole 99-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-32 26742940-0 2016 Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. folfirinox 19-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-87 26742940-1 2016 PURPOSE: hENT1 is a transmembrane protein which acts as a nucleoside transporter and is the main mediator of Gemcitabine (GEM) uptake into human cells. gemcitabine 109-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-14 26742940-1 2016 PURPOSE: hENT1 is a transmembrane protein which acts as a nucleoside transporter and is the main mediator of Gemcitabine (GEM) uptake into human cells. gemcitabine 122-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-14 26742940-7 2016 RESULTS: The survival analysis, carried out on 70 patients regardless of hENT1 expression, showed a statistically longer OS and PFS in the group treated with FOLFIRINOX compared to GEM. folfirinox 158-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 73-78 26742940-9 2016 GEM-treated hENT1 positive patients showed a statistically significant improvement both of OS (8 vs 2 months; p = 0.0012) and PFS (5 vs 1 months; p = 0.0004) in comparison to GEM-treated hENT1 negative patients. gemcitabine 0-3 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 26742940-9 2016 GEM-treated hENT1 positive patients showed a statistically significant improvement both of OS (8 vs 2 months; p = 0.0012) and PFS (5 vs 1 months; p = 0.0004) in comparison to GEM-treated hENT1 negative patients. gemcitabine 0-3 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-192 26742940-9 2016 GEM-treated hENT1 positive patients showed a statistically significant improvement both of OS (8 vs 2 months; p = 0.0012) and PFS (5 vs 1 months; p = 0.0004) in comparison to GEM-treated hENT1 negative patients. gemcitabine 175-178 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-192 27432881-4 2016 Imatinib inhibited hCNT2 with an IC50 value of 2.3 mum Ponatinib inhibited all five hNTs with the greatest effect seen for hENT1 (IC50 value, 9 mum). Imatinib Mesylate 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 27480168-0 2016 N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. Nitrogen 0-1 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-84 27432881-4 2016 Imatinib inhibited hCNT2 with an IC50 value of 2.3 mum Ponatinib inhibited all five hNTs with the greatest effect seen for hENT1 (IC50 value, 9 mum). ponatinib 55-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 27432881-6 2016 Studies in yeast with mutants at two amino acid residues of hENT1 (L442I, L442T, M33A, M33A/L442I) previously shown to be involved in uridine and dipyridamole binding, suggested that BCR-ABL TKIs interacted with Met(33) (TM1) and Leu(442) (TM11) residues of hENT1. Uridine 134-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 27432881-6 2016 Studies in yeast with mutants at two amino acid residues of hENT1 (L442I, L442T, M33A, M33A/L442I) previously shown to be involved in uridine and dipyridamole binding, suggested that BCR-ABL TKIs interacted with Met(33) (TM1) and Leu(442) (TM11) residues of hENT1. Uridine 134-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 258-263 27432881-6 2016 Studies in yeast with mutants at two amino acid residues of hENT1 (L442I, L442T, M33A, M33A/L442I) previously shown to be involved in uridine and dipyridamole binding, suggested that BCR-ABL TKIs interacted with Met(33) (TM1) and Leu(442) (TM11) residues of hENT1. Dipyridamole 146-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 27432881-6 2016 Studies in yeast with mutants at two amino acid residues of hENT1 (L442I, L442T, M33A, M33A/L442I) previously shown to be involved in uridine and dipyridamole binding, suggested that BCR-ABL TKIs interacted with Met(33) (TM1) and Leu(442) (TM11) residues of hENT1. Leucine 230-233 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 27422302-1 2016 PURPOSE: The solute carrier family 29 (equilibrative nucleoside transporter), member 1 (SLC29A1) is known to be involved in the transportation and resistance of the nucleoside analog cytosine arabinoside (AraC), one of the most effective drugs in the treatment of acute myeloid leukemia (AML). Nucleosides 53-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 27422302-1 2016 PURPOSE: The solute carrier family 29 (equilibrative nucleoside transporter), member 1 (SLC29A1) is known to be involved in the transportation and resistance of the nucleoside analog cytosine arabinoside (AraC), one of the most effective drugs in the treatment of acute myeloid leukemia (AML). Cytarabine 183-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 27422302-1 2016 PURPOSE: The solute carrier family 29 (equilibrative nucleoside transporter), member 1 (SLC29A1) is known to be involved in the transportation and resistance of the nucleoside analog cytosine arabinoside (AraC), one of the most effective drugs in the treatment of acute myeloid leukemia (AML). Cytarabine 205-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 27480168-0 2016 N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. Nitrogen 0-1 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 27480168-0 2016 N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. CHEMBL4096095 26-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-84 27480168-0 2016 N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function. CHEMBL4096095 26-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 27480168-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleosides and nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-cancer, anti-parasitic and anti-viral drugs. Nucleosides 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 27480168-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleosides and nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-cancer, anti-parasitic and anti-viral drugs. Nucleosides 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27480168-1 2016 Human equilibrative nucleoside transporter 1 (hENT1) transports nucleosides and nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-cancer, anti-parasitic and anti-viral drugs. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27480168-2 2016 Previous work, and in silico prediction, suggest that hENT1 is glycosylated at Asn(48) in the first extracellular loop of the protein and that glycosylation plays a role in correct localization and function of hENT1. Asparagine 79-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 27480168-5 2016 Substitution of N48 prevents hENT1 glycosylation, confirming a single N-linked glycosylation site. Nitrogen 16-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-34 27480168-6 2016 N48Q-hENT1 protein is found at the plasma membrane in HEK293 cells but at lower levels compared with wt hENT1 based on S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding analysis (wt 3xFLAG-ENT1 Bmax, 41.5+-2.9 pmol/mg protein; N48Q-3xFLAG-ENT1 Bmax, 13.5+-0.45 pmol/mg protein) and immunofluorescence microscopy. Sulfur 119-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 27480168-6 2016 N48Q-hENT1 protein is found at the plasma membrane in HEK293 cells but at lower levels compared with wt hENT1 based on S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding analysis (wt 3xFLAG-ENT1 Bmax, 41.5+-2.9 pmol/mg protein; N48Q-3xFLAG-ENT1 Bmax, 13.5+-0.45 pmol/mg protein) and immunofluorescence microscopy. Sulfur 119-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-10 27480168-6 2016 N48Q-hENT1 protein is found at the plasma membrane in HEK293 cells but at lower levels compared with wt hENT1 based on S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding analysis (wt 3xFLAG-ENT1 Bmax, 41.5+-2.9 pmol/mg protein; N48Q-3xFLAG-ENT1 Bmax, 13.5+-0.45 pmol/mg protein) and immunofluorescence microscopy. 4-nitrobenzylthioinosine 121-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 27480168-6 2016 N48Q-hENT1 protein is found at the plasma membrane in HEK293 cells but at lower levels compared with wt hENT1 based on S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding analysis (wt 3xFLAG-ENT1 Bmax, 41.5+-2.9 pmol/mg protein; N48Q-3xFLAG-ENT1 Bmax, 13.5+-0.45 pmol/mg protein) and immunofluorescence microscopy. 4-nitrobenzylthioinosine 121-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-10 27480168-6 2016 N48Q-hENT1 protein is found at the plasma membrane in HEK293 cells but at lower levels compared with wt hENT1 based on S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding analysis (wt 3xFLAG-ENT1 Bmax, 41.5+-2.9 pmol/mg protein; N48Q-3xFLAG-ENT1 Bmax, 13.5+-0.45 pmol/mg protein) and immunofluorescence microscopy. 4-nitrobenzylthioinosine 152-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 27480168-6 2016 N48Q-hENT1 protein is found at the plasma membrane in HEK293 cells but at lower levels compared with wt hENT1 based on S-(4-nitrobenzyl)-6-thioinosine (NBTI) binding analysis (wt 3xFLAG-ENT1 Bmax, 41.5+-2.9 pmol/mg protein; N48Q-3xFLAG-ENT1 Bmax, 13.5+-0.45 pmol/mg protein) and immunofluorescence microscopy. 4-nitrobenzylthioinosine 152-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-10 27009875-3 2016 Here we report the identification of the calcium signaling transducer calmodulin (CaM) as an ENT1-interacting protein, via a conserved classic 1-5-10 motif in ENT1. Calcium 41-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-97 27391351-3 2016 Cytarabine is transported into cells by Human Equilibrative Nucleoside Transporter-1 (hENT1, SLC29A1), but the mechanisms that regulate hENT1 in acute leukemia have been scarcely studied.We explored the expression and functional link between FLT3 and main cytarabine transporters in 50 pediatric patients diagnosed with acute lymphoblastic leukemia and MLL rearrangement (ALL-MLL+) and other subtypes of leukemia, and in leukemia cell lines.A significant positive correlation was found between FLT3 and hENT1 expression in patients. Cytarabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-84 27391351-3 2016 Cytarabine is transported into cells by Human Equilibrative Nucleoside Transporter-1 (hENT1, SLC29A1), but the mechanisms that regulate hENT1 in acute leukemia have been scarcely studied.We explored the expression and functional link between FLT3 and main cytarabine transporters in 50 pediatric patients diagnosed with acute lymphoblastic leukemia and MLL rearrangement (ALL-MLL+) and other subtypes of leukemia, and in leukemia cell lines.A significant positive correlation was found between FLT3 and hENT1 expression in patients. Cytarabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 27391351-3 2016 Cytarabine is transported into cells by Human Equilibrative Nucleoside Transporter-1 (hENT1, SLC29A1), but the mechanisms that regulate hENT1 in acute leukemia have been scarcely studied.We explored the expression and functional link between FLT3 and main cytarabine transporters in 50 pediatric patients diagnosed with acute lymphoblastic leukemia and MLL rearrangement (ALL-MLL+) and other subtypes of leukemia, and in leukemia cell lines.A significant positive correlation was found between FLT3 and hENT1 expression in patients. Cytarabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-100 27391351-4 2016 Cytarabine uptake into cells was mediated mainly by hENT1, hENT2 and hCNT1. Cytarabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 27391351-5 2016 hENT1-mediated uptake of cytarabine was transiently abolished by the FLT3 inhibitor PKC412, and this effect was associated with decreased hENT1 mRNA and protein levels. Cytarabine 25-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 27391351-6 2016 Noticeably, the cytotoxicity of cytarabine was lower when cells were first exposed to FLT3 inhibitors (PKC412 or AC220), probably due to decreased hENT1 activity, but we observed a higher cytotoxic effect if FLT3 inhibitors were administered after cytarabine.FLT3 regulates hENT1 activity and thereby affects cytarabine cytotoxicity. Cytarabine 32-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-152 27391351-6 2016 Noticeably, the cytotoxicity of cytarabine was lower when cells were first exposed to FLT3 inhibitors (PKC412 or AC220), probably due to decreased hENT1 activity, but we observed a higher cytotoxic effect if FLT3 inhibitors were administered after cytarabine.FLT3 regulates hENT1 activity and thereby affects cytarabine cytotoxicity. Cytarabine 32-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 274-279 27247050-5 2016 Among those with high HuR expression and high hENT1 expression, the disease-free survival (DFS) was significantly higher with gemcitabine than with S-1 (MST: 26.2 vs. 11.8 months, P = 0.024; 20.2 vs. 10.2 months, P = 0.029, respectively). gemcitabine 126-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 27247050-6 2016 Moreover, high HuR/hENT1 (high HuR or high hENT1) was significantly associated with better outcome for gemcitabine (HR for DFS: 0.43, P = 0.027) and low HuR/hENT1 was significantly associated with worse outcome for gemcitabine (HR for DFS: 2.24, P = 0.021). gemcitabine 103-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-24 27247050-6 2016 Moreover, high HuR/hENT1 (high HuR or high hENT1) was significantly associated with better outcome for gemcitabine (HR for DFS: 0.43, P = 0.027) and low HuR/hENT1 was significantly associated with worse outcome for gemcitabine (HR for DFS: 2.24, P = 0.021). gemcitabine 103-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 27247050-6 2016 Moreover, high HuR/hENT1 (high HuR or high hENT1) was significantly associated with better outcome for gemcitabine (HR for DFS: 0.43, P = 0.027) and low HuR/hENT1 was significantly associated with worse outcome for gemcitabine (HR for DFS: 2.24, P = 0.021). gemcitabine 103-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 27247050-6 2016 Moreover, high HuR/hENT1 (high HuR or high hENT1) was significantly associated with better outcome for gemcitabine (HR for DFS: 0.43, P = 0.027) and low HuR/hENT1 was significantly associated with worse outcome for gemcitabine (HR for DFS: 2.24, P = 0.021). gemcitabine 215-226 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-24 27247050-6 2016 Moreover, high HuR/hENT1 (high HuR or high hENT1) was significantly associated with better outcome for gemcitabine (HR for DFS: 0.43, P = 0.027) and low HuR/hENT1 was significantly associated with worse outcome for gemcitabine (HR for DFS: 2.24, P = 0.021). gemcitabine 215-226 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 27247050-6 2016 Moreover, high HuR/hENT1 (high HuR or high hENT1) was significantly associated with better outcome for gemcitabine (HR for DFS: 0.43, P = 0.027) and low HuR/hENT1 was significantly associated with worse outcome for gemcitabine (HR for DFS: 2.24, P = 0.021). gemcitabine 215-226 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 26750805-7 2016 RBV-induced anemia was independently correlated with SLC29A1 rs760370 AA genotype (OR, 2.90; 95% CI, 1.29-6.54, P = 0.010), and the severity of IFN-induced thrombocytopenia was related to GG genotype (OR, 4.98; 95% CI, 1.27-19.61; P = 0.021); the detected effects held true for HCV-2a patients but weakened in HCV-1b patients. Ribavirin 0-3 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-60 27177126-7 2016 A pro-apoptotic effect of verapamil was observed in L3.6pl cells, but not in L3.6plGres cells, which was linked to their differential expression of P-gp and equilibrative nucleoside transporter-1 (ENT-1). Verapamil 26-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 157-195 27177126-7 2016 A pro-apoptotic effect of verapamil was observed in L3.6pl cells, but not in L3.6plGres cells, which was linked to their differential expression of P-gp and equilibrative nucleoside transporter-1 (ENT-1). Verapamil 26-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 197-202 27009875-3 2016 Here we report the identification of the calcium signaling transducer calmodulin (CaM) as an ENT1-interacting protein, via a conserved classic 1-5-10 motif in ENT1. Calcium 41-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 159-163 27009875-4 2016 Calcium-dependent human ENT1-CaM protein interactions were confirmed in human cell lines (HEK293, RT4, U-87 MG) using biochemical assays (HEK293) and the functional assays (HEK293, RT4), which confirmed modified nucleoside uptake that occurred in the presence of pharmacological manipulations of calcium levels and CaM function. Calcium 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 27009875-4 2016 Calcium-dependent human ENT1-CaM protein interactions were confirmed in human cell lines (HEK293, RT4, U-87 MG) using biochemical assays (HEK293) and the functional assays (HEK293, RT4), which confirmed modified nucleoside uptake that occurred in the presence of pharmacological manipulations of calcium levels and CaM function. Nucleosides 212-222 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 27009875-4 2016 Calcium-dependent human ENT1-CaM protein interactions were confirmed in human cell lines (HEK293, RT4, U-87 MG) using biochemical assays (HEK293) and the functional assays (HEK293, RT4), which confirmed modified nucleoside uptake that occurred in the presence of pharmacological manipulations of calcium levels and CaM function. Calcium 296-303 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-28 27009875-7 2016 These data support the existence of a previously unidentified novel receptor-dependent regulatory mechanism, whereby intracellular calcium modulates nucleoside and NA drug uptake via CaM-dependent interaction of ENT1. Calcium 131-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 212-216 27009875-7 2016 These data support the existence of a previously unidentified novel receptor-dependent regulatory mechanism, whereby intracellular calcium modulates nucleoside and NA drug uptake via CaM-dependent interaction of ENT1. Nucleosides 149-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 212-216 27009875-8 2016 These findings suggest that ENT1 is regulated via receptor-dependent calcium-linked pathways resulting in an alteration of purine flux, which may modulate purinergic signaling and influence NA drug efficacy. purine 123-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-32 26944860-0 2016 High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome. Decitabine 101-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 26784908-0 2016 Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy. gemcitabine 252-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 26266900-1 2016 AIMS: Equilibrative nucleoside transporter 1 (ENT1) is the major transporter of the chemotherapeutic drug gemcitabine, the current therapy for advanced gallbladder cancer (GBC). gemcitabine 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 26266900-1 2016 AIMS: Equilibrative nucleoside transporter 1 (ENT1) is the major transporter of the chemotherapeutic drug gemcitabine, the current therapy for advanced gallbladder cancer (GBC). gemcitabine 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-50 26266900-2 2016 ENT1 expression has been proposed as a predictive marker for gemcitabine-treated pancreatic cancer patients. gemcitabine 61-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 26266900-12 2016 Additional studies are needed to determine whether ENT1 has predictive value for gemcitabine response in GBC. gemcitabine 81-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 26944860-12 2016 HENT1 expression knockdown weakens the demethylation effect of decitabine. Decitabine 63-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 27032872-0 2016 Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. gemcitabine 118-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-69 27032872-2 2016 Human equilibrative nucleoside transporter 1 (hENT-1) is the major transporter involved in gemcitabine intracellular uptake. gemcitabine 91-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 27032872-2 2016 Human equilibrative nucleoside transporter 1 (hENT-1) is the major transporter involved in gemcitabine intracellular uptake. gemcitabine 91-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-52 27032872-9 2016 Notably, the association between DFS and membrane hENT-1 was dependent on the number of gemcitabine cycles (one to two cycles: HR 0.96, 95% CI 0.34-2.68; three to four cycles: HR 0.99, 95% CI 0.34-2.90; five to six cycles: HR 0.27, 95% CI 0.10-0.77). gemcitabine 88-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-56 27032872-10 2016 CONCLUSION: hENT-1 localization on tumor cell membrane may predict response to adjuvant gemcitabine in CC patients receiving more than four cycles of chemotherapy. gemcitabine 88-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-18 27032872-13 2016 In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. gemcitabine 68-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-138 27032872-13 2016 In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. gemcitabine 68-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 140-146 27032872-13 2016 In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. gemcitabine 182-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-138 27032872-13 2016 In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. gemcitabine 182-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 140-146 27032872-13 2016 In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. gemcitabine 182-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 322-328 27199754-11 2016 The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r < -0.79; p < 0.05). Rifampin 15-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-83 27199754-11 2016 The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r < -0.79; p < 0.05). Rifampin 15-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-220 27199754-11 2016 The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r < -0.79; p < 0.05). Rifampin 130-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-83 27199754-11 2016 The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r < -0.79; p < 0.05). Rifampin 130-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-220 26944860-2 2016 In this study, we investigated whether the expression levels of human equilibrative nucleoside transporter 1 (hENT1), hENT2, deoxycytidine kinase (DCK) and cytidine deaminase (CDA) genes could predict response to decitabine in MDS. Decitabine 213-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-108 26944860-6 2016 RESULTS: Patients responding to decitabine presented with significantly higher hENT1 expression levels than non-responders (p = 0.004). Decitabine 32-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-84 26944860-10 2016 Knockdown of hENT1 in SKM-1 cells weakened the demethylation effect on LINE1 induced by decitabine. Decitabine 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-18 26944860-11 2016 CONCLUSIONS: High expression of hENT1 appears to predict a good response to decitabine and a prolonged survival in higher-risk MDS patients treated with decitabine. Decitabine 76-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 26944860-11 2016 CONCLUSIONS: High expression of hENT1 appears to predict a good response to decitabine and a prolonged survival in higher-risk MDS patients treated with decitabine. Decitabine 153-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 26593410-0 2015 Effect of Hypoxanthine on Functional Activity of Nucleoside Transporters ENT1 and ENT2 in Caco-2 Polar Epithelial Intestinal Cells. Hypoxanthine 10-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 73-77 27119162-0 2016 Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine. Cytarabine 173-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-65 27119162-1 2016 BACKGROUND: Cytarabine (Ara-C) is the primary drug in different treatment schemas for acute myeloid leukemia (AML) and requires the human equilibrative nucleoside transporter (hENT1) to enter cells. Cytarabine 12-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 176-181 27119162-1 2016 BACKGROUND: Cytarabine (Ara-C) is the primary drug in different treatment schemas for acute myeloid leukemia (AML) and requires the human equilibrative nucleoside transporter (hENT1) to enter cells. Cytarabine 24-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 176-181 26688730-2 2015 In beta-thalassemia major, where hemoglobin instability imposes oxidative stress, erythrocytes show reduced hENT1 nucleoside transporter expression and decreased nucleoside uptake. Nucleosides 114-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-113 26162242-1 2015 Human equilibrative nucleoside transporter-1 (hENT1) is the major plasma membrane transporter involved in transportation of natural nucleosides as well as nucleoside analog drugs, used in anti-cancer and anti-viral therapies. Nucleosides 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 26445094-3 2015 Increasing translational data on the predictive value of hENT1 for determining gemcitabine efficacy suggest that a non-gemcitabine-based regimen is favored in about 60 % of patients with PAC due to high resistance of PAC to this cytotoxic drug. gemcitabine 79-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 26162242-1 2015 Human equilibrative nucleoside transporter-1 (hENT1) is the major plasma membrane transporter involved in transportation of natural nucleosides as well as nucleoside analog drugs, used in anti-cancer and anti-viral therapies. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 26162242-5 2015 hENT1 expressed by Sf9 cells is functionally active as demonstrated by saturation binding with a Kd of 1.2+-0.2nM and Bmax of 110+-5pmol/mg for [(3)H]nitrobenzylmercaptopurine ribonucleoside ([(3)H]NBMPR). Ribonucleosides 176-190 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 26162242-6 2015 We also demonstrate purification of hENT1 using FLAG antibody affinity resin in lauryl maltose neopentyl glycol detergent with a Kd of 4.3+-0.7nM. Lauryl Maltose Neopentyl Glycol 80-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-41 25869606-7 2015 hENT1-adenosine maximal transport activity was reduced (P=0.041), but the expression was increased (P=0.001) in HUVECs from this group. Adenosine 6-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 26156883-9 2015 Ticagrelor is a more potent P2Y12 inhibitor than clopidogrel and also inhibits cellular adenosine uptake via equilibrative nucleoside transporter (ENT) 1, whereas clopidogrel does not. Ticagrelor 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-153 26156883-9 2015 Ticagrelor is a more potent P2Y12 inhibitor than clopidogrel and also inhibits cellular adenosine uptake via equilibrative nucleoside transporter (ENT) 1, whereas clopidogrel does not. Adenosine 88-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-153 26049689-1 2015 BACKGROUND: High expression of human equilibrative nucleoside transporter 1 (hENT1) is considered to predict survival in patients treated with adjuvant gemcitabine for pancreatic cancer. gemcitabine 152-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-75 26049689-1 2015 BACKGROUND: High expression of human equilibrative nucleoside transporter 1 (hENT1) is considered to predict survival in patients treated with adjuvant gemcitabine for pancreatic cancer. gemcitabine 152-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 26037416-0 2015 Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2. gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-149 25869606-8 2015 CPZ increased hENT1-adenosine transport (P=0.040) and hENT1 plasma membrane accumulation only in cells from pGWG. Adenosine 20-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 26176887-7 2015 RESULTS: Fasted pancreatic cancer cells showed increased levels of equilibrative nucleoside transporter (hENT1), the transporter of gemcitabine across the cell membrane, and decreased ribonucleotide reductase M1 (RRM1) levels as compared to those cultured in standard medium. gemcitabine 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-110 25998688-5 2015 Using reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR and western blot analyses, gemcitabine-resistant cells showed upregulation of RRM1 and downregulation of hENT1 and dCK. gemcitabine 105-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 183-188 25672581-7 2015 Immunoblot analysis of signaling molecules reported to indicate gemcitabine sensitivity showed higher expression of PAK4 and lower expression of human equilibrative nucleoside transporter 1 (hENT1), a well-known predictive marker for gemcitabine activity, in the resistant cell lines. gemcitabine 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-189 25672581-7 2015 Immunoblot analysis of signaling molecules reported to indicate gemcitabine sensitivity showed higher expression of PAK4 and lower expression of human equilibrative nucleoside transporter 1 (hENT1), a well-known predictive marker for gemcitabine activity, in the resistant cell lines. gemcitabine 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-196 25672581-7 2015 Immunoblot analysis of signaling molecules reported to indicate gemcitabine sensitivity showed higher expression of PAK4 and lower expression of human equilibrative nucleoside transporter 1 (hENT1), a well-known predictive marker for gemcitabine activity, in the resistant cell lines. gemcitabine 234-245 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-196 26031529-4 2015 The proliferation ratio of SKM-1 cells treated with different concentrations (0.5, 1, 5 mmol/L) of DAC for 24, 48 and 72 h was detected by CCK-8 method after hENT1 silencing. Decitabine 99-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 158-163 26111057-5 2015 In analyzing the molecular mechanisms of zidovudine effects, we found that the epithelial-to-mesenchymal transition (EMT)-like phenotype and downregulation of human equilibrative nucleoside transporter 1 (hENT1) are essential for the acquisition of gemcitabine resistance, and zidovudine restored these changes. Zidovudine 41-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-203 26111057-5 2015 In analyzing the molecular mechanisms of zidovudine effects, we found that the epithelial-to-mesenchymal transition (EMT)-like phenotype and downregulation of human equilibrative nucleoside transporter 1 (hENT1) are essential for the acquisition of gemcitabine resistance, and zidovudine restored these changes. Zidovudine 41-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 205-210 26111057-5 2015 In analyzing the molecular mechanisms of zidovudine effects, we found that the epithelial-to-mesenchymal transition (EMT)-like phenotype and downregulation of human equilibrative nucleoside transporter 1 (hENT1) are essential for the acquisition of gemcitabine resistance, and zidovudine restored these changes. gemcitabine 249-260 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-203 26111057-5 2015 In analyzing the molecular mechanisms of zidovudine effects, we found that the epithelial-to-mesenchymal transition (EMT)-like phenotype and downregulation of human equilibrative nucleoside transporter 1 (hENT1) are essential for the acquisition of gemcitabine resistance, and zidovudine restored these changes. gemcitabine 249-260 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 205-210 26111057-5 2015 In analyzing the molecular mechanisms of zidovudine effects, we found that the epithelial-to-mesenchymal transition (EMT)-like phenotype and downregulation of human equilibrative nucleoside transporter 1 (hENT1) are essential for the acquisition of gemcitabine resistance, and zidovudine restored these changes. Zidovudine 277-287 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-203 26111057-5 2015 In analyzing the molecular mechanisms of zidovudine effects, we found that the epithelial-to-mesenchymal transition (EMT)-like phenotype and downregulation of human equilibrative nucleoside transporter 1 (hENT1) are essential for the acquisition of gemcitabine resistance, and zidovudine restored these changes. Zidovudine 277-287 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 205-210 26111057-7 2015 Moreover, our in vivo study demonstrated that co-administration of zidovudine and gemcitabine strongly suppressed the formation of tumors by gemcitabine-resistant pancreatic cancer and prevented gemcitabine-sensitive pancreatic tumors from acquiring gemcitabine-resistant properties, inducing an EMT-like phenotype and downregulating hENT1 expression. Zidovudine 67-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 334-339 26111057-7 2015 Moreover, our in vivo study demonstrated that co-administration of zidovudine and gemcitabine strongly suppressed the formation of tumors by gemcitabine-resistant pancreatic cancer and prevented gemcitabine-sensitive pancreatic tumors from acquiring gemcitabine-resistant properties, inducing an EMT-like phenotype and downregulating hENT1 expression. gemcitabine 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 334-339 25896650-3 2015 The resulting p.Glu391Lys variation in the last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its ability to transport nucleosides and nucleoside analog drugs. Nucleosides 188-199 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-112 25896650-3 2015 The resulting p.Glu391Lys variation in the last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its ability to transport nucleosides and nucleoside analog drugs. Nucleosides 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 25896650-3 2015 The resulting p.Glu391Lys variation in the last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is known not to alter its ability to transport nucleosides and nucleoside analog drugs. Nucleosides 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 132-139 26070128-4 2015 By reducing the uptake of extracellular adenosine, ENT1 inhibitors potentiate the cardioprotective effect of endogenous adenosine. Adenosine 40-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 26070128-4 2015 By reducing the uptake of extracellular adenosine, ENT1 inhibitors potentiate the cardioprotective effect of endogenous adenosine. Adenosine 120-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 26070128-7 2015 ENT1 inhibitors may also affect the cellular transport, and hence the efficacy, of anticancer and antiviral nucleoside analogs used in chemotherapy. Nucleosides 108-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 25725289-12 2015 This signaling pathway represents a feedback loop whereby adenosine receptor signaling can lead to increased adenosine reuptake into cells via hENT1. Adenosine 58-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-148 25725289-0 2015 Adenosine A1 receptor activation modulates human equilibrative nucleoside transporter 1 (hENT1) activity via PKC-mediated phosphorylation of serine-281. Serine 141-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-87 25725289-0 2015 Adenosine A1 receptor activation modulates human equilibrative nucleoside transporter 1 (hENT1) activity via PKC-mediated phosphorylation of serine-281. Serine 141-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-94 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Nucleosides 128-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-46 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Nucleosides 128-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Adenosine 148-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-46 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Adenosine 148-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 25725289-1 2015 Equilibrative nucleoside transporter subtype 1 (ENT1) is critical for the regulation of the biological activities of endogenous nucleosides such as adenosine, and for the cellular uptake of chemotherapeutic nucleoside analogs. Nucleosides 14-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 25725289-5 2015 Using [(3)H]nitrobenzylthioinosine (NBMPR) binding and [(3)H]2-chloroadenosine uptake analyses, it was determined that S281A-hENT1 exhibited functional characteristics similar to WT-hENT1. [(3)h]2-chloroadenosine 55-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-130 25725289-6 2015 Direct activation of PKC with PMA or indirect activation with the adenosine A1 receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) led to significant increases in [(3)H]NBMPR binding and [(3)H]2-chloroadenosine uptake in WT-hENT1 transfected cells. 2-chloro-N(6)cyclopentyladenosine 96-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 231-236 25725289-6 2015 Direct activation of PKC with PMA or indirect activation with the adenosine A1 receptor agonist 2-chloro-N(6)-cyclopentyladenosine (CCPA) led to significant increases in [(3)H]NBMPR binding and [(3)H]2-chloroadenosine uptake in WT-hENT1 transfected cells. 2-chloro-N(6)cyclopentyladenosine 132-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 231-236 25725289-10 2015 Immunocytochemical analysis and cell surface biotinylation assays showed that activation of PKC with PMA, but not CCPA, led to a significant increase in the plasma membrane localization of hENT1. Tetradecanoylphorbol Acetate 101-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 189-194 26031529-0 2015 [Functional study of hENT1 on SKM-1 cell resistance to decitabine]. Decitabine 55-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-26 26031529-8 2015 Compared with control, the proliferation inhibition rate of hENT1 silenced group was significantly decreased by different concentrations of DAC (0.5, 1, 5 mumol/L) treatment for 24, 48, 72 h (P<0.05), which was (49.41+-4.02)% and (33.03+-2.47)%, respectively (P=0.007) at 5 mumol/L DAC treatment for 72 h in hENT1 silenced group and the control group. Decitabine 140-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 26031529-8 2015 Compared with control, the proliferation inhibition rate of hENT1 silenced group was significantly decreased by different concentrations of DAC (0.5, 1, 5 mumol/L) treatment for 24, 48, 72 h (P<0.05), which was (49.41+-4.02)% and (33.03+-2.47)%, respectively (P=0.007) at 5 mumol/L DAC treatment for 72 h in hENT1 silenced group and the control group. Decitabine 140-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 311-316 26031529-8 2015 Compared with control, the proliferation inhibition rate of hENT1 silenced group was significantly decreased by different concentrations of DAC (0.5, 1, 5 mumol/L) treatment for 24, 48, 72 h (P<0.05), which was (49.41+-4.02)% and (33.03+-2.47)%, respectively (P=0.007) at 5 mumol/L DAC treatment for 72 h in hENT1 silenced group and the control group. Decitabine 285-288 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 25661337-1 2015 Ribavirin is phosphorylated by adenosine kinase 1 (AK1) and cytosolic 5"-nucleotidase 2 and it is transported into cells by concentrative nucleoside transporters (CNT) 2/3, coded by SLC28A2/3 genes, and equilibrative nucleoside transporters (ENT) 1/2, coded by SLC29A1/2 genes. Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 261-268 25583751-0 2015 SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir. telaprevir 123-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-7 25583751-1 2015 OBJECTIVES: The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 94-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-54 25583751-1 2015 OBJECTIVES: The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 94-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 64-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. telaprevir 139-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. telaprevir 139-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 25583751-2 2015 Polymorphisms at the SLC29A1 gene, encoding ENT1, may influence ribavirin-associated anaemia, which is observed at a higher incidence with telaprevir in combination with pegylated-IFNalpha and ribavirin than with pegylated-IFNalpha and ribavirin alone. Ribavirin 193-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25583751-3 2015 In this study, we investigated the role of the rs760370 SLC29A1 variant in ribavirin-induced anaemia in chronic hepatitis C patients treated with telaprevir-based triple therapy. Ribavirin 75-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-63 25583751-7 2015 In multivariate analysis, older age (P=0.03), lower baseline Hb concentration (P=0.02) and SLC29A1 rs760370 GG (P=0.02) were associated with the development of severe anaemia during treatment, whereas no association was found with ITPA SNPs in our population receiving telaprevir-based therapy. telaprevir 269-279 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-98 25583751-8 2015 CONCLUSIONS: In patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin. telaprevir 60-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 112-119 25583751-8 2015 CONCLUSIONS: In patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin. Ribavirin 152-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 112-119 25583751-8 2015 CONCLUSIONS: In patients with chronic hepatitis C receiving telaprevir-based therapy, SNP rs760370A>G at the SLC29A1 gene influences the severity of ribavirin-induced anaemia, possibly mirroring the erythrocyte uptake of ribavirin. Ribavirin 224-233 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 112-119 25713533-5 2015 SLC29 genes encode four members, being hENT1 and hENT2 the only two which are unequivocally implicated in the translocation of nucleosides and nucleobases (the latter mostly via hENT2) at the cell plasma membrane. Nucleosides 127-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 25713533-5 2015 SLC29 genes encode four members, being hENT1 and hENT2 the only two which are unequivocally implicated in the translocation of nucleosides and nucleobases (the latter mostly via hENT2) at the cell plasma membrane. nucleobases 143-154 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 25898165-4 2015 Here we show that the membrane-binding domains of two conserved clathrin adaptors, Sla2 and Ent1, co-assemble in a PI(4,5)P2-dependent manner to form organized lattices on membranes. pi(4,5)p2 115-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 92-96 25713072-8 2015 siRNA knockdown experiments demonstrate that the nucleoside transporter, hENT1, plays a key role in the cellular entry of Ir(III)-PPY nucleoside. Nucleosides 49-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 73-78 25661339-3 2015 The aim of this retrospective study was the evaluation of the influence of some single nucleotide polymorphisms (SNPs) of genes (ABCB1, SLC28A2/3, SLC29A1) involved in TLV and RBV transport and their correlation with plasma TLV drug exposure at 1 month of therapy. Ribavirin 176-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-154 25011570-3 2015 The CNT1- and ENT1-mediated ribavirin uptake showed concentration dependency with the following kinetics parameters: Km 26.3 muM and Vmax 426.2 fmol/min/oocyte for CNT1; Km 70.5 muM and Vmax 134.3 fmol/min/oocyte for ENT1. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 217-221 25298108-1 2015 AIMS: The human equilibrative nucleoside transporter 1 (hENT1) expression level in pancreatic ductal adenocarcinoma (PDAC) may predict survival in gemcitabine-treated patients after resection. gemcitabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-54 25298108-1 2015 AIMS: The human equilibrative nucleoside transporter 1 (hENT1) expression level in pancreatic ductal adenocarcinoma (PDAC) may predict survival in gemcitabine-treated patients after resection. gemcitabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-61 25298108-8 2015 The rate of "hENT1 high" cases was lower with SP120 (set 1, 7% versus 48%; set 2, 11% versus 38%). 3-ALLYL-4-ETHOXYBENZALDEHYDE 46-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-18 25298108-13 2015 Further prospective studies seem to be warranted before hENT1 testing for PDAC is used in daily practise. pdac 74-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-61 25533931-0 2015 The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome. Decitabine 37-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-9 25533931-2 2015 To determine the mechanisms underlying decitabine resistance, we measured the mRNA expression of metabolism (hENT1, DCK, CDA) and apoptosis (BCL2L10) genes and found that the hENT1 mRNA level was significantly higher in response compared with non-response patients (P=0.004). Decitabine 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-114 25533931-2 2015 To determine the mechanisms underlying decitabine resistance, we measured the mRNA expression of metabolism (hENT1, DCK, CDA) and apoptosis (BCL2L10) genes and found that the hENT1 mRNA level was significantly higher in response compared with non-response patients (P=0.004). Decitabine 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-180 25533931-4 2015 These findings indicate that the decitabine metabolic pathway affects its therapeutic effects, lower hENT1 expression may induce primary resistance and down-regulated DCK expression may be related to secondary resistance. Decitabine 33-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 25011570-6 2015 Real-time polymerase chain reaction analysis of CNT1 and ENT1 expressions in the hepatocytes showed that ENT1 mRNA expression was closely correlated with ribavirin uptake (R = 0.95, P = 0.003) while CNT1 was not. Ribavirin 154-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-109 25011570-7 2015 The findings indicated that ENT1 was the major transporter controlling the hepatic uptake of ribavirin. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-32 25011570-0 2015 Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes. Ribavirin 33-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-29 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 76-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 76-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 110-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 25011570-2 2015 The initial studies in oocytes expressing CNT1 and ENT1 showed increases in ribavirin uptake, indicating that ribavirin was a substrate for both CNT1 and ENT1. Ribavirin 110-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 26235575-7 2015 The uptake of these agents was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), an inhibitor of equilibrative nucleoside transporters (ENTs), and was also decreased in cells treated with ENT1 small interfering RNA. 4-nitrobenzylthioinosine 44-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 192-196 25011570-3 2015 The CNT1- and ENT1-mediated ribavirin uptake showed concentration dependency with the following kinetics parameters: Km 26.3 muM and Vmax 426.2 fmol/min/oocyte for CNT1; Km 70.5 muM and Vmax 134.3 fmol/min/oocyte for ENT1. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-18 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 74-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 74-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 25011570-5 2015 Estimation of the contributions of CNT1 and ENT1 to the hepatic uptake of ribavirin by using a relative activity factor method indicated that the relative contribution of ENT1 to the ribavirin uptake was 82.8 +- 3.9%. Ribavirin 183-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-175 26235575-7 2015 The uptake of these agents was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), an inhibitor of equilibrative nucleoside transporters (ENTs), and was also decreased in cells treated with ENT1 small interfering RNA. 4-nitrobenzylthioinosine 77-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 192-196 25351985-1 2015 Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-73 25351985-1 2015 Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 25351985-1 2015 Reduced adenosine uptake via human equilibrative nucleoside transporter 1 (hENT1) in human umbilical vein endothelial cells (HUVECs) from gestational diabetes mellitus (GDM) is reversed by insulin by restoring hENT1 expression. Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 25246379-0 2014 Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients. gemcitabine 60-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 25339775-4 2015 We found that HCV replication in persistently infected cultures induces an autophagy response that impairs RBV uptake by preventing the expression of equilibrative nucleoside transporter 1 (ENT1). Ribavirin 107-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 190-194 25339775-6 2015 In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity. Hydroxychloroquine 38-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 25339775-6 2015 In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity. Hydroxychloroquine 58-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 25339775-6 2015 In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity. 3-methyladenine 64-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 25339775-6 2015 In contrast, the autophagy inhibitors hydroxychloroquine (HCQ), 3-methyladenine (3-MA), and bafilomycin A1 (BafA1) prevented ENT1 degradation and enhanced RBV antiviral activity. 3-methyladenine 81-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 25519698-4 2015 Axitinib, pazopanib, and sunitinib inhibited hENT1 at low micromolar concentrations. Axitinib 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 25519698-4 2015 Axitinib, pazopanib, and sunitinib inhibited hENT1 at low micromolar concentrations. pazopanib 10-19 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 25519698-4 2015 Axitinib, pazopanib, and sunitinib inhibited hENT1 at low micromolar concentrations. Sunitinib 25-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 25519698-6 2015 Pazopanib > axitinib >= sunitinib inhibited hENT1 with IC50 values of 2, 7, and 29 mumol/L, respectively, leading to reduced intracellular gemcitabine and FLT accumulation. pazopanib 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 25519698-6 2015 Pazopanib > axitinib >= sunitinib inhibited hENT1 with IC50 values of 2, 7, and 29 mumol/L, respectively, leading to reduced intracellular gemcitabine and FLT accumulation. Axitinib 15-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 25519698-6 2015 Pazopanib > axitinib >= sunitinib inhibited hENT1 with IC50 values of 2, 7, and 29 mumol/L, respectively, leading to reduced intracellular gemcitabine and FLT accumulation. Sunitinib 30-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 25519698-6 2015 Pazopanib > axitinib >= sunitinib inhibited hENT1 with IC50 values of 2, 7, and 29 mumol/L, respectively, leading to reduced intracellular gemcitabine and FLT accumulation. gemcitabine 145-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 25519698-9 2015 In clinical settings, TKI inhibitor concentrations in tumor tissues are sufficient to inhibit hENT1 activity, thereby reducing nucleoside chemotherapy drug levels in cancer cells and reducing efficacy in combination schedules. Nucleosides 127-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-99 26279293-0 2015 ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Ribavirin 50-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-16 26279293-5 2015 Here, we investigated haemoglobin levels and the best-known functional SNPs in ITPA and SLC29A1 genes in 22 patients treated with triple therapy with BOC/Peg-IFN/RBV. N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 150-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 26279293-5 2015 Here, we investigated haemoglobin levels and the best-known functional SNPs in ITPA and SLC29A1 genes in 22 patients treated with triple therapy with BOC/Peg-IFN/RBV. peg-ifn 154-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 26279293-5 2015 Here, we investigated haemoglobin levels and the best-known functional SNPs in ITPA and SLC29A1 genes in 22 patients treated with triple therapy with BOC/Peg-IFN/RBV. Ribavirin 162-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 26279293-6 2015 The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in RBV dosing during hepatitis C virus therapy with DAAs. Ribavirin 110-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-49 25454272-0 2014 Dilazep analogues for the study of equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2). Dilazep 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 25454272-4 2014 Dilazep and analogues with minor structural changes are potent and selective ENT1 inhibitors. Dilazep 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-81 25664003-3 2014 Several molecules involved in gemcitabine metabolism, including human equilibrative nucleoside transporter (hENT1) and ribonucleotide reductase subunit M1 (RRM1), have been investigated as predictive biomarkers of chemotherapy efficacy. gemcitabine 30-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-113 25664003-11 2014 CONCLUSIONS: The expression of hENT1 and RRM1 was associated with gemcitabine efficacy. gemcitabine 66-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-36 25246379-1 2014 AIM: To identify the single-nucleotide polymorphism (SNP) of hENT1 G-706C that is associated with response to gemcitabine-containing chemotherapy, and to determine the prognosis in patients with non-small-cell lung cancer (NSCLC). gemcitabine 110-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-66 25246379-10 2014 CONCLUSIONS: The hENT1 genetic polymorphism of hENT1 G-706C was associated with response to the gemcitabine-containing chemotherapy and prognosis of NSCLC. gemcitabine 96-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-22 25246379-10 2014 CONCLUSIONS: The hENT1 genetic polymorphism of hENT1 G-706C was associated with response to the gemcitabine-containing chemotherapy and prognosis of NSCLC. gemcitabine 96-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 25469211-3 2014 Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP. 5'-oleoyl cytarabine 0-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 204-242 25469211-7 2014 Use of hENT1 expression as a predictive marker for cytarabine or elacytarabine response has been studied with no conclusive validation to date. Cytarabine 51-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 7-12 25469211-3 2014 Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP. 5'-oleoyl cytarabine 0-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 244-249 25469211-7 2014 Use of hENT1 expression as a predictive marker for cytarabine or elacytarabine response has been studied with no conclusive validation to date. 5'-oleoyl cytarabine 65-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 7-12 25469211-3 2014 Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP. Cytarabine 3-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 204-242 25469211-3 2014 Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP. Cytarabine 3-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 244-249 25398670-11 2014 CONCLUSIONS: AML patients with low activity of SLC29A1 genotype have shorter DFS and OS in Ara-C based therapy. Cytarabine 91-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-54 24255981-4 2014 The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. 5'-oleoyl cytarabine 96-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-9 25199538-0 2014 Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients. gemcitabine 121-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-74 25032731-0 2014 Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy. gemcitabine 212-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 25032731-1 2014 BACKGROUND: The aim of this study was to investigate the predictive and prognostic values of intratumoural human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase subunit 1 (RRM1) expression in advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC). gemcitabine 279-290 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-151 25032731-1 2014 BACKGROUND: The aim of this study was to investigate the predictive and prognostic values of intratumoural human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase subunit 1 (RRM1) expression in advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC). gemcitabine 279-290 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-158 24788480-2 2014 Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. Nucleosides 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 24788480-2 2014 Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. Nucleosides 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 223-228 24788480-2 2014 Given the role of hENT1 in the transport of nucleoside drugs, an important class of therapeutics in the treatment of various cancers and viral infections, efforts have been made to better understand the mechanisms by which hENT1 modulates nucleoside transport. Nucleosides 239-249 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 223-228 24788480-6 2014 Cross-membrane transport of labeled uridine by hENT1 was inhibited to a weaker extent by the 4-nitrobenzylated tubercidin and sangivamycin analogues than was observed with 6-N-(4-nitrobenzyl)adenosine. Uridine 36-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 24788480-6 2014 Cross-membrane transport of labeled uridine by hENT1 was inhibited to a weaker extent by the 4-nitrobenzylated tubercidin and sangivamycin analogues than was observed with 6-N-(4-nitrobenzyl)adenosine. 4-nitrobenzylated tubercidin 93-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 24788480-6 2014 Cross-membrane transport of labeled uridine by hENT1 was inhibited to a weaker extent by the 4-nitrobenzylated tubercidin and sangivamycin analogues than was observed with 6-N-(4-nitrobenzyl)adenosine. sangivamycin 126-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 24788480-6 2014 Cross-membrane transport of labeled uridine by hENT1 was inhibited to a weaker extent by the 4-nitrobenzylated tubercidin and sangivamycin analogues than was observed with 6-N-(4-nitrobenzyl)adenosine. 6-n-(4-nitrobenzyl)adenosine 172-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 24976360-4 2014 We studied the impact of reactive oxygen species on the function of ENT1 and ENBT1 in primary (CMVEC) and immortalized (HMEC-1) human microvascular endothelial cells. Reactive Oxygen Species 25-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 24255981-6 2014 There is a trend suggesting that hENT1 expression influences response to cytarabine, but not sufficient to support it as a biomarker for guiding treatment. Cytarabine 73-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 25024604-0 2014 hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. gemcitabine 34-45 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 24976360-5 2014 Both cell types displayed similar transporter expression profiles, with the majority (>90%) of 2-chloro[(3)H]adenosine (nucleoside) uptake mediated by ENT1 and [(3)H]hypoxanthine (nucleobase) uptake mediated by ENBT1. 2-chloro[(3)h]adenosine 98-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 24976360-5 2014 Both cell types displayed similar transporter expression profiles, with the majority (>90%) of 2-chloro[(3)H]adenosine (nucleoside) uptake mediated by ENT1 and [(3)H]hypoxanthine (nucleobase) uptake mediated by ENBT1. Nucleosides 123-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 24976360-5 2014 Both cell types displayed similar transporter expression profiles, with the majority (>90%) of 2-chloro[(3)H]adenosine (nucleoside) uptake mediated by ENT1 and [(3)H]hypoxanthine (nucleobase) uptake mediated by ENBT1. nucleobase 183-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 24976360-9 2014 SIN-1 did, however, enhance ENT1-mediated 2-chloro[(3)H]adenosine uptake. 2-chloro[(3)h]adenosine 42-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-32 25278310-1 2014 BACKGROUND: Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into cells. gemcitabine 131-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-88 25278310-1 2014 BACKGROUND: Nucleotide transporters such as human equilibrative nucleoside transporter-1 (hENT1) play a major role in transporting gemcitabine into cells. gemcitabine 131-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-95 25278310-2 2014 CO-1.01 (gemcitabine-5"-elaidate) is a novel cytotoxic agent consisting of a fatty acid derivative of gemcitabine, which is transported intracellularly independent of hENT1. gemcitabine-5"-elaidate 9-32 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 167-172 25070259-1 2014 BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. nine-beta-d-arabinofuranosylguanine 12-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-167 25070259-1 2014 BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. 9-arabinofuranosylguanine 49-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-167 25070259-1 2014 BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. nelarabine 81-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-167 25070259-1 2014 BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. ara-g triphosphate 234-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-167 25070259-1 2014 BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Ara-GTP 254-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-167 24687871-8 2014 Gene expression profiling of the ICE-T treated tumorgrafts identified cytarabine (SLC29A1) as a potential therapy, which was shown, along with BGJ398, to be highly active in vivo. Cytarabine 70-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-89 25024604-1 2014 High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. gemcitabine 141-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 11-49 25024604-1 2014 High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. gemcitabine 141-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 25024604-2 2014 The aim of this systematic review was to summarize the results and try to assess the predictive value of hENT1 for determining gemcitabine outcome in pancreatic cancer. gemcitabine 127-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-110 25024604-4 2014 Studies evaluating hENT1-expression in pancreatic tumor cells from patients treated with gemcitabine were selected. gemcitabine 89-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-24 25024604-10 2014 This review provides evidence that hENT1 is a predictive marker for pancreatic cancer patients treated with gemcitabine. gemcitabine 108-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 24857044-1 2014 BACKGROUND: The role of human equilibrative nucleoside transporter 1 (hENT1) as a predictive biomarker for gemcitabine efficacy in advanced pancreatic cancer remains unclear to date. gemcitabine 107-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-68 24857044-1 2014 BACKGROUND: The role of human equilibrative nucleoside transporter 1 (hENT1) as a predictive biomarker for gemcitabine efficacy in advanced pancreatic cancer remains unclear to date. gemcitabine 107-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-75 24857044-8 2014 In 101 patients receiving gemcitabine at any time during study treatment (either within the 1st- or 2nd-line setting) hENT1(low) cases had a median overall survival of 7.5 months and hENT1(high) patients an overall survival of 4.4 months (HR 1.30, 95% CI 0.84-2.03, p=0.24), respectively. gemcitabine 26-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-123 24768873-2 2014 The effect is mediated by inhibition of the adenosine transporter ENT1 (type 1 equilibrative nucleoside transporter), which provides protection for adenosine from intracellular metabolism, thus increasing its concentration and biological activity, particularly at sites of ischemia and tissue injury where it is formed. Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-70 24700669-1 2014 A facile enantiospecific approach to (+)-ligudentatol (1) and (-)-ligudentatol (ent-1) is reported. ligudentatol 37-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 24700669-1 2014 A facile enantiospecific approach to (+)-ligudentatol (1) and (-)-ligudentatol (ent-1) is reported. ligudentatol 62-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 24626203-6 2014 Furthermore, bendamustine increased the expression of ENT1 at both mRNA and protein levels and enhanced the uptake of Ara-C and subsequent increase in Ara-C triphosphate (Ara-CTP) in HBL-2 cells to an extent comparable with the purine analog fludarabine. Bendamustine Hydrochloride 13-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-58 24625353-0 2014 Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. gemcitabine 111-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 24625353-1 2014 CONTEXT: Increasing scientific evidence suggests that human equilibrative nucleoside transporter 1 (hENT1) may be a powerful predictor of survival in patients with pancreatic cancer treated with adjuvant gemcitabine-based chemotherapy after operative resection, but many existing studies have yielded inconclusive results. gemcitabine 204-215 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-98 24625353-1 2014 CONTEXT: Increasing scientific evidence suggests that human equilibrative nucleoside transporter 1 (hENT1) may be a powerful predictor of survival in patients with pancreatic cancer treated with adjuvant gemcitabine-based chemotherapy after operative resection, but many existing studies have yielded inconclusive results. gemcitabine 204-215 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 24625353-2 2014 OBJECTIVE: This meta-analysis aims to assess the prognostic role of hENT1 in predicting survival in patients with pancreatic cancer treated with gemcitabine. gemcitabine 145-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 24625353-10 2014 CONCLUSION: In conclusion, our meta-analysis suggests that high hENT1 expression may be associated with improved OS and DFS of pancreatic cancer patients treated with gemcitabine. gemcitabine 167-178 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 24625353-11 2014 Detection of hENT1 expression may be a promising biomarker for gemcitabine response and prognosis in pancreatic cancer patients. gemcitabine 63-74 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-18 24692694-2 2014 Cytarabine uses hENT1 and dCK for its activation. Cytarabine 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-21 24614108-8 2014 Gemcitabine incorporation into tumor DNA was inversely related to CT-derived transport parameters and PDAC stromal score, after accounting for hENT1 levels. gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-148 24361227-0 2014 Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. gemcitabine 128-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-41 24361227-0 2014 Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. Paclitaxel 145-155 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-41 24361227-11 2014 CONCLUSION: Genetic polymorphisms in SLC28A3, SLC29A1 and RRM1 can influence the clinical outcome of MBC patients treated with PG chemotherapy. pg 127-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-53 24163005-7 2014 These data suggest that the presence of ethanol may compromise ENT1-dependent nucleoside analog drug cytotoxicity, and indeed, ethanol (5 mM) reduces the cytotoxic effects of gemcitabine (2 nM), an anti-cancer drug, in the human cancer cell line, HTB2. Ethanol 40-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-67 24192812-3 2014 We determined the expression levels of genes involved in AZA metabolism: UCK1, UCK2, DCK, hENT1, RRM1 and RRM2 using quantitative PCR in samples from 57 patients with MDS who received AZA. Azacitidine 57-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-95 24522200-1 2014 Human equilibrative nucleoside transporter 1 (hENT1) transports various nucleoside analogues into cells. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 24301456-8 2014 Median survival for patients treated with gemcitabine was 17.1 (95% CI = 14.3 to 23.8) months for those with low hENT1 expression vs 26.2 (95% CI = 21.2 to 31.4) months for those with high hENT1 expression (chi(2)1= 9.87; P = .002). gemcitabine 42-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 189-194 24301456-11 2014 Multivariable analysis confirmed hENT1 expression as a predictive marker in gemcitabine-treated (Wald chi(2) = 9.16; P = .003) but not 5-fluorouracil-treated (Wald chi(2) = 1.22; P = .27) patients. gemcitabine 76-87 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 23851183-1 2014 PURPOSE: In pancreatic cancer, deoxycytidine kinase and the human equilibrative nucleoside transporter 1 have been validated as predictive markers for benefit from gemcitabine therapy. gemcitabine 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-104 24586402-2 2014 Type 1 equilibrative nucleoside transporter (ENT1) is responsible for the majority of adenosine transport across the plasma membrane and is ubiquitously expressed in both humans and mice. Adenosine 86-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-49 24170548-6 2014 Treatment of cell lines with erlotinib, gefitinib, or vandetanib for 24 hours reduced hENT1 activity which was reversed by subsequent incubation in drug-free media for 24 hours. Erlotinib Hydrochloride 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 24170548-6 2014 Treatment of cell lines with erlotinib, gefitinib, or vandetanib for 24 hours reduced hENT1 activity which was reversed by subsequent incubation in drug-free media for 24 hours. Gefitinib 40-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 24170548-6 2014 Treatment of cell lines with erlotinib, gefitinib, or vandetanib for 24 hours reduced hENT1 activity which was reversed by subsequent incubation in drug-free media for 24 hours. vandetanib 54-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 24170548-8 2014 CONCLUSIONS: Vandetanib inhibited hENT1, hENT2, hCNT1, hCNT2, and hCNT3, whereas erlotinib inhibited hENT1 and hCNT3 and gefitinib inhibited hENT1 and hCNT1. vandetanib 13-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-39 24170548-8 2014 CONCLUSIONS: Vandetanib inhibited hENT1, hENT2, hCNT1, hCNT2, and hCNT3, whereas erlotinib inhibited hENT1 and hCNT3 and gefitinib inhibited hENT1 and hCNT1. Erlotinib Hydrochloride 81-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 24170548-8 2014 CONCLUSIONS: Vandetanib inhibited hENT1, hENT2, hCNT1, hCNT2, and hCNT3, whereas erlotinib inhibited hENT1 and hCNT3 and gefitinib inhibited hENT1 and hCNT1. Erlotinib Hydrochloride 81-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 25400187-5 2014 An immunohistochemical analysis revealed that the tumor was highly expressive of gemcitabine transporter human equilibrative nucleoside transporter 1, thus suggesting a high sensitivity to gemcitabine. gemcitabine 81-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-149 24301456-0 2014 Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. gemcitabine 53-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 24301456-1 2014 BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection. gemcitabine 155-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 24301456-1 2014 BACKGROUND: Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection. gemcitabine 155-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 24301456-8 2014 Median survival for patients treated with gemcitabine was 17.1 (95% CI = 14.3 to 23.8) months for those with low hENT1 expression vs 26.2 (95% CI = 21.2 to 31.4) months for those with high hENT1 expression (chi(2)1= 9.87; P = .002). gemcitabine 42-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-118 24163005-0 2014 The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity. Ethanol 81-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 24163005-0 2014 The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity. Ethanol 136-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 24163005-0 2014 The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity. Nucleosides 175-185 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 24163005-1 2014 The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. Nucleosides 46-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 24163005-1 2014 The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. Adenosine 4-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 24163005-1 2014 The adenosine transporter 1 (ENT1) transports nucleosides, such as adenosine, and cytotoxic nucleoside analog drugs. Nucleosides 46-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-33 24163005-2 2014 ENT1 is well established to play a role in adenosinergic signaling in the cardiovascular system by modulating adenosine levels. Adenosine 43-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 24163005-4 2014 Here, we show that ethanol (5-200 mM) significantly reduces ENT1-dependent [(3)H] 2-chloroadenosine uptake (by up to 27 %) in the cardiomyocyte cell line, HL-1. Ethanol 19-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-64 24163005-4 2014 Here, we show that ethanol (5-200 mM) significantly reduces ENT1-dependent [(3)H] 2-chloroadenosine uptake (by up to 27 %) in the cardiomyocyte cell line, HL-1. 2-Chloroadenosine 82-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-64 24163005-5 2014 Inhibition or absence of ENT1 is known to be cardioprotective, suggesting that the interaction of ethanol with ENT1 may promote adenosinergic cardioprotective pathways in the cardiovasculature.Ethanol sensitivity of adenosine uptake is altered by pharmacological activation of PKA and PKC. Ethanol 98-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-115 24163005-5 2014 Inhibition or absence of ENT1 is known to be cardioprotective, suggesting that the interaction of ethanol with ENT1 may promote adenosinergic cardioprotective pathways in the cardiovasculature.Ethanol sensitivity of adenosine uptake is altered by pharmacological activation of PKA and PKC. Ethanol 193-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-115 24163005-5 2014 Inhibition or absence of ENT1 is known to be cardioprotective, suggesting that the interaction of ethanol with ENT1 may promote adenosinergic cardioprotective pathways in the cardiovasculature.Ethanol sensitivity of adenosine uptake is altered by pharmacological activation of PKA and PKC. Adenosine 128-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-115 24163005-7 2014 These data suggest that the presence of ethanol may compromise ENT1-dependent nucleoside analog drug cytotoxicity, and indeed, ethanol (5 mM) reduces the cytotoxic effects of gemcitabine (2 nM), an anti-cancer drug, in the human cancer cell line, HTB2. Nucleosides 78-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-67 24163005-8 2014 Thus, the pharmacological inhibition of ENT1 by ethanol may contribute to ethanol-dependent cardioprotection but compromise gemcitabine cytotoxicity. Ethanol 48-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 24163005-8 2014 Thus, the pharmacological inhibition of ENT1 by ethanol may contribute to ethanol-dependent cardioprotection but compromise gemcitabine cytotoxicity. Ethanol 74-81 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 24163005-8 2014 Thus, the pharmacological inhibition of ENT1 by ethanol may contribute to ethanol-dependent cardioprotection but compromise gemcitabine cytotoxicity. gemcitabine 124-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 24220555-5 2013 The study also tested the hypothesis that gemcitabine is more active in patients with mPDAC tumors with high versus low hENT1 expression. gemcitabine 42-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-125 24083589-12 2013 CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. gemcitabine 178-189 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-36 24220555-2 2013 Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). gemcitabine 85-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-62 24220555-2 2013 Low expression of human equilibrative nucleoside transporter-1 (hENT1) may result in gemcitabine resistance in pancreatic ductal adenocarcinoma (PDAC). gemcitabine 85-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 24220555-3 2013 CO-101, a lipid-drug conjugate of gemcitabine, was rationally designed to enter cells independently of hENT1. CP 4126 0-6 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 24119573-3 2013 Altered adenosine metabolism and uptake by the endothelium leads to increased NO synthesis which then turns-off the expression of genes coding for a family of nucleoside membrane transporters belonging to equilibrative nucleoside transporters, particularly isoforms 1 (hENT1) and 2 (hENT2). Adenosine 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 269-274 24083589-12 2013 CONCLUSIONS: The expression of hENT1 and ERCC1 genes in tumor tissues were closely correlated with the response to chemotherapy and prognosis of patients with NSCLC treated with gemcitabine plus cisplatin. Cisplatin 195-204 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-36 24280569-3 2013 SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. Purines 135-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-7 24122028-13 2013 Thus, ADO specifically inhibits FcepsilonRI-induced degranulation of hSMCs primarily by an intracellular mechanism that requires its influx via equilibrative nucleoside transporter 1 (ENT1). Adenosine 6-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 144-182 24122028-13 2013 Thus, ADO specifically inhibits FcepsilonRI-induced degranulation of hSMCs primarily by an intracellular mechanism that requires its influx via equilibrative nucleoside transporter 1 (ENT1). Adenosine 6-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-188 24280569-3 2013 SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. Purines 135-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-65 24280569-3 2013 SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. Purines 135-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-72 24280569-3 2013 SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. Pyrimidines 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-7 24280569-3 2013 SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. Pyrimidines 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-65 24280569-3 2013 SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating the transport of nucleotides, both purines and pyrimidines, into the tumor cells. Pyrimidines 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-72 24280569-5 2013 Increased expression of SLC29A1 in vitro has been described as a potential critical factor determining the sensitivity of pancreatic cancer cells to gemcitabine and 5-fluorouracil, the principal cytotoxic agents used in the treatment of pancreatic cancer. gemcitabine 149-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-31 24280569-5 2013 Increased expression of SLC29A1 in vitro has been described as a potential critical factor determining the sensitivity of pancreatic cancer cells to gemcitabine and 5-fluorouracil, the principal cytotoxic agents used in the treatment of pancreatic cancer. Fluorouracil 165-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-31 24280569-7 2013 However, majority of studies on patients with resected pancreatic cancer have suggested that high SLC29A1expression may be predictive of improved survival in patients treated with gemcitabine. gemcitabine 180-191 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-105 23814180-0 2013 The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Azacitidine 123-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 23814180-0 2013 The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. CP 4200 141-148 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 23814180-7 2013 Transport assays using [14C]5-azacytidine demonstrated Na+-independent uptake of the drug into the cells, which was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBTI), a hENT1 inhibitor. [14c]5-azacytidine 23-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-176 23814180-7 2013 Transport assays using [14C]5-azacytidine demonstrated Na+-independent uptake of the drug into the cells, which was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBTI), a hENT1 inhibitor. 4-nitrobenzylthioinosine 129-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-176 23814180-7 2013 Transport assays using [14C]5-azacytidine demonstrated Na+-independent uptake of the drug into the cells, which was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBTI), a hENT1 inhibitor. 4-nitrobenzylthioinosine 162-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 171-176 23814180-8 2013 The cellular toxicity of 5-azacytidine and its DNA demethylating activity were strongly reduced after hENT1 inhibition. Azacitidine 25-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 23814180-9 2013 In contrast, the cellular activity of the 5-azacytidine derivative 5-azacytidine-5"-elaidate (CP-4200), a nucleoside transporter-independent drug, persisted after hENT1 inhibition. Azacitidine 42-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 163-168 23814180-9 2013 In contrast, the cellular activity of the 5-azacytidine derivative 5-azacytidine-5"-elaidate (CP-4200), a nucleoside transporter-independent drug, persisted after hENT1 inhibition. 5-azacytidine-5"-elaidate 67-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 163-168 23814180-9 2013 In contrast, the cellular activity of the 5-azacytidine derivative 5-azacytidine-5"-elaidate (CP-4200), a nucleoside transporter-independent drug, persisted after hENT1 inhibition. CP 4200 94-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 163-168 23814180-10 2013 A strong dependence of 5-azacytidine-induced DNA demethylation on hENT1 activity was also confirmed by array-based DNA methylation profiling, which uncovered hundreds of loci that became demethylated only when hENT1-mediated transport was active. Azacitidine 23-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-71 23814180-10 2013 A strong dependence of 5-azacytidine-induced DNA demethylation on hENT1 activity was also confirmed by array-based DNA methylation profiling, which uncovered hundreds of loci that became demethylated only when hENT1-mediated transport was active. Azacitidine 23-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 23814180-11 2013 Our data establish hENT1 as a key transporter for the cellular uptake of 5-azacytidine in leukemia cells and raise the possibility that hENT1 expression might be a useful biomarker to predict the efficiency of 5-azacytidine treatments. Azacitidine 73-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-24 23814180-11 2013 Our data establish hENT1 as a key transporter for the cellular uptake of 5-azacytidine in leukemia cells and raise the possibility that hENT1 expression might be a useful biomarker to predict the efficiency of 5-azacytidine treatments. Azacitidine 210-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-24 23814180-11 2013 Our data establish hENT1 as a key transporter for the cellular uptake of 5-azacytidine in leukemia cells and raise the possibility that hENT1 expression might be a useful biomarker to predict the efficiency of 5-azacytidine treatments. Azacitidine 210-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-141 23244671-13 2013 Using hENT1 testing to select patients for gemcitabine therapy would save $8.6 million in Sweden each year. gemcitabine 43-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-11 23846920-9 2013 presented the impact of hENT1 tumor levels on the outcome of the patients with pancreatic cancer (Abstract #4006) who had received adjuvant chemotherapy with either 5-flurouracil or gemcitabine in the ESPAC trial. 5-flurouracil 165-178 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 23902239-2 2013 Elacytarabine was rationally designed to circumvent cytarabine resistance related to decreased cellular uptake, due to the ability of the lipophilic drug moiety to enter the cell without the requirement of specialized nuclear transport proteins, including the hENT1. 5'-oleoyl cytarabine 0-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 260-265 23902239-2 2013 Elacytarabine was rationally designed to circumvent cytarabine resistance related to decreased cellular uptake, due to the ability of the lipophilic drug moiety to enter the cell without the requirement of specialized nuclear transport proteins, including the hENT1. Cytarabine 3-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 260-265 23846920-9 2013 presented the impact of hENT1 tumor levels on the outcome of the patients with pancreatic cancer (Abstract #4006) who had received adjuvant chemotherapy with either 5-flurouracil or gemcitabine in the ESPAC trial. gemcitabine 182-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 23846927-5 2013 First, the predictive role of hENT1, which codes for a gemcitabine transporter into cells, was highlighted and might help us decide whether we benefit from gemcitabine or 5-fluorouracil in the adjuvant setting (Abstract #4006). gemcitabine 55-66 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-35 23846927-5 2013 First, the predictive role of hENT1, which codes for a gemcitabine transporter into cells, was highlighted and might help us decide whether we benefit from gemcitabine or 5-fluorouracil in the adjuvant setting (Abstract #4006). Fluorouracil 171-185 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-35 23790123-3 2013 Assignments of the absolute stereochemistries of the natural (+)-amphidinolide O (ent-1) and P (ent-2) are also discussed in detail. (+)-amphidinolide 61-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-94 23650783-4 2013 We have demonstrated the ability of the metabolizing gemcitabine protein (the human Equilibrative nucleoside transporter 1 and the deoxycytidine kinase) in predicting the benefit of adjuvant gemcitabine-based therapy in resected PDAC patients. gemcitabine 53-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-122 23388705-6 2013 In summary, ENT1 was shown to mediate the transport of tecadenoson in vitro with recombinant and native human protein and in vivo with mice. tecadenoson 55-66 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-16 23388705-7 2013 The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials. tecadenoson 36-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 23388705-7 2013 The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials. tecadenoson 36-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 23388705-7 2013 The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials. tecadenoson 36-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 23371859-9 2013 The LXFE 397 tumor possessed elevated expression of the equilibrative nucleoside transporter-1 (ENT1) important for gemcitabine uptake but not prodrug uptake and responded significantly better to treatment with LY2334737 than gemcitabine (P <= 0.001). gemcitabine 116-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-94 23371859-9 2013 The LXFE 397 tumor possessed elevated expression of the equilibrative nucleoside transporter-1 (ENT1) important for gemcitabine uptake but not prodrug uptake and responded significantly better to treatment with LY2334737 than gemcitabine (P <= 0.001). gemcitabine 116-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-100 23371859-9 2013 The LXFE 397 tumor possessed elevated expression of the equilibrative nucleoside transporter-1 (ENT1) important for gemcitabine uptake but not prodrug uptake and responded significantly better to treatment with LY2334737 than gemcitabine (P <= 0.001). LY2334737 211-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-94 23371859-9 2013 The LXFE 397 tumor possessed elevated expression of the equilibrative nucleoside transporter-1 (ENT1) important for gemcitabine uptake but not prodrug uptake and responded significantly better to treatment with LY2334737 than gemcitabine (P <= 0.001). LY2334737 211-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-100 23371859-9 2013 The LXFE 397 tumor possessed elevated expression of the equilibrative nucleoside transporter-1 (ENT1) important for gemcitabine uptake but not prodrug uptake and responded significantly better to treatment with LY2334737 than gemcitabine (P <= 0.001). gemcitabine 226-237 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 96-100 23371859-13 2013 Elevated CES2 or ENT1 expression may enhance LY2334737 tumor response. LY2334737 45-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-21 23253379-0 2013 Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. gemcitabine 252-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-78 23253379-0 2013 Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. gemcitabine 252-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 23253379-2 2013 The aim of this study was to determine the usefulness of intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) as predictive markers of the efficacy of adjuvant gemcitabine-based chemotherapy for pancreatic carcinoma after operative resection. gemcitabine 245-256 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-128 23253379-2 2013 The aim of this study was to determine the usefulness of intratumoral expression of human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) as predictive markers of the efficacy of adjuvant gemcitabine-based chemotherapy for pancreatic carcinoma after operative resection. gemcitabine 245-256 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 130-135 23253379-3 2013 METHODS: The expression of intratumoral hENT1 and RRM1 was examined immunohistochemically in 109 patients with pancreatic carcinoma who received adjuvant gemcitabine-based chemotherapy after operative resection. gemcitabine 154-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 23253379-9 2013 CONCLUSION: Expression of hENT1 and RRM1 is predictive of the efficacy of adjuvant gemcitabine-based chemotherapy for pancreatic carcinoma after operative resection. gemcitabine 83-94 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 23649592-3 2013 After a threefold oxidation and an intramolecular acylation, the tetrahydroxanthenone 4 was obtained, which could be transformed into (-)-blennolide A (ent-1) in a few steps. tetrahydroxanthenone 65-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 152-157 23649592-3 2013 After a threefold oxidation and an intramolecular acylation, the tetrahydroxanthenone 4 was obtained, which could be transformed into (-)-blennolide A (ent-1) in a few steps. blennolide A 134-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 152-157 23710668-10 2013 CONCLUSIONS: hENT1 is the most reliable predictive marker of survival in patients with advanced BTC treated with gemcitabine. gemcitabine 113-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-18 23492684-0 2013 Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer. gemcitabine 68-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 23417866-1 2013 For the synthesis of (-)-diversonol (ent-1), an enantioselective domino-Wacker/carbonylation/methoxylation reaction and an enantioselective Wacker oxidation were used to give the chroman in high yield and 96% and 93% ee, respectively. diversonol 21-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 23417866-2 2013 Dihydroxylation at the vinyl moiety using the Sharpless procedure and a Wittig-Horner reaction followed by hydrogenation, benzylic oxidation, and an intramolecular acylation provided the tetrahydroxanthenone, from which ent-1 is accessible in a few steps. tetrahydroxanthenone 187-207 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-225 23650783-4 2013 We have demonstrated the ability of the metabolizing gemcitabine protein (the human Equilibrative nucleoside transporter 1 and the deoxycytidine kinase) in predicting the benefit of adjuvant gemcitabine-based therapy in resected PDAC patients. gemcitabine 191-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-122 23650783-8 2013 Overall our results suggested that (i) the benefit of an adjuvant gemcitabine-based therapy can be predicted based on the tumour expression of hENT1 and dCK, (ii) CXCR4 is an independent negative prognostic factor and an independent predictor of distant relapse suggesting that anti-CXCR4 targeting therapies can be a promising treatment in combination with cytotoxic chemotherapy in the adjuvant setting. gemcitabine 66-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-148 23271323-3 2013 This study investigated the role of nucleoside transporters, particularly human equilibrative nucleoside transporter 1 (hENT1), in predicting clinical treatment outcome with 5FU-based therapy. Fluorouracil 174-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-118 23271323-3 2013 This study investigated the role of nucleoside transporters, particularly human equilibrative nucleoside transporter 1 (hENT1), in predicting clinical treatment outcome with 5FU-based therapy. Fluorouracil 174-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-125 23271323-5 2013 To provide mechanistic support for the role of hENT1 in 5FU resistance, cell viability of Caco-2 cells was measured, following incubation with varying concentrations of 5FU and a hENT1 inhibitor. Fluorouracil 56-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 23574652-0 2013 Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 23574652-0 2013 Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 23574652-3 2013 We studied the relationship between human equilibrative nucleoside transporter 1 (hENT1) expression in tumor cells and the Asian patient response to gemcitabine-based chemotherapy. gemcitabine 149-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 23574652-3 2013 We studied the relationship between human equilibrative nucleoside transporter 1 (hENT1) expression in tumor cells and the Asian patient response to gemcitabine-based chemotherapy. gemcitabine 149-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-87 23574652-8 2013 CONCLUSIONS: Our studies suggest that hENT1 expression is related to the patient response to gemcitabine-based chemotherapy in Asian patients with pancreatic cancer. gemcitabine 93-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 23459628-1 2013 Ribavirin (RBV), a guanosine analog for treatment of hepatitis C, is a substrate of a nucleoside transporter, solute carrier family 29 member 1 (SLC29A1). Ribavirin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-152 23232555-0 2013 Etoposide increases equilibrative nucleoside transporter 1 activity and fluorothymidine uptake: screening of 60 cytotoxic agents. Etoposide 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-58 23232555-1 2013 Equilibrative nucleoside transporter 1 (ENT1) is a major regulator for the uptake of [(18)F]fluorothymidine ([(18)F]FLT), a promising positron emission tomography tracer for treatment monitoring. alovudine 92-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 23232555-1 2013 Equilibrative nucleoside transporter 1 (ENT1) is a major regulator for the uptake of [(18)F]fluorothymidine ([(18)F]FLT), a promising positron emission tomography tracer for treatment monitoring. alovudine 92-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 23232555-2 2013 Various antimetabolites such as 5-fluorouracil often increase ENT1 activity and [(18)F]FLT uptake (flare) in spite of cell death. Fluorouracil 32-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-66 23232555-6 2013 Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells. Etoposide 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-38 23232555-6 2013 Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells. Etoposide 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 172-176 23232555-6 2013 Etoposide significantly increased ENT1 activity and [(3)H]FLT uptake accompanying cell cycle arrest at S/G2/M phase and the increase in TK1 expression and activity in both ENT1-low expressing HT29 and ENT1-high expressing MDA-MB-231 cells. Etoposide 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 172-176 23232555-7 2013 The inhibition of ENT1 activity by dipyridamol or S-(p-nitrobenzyl)-6-thioinosine repressed the etoposide-induced cell death in HeLa cells, whereas it induced no changes in the other cell lines. Dipyridamole 35-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-22 23232555-7 2013 The inhibition of ENT1 activity by dipyridamol or S-(p-nitrobenzyl)-6-thioinosine repressed the etoposide-induced cell death in HeLa cells, whereas it induced no changes in the other cell lines. s-(p-nitrobenzyl)-6-thioinosine 50-81 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-22 23232555-7 2013 The inhibition of ENT1 activity by dipyridamol or S-(p-nitrobenzyl)-6-thioinosine repressed the etoposide-induced cell death in HeLa cells, whereas it induced no changes in the other cell lines. Etoposide 96-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-22 23232555-8 2013 In conclusion, etoposide is identified as a potent inducer for ENT1 activity and [(3)H]FLT uptake. Etoposide 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-67 23232555-9 2013 The role of ENT1 activity by etoposide was cell-type dependent, which requests caution for the application of ENT1-mediated [(18)F]FLT flare for treatment monitoring. Etoposide 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-16 23459628-1 2013 Ribavirin (RBV), a guanosine analog for treatment of hepatitis C, is a substrate of a nucleoside transporter, solute carrier family 29 member 1 (SLC29A1). Ribavirin 11-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-152 23459628-1 2013 Ribavirin (RBV), a guanosine analog for treatment of hepatitis C, is a substrate of a nucleoside transporter, solute carrier family 29 member 1 (SLC29A1). Guanosine 19-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-152 23459628-7 2013 The reduction rate of the AUC of erythrocyte RBV in the DP phase was associated with SLC29A1 mRNA expression: higher mRNA expression showed greater AUC reduction. Dipyridamole 56-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-92 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Ribavirin 27-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Dipyridamole 31-33 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Ribavirin 80-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 23459628-9 2013 These results suggest that RBV/DP coadministration reduces the concentration of RBV in blood by inhibiting an important role of SLC29A1 in gastrointestinal absorption of RBV. Ribavirin 80-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 22985987-1 2012 UNLABELLED: 3"-Fluoro-3"-deoxythymidine (FLT) has been proposed for positron emission tomography (PET)-based identification of tumor chemosensitivity that is mediated by the human equilibrative nucleoside transporter-1 (ENT1). alovudine 12-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 180-218 22426593-2 2012 Human equilibrative nucleoside transporter 1 (hENT1) is a major transporter responsible for gemcitabine uptake into cells. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 22426593-2 2012 Human equilibrative nucleoside transporter 1 (hENT1) is a major transporter responsible for gemcitabine uptake into cells. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 22426593-3 2012 This study was conducted to elucidate the association between expression level of hENT1 and outcome for pancreatic cancer patients treated with neoadjuvant therapy including gemcitabine. gemcitabine 174-185 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-87 22837314-1 2012 Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Cysteine 125-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 22837314-1 2012 Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Cysteine 125-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 22837314-1 2012 Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Cysteine 125-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 22837314-2 2012 A previous study from our laboratory established Cys222 in transmembrane (TM) 6 as the residue responsible for methyl methanethiosulfonate (a membrane-permeable sulfhydryl modifier)-mediated enhancement of the binding of the ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR) in intact cells. methyl methanethiosulfonate 111-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 225-229 22837314-2 2012 A previous study from our laboratory established Cys222 in transmembrane (TM) 6 as the residue responsible for methyl methanethiosulfonate (a membrane-permeable sulfhydryl modifier)-mediated enhancement of the binding of the ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR) in intact cells. Sulfhydryl Compounds 161-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 225-229 22837314-2 2012 A previous study from our laboratory established Cys222 in transmembrane (TM) 6 as the residue responsible for methyl methanethiosulfonate (a membrane-permeable sulfhydryl modifier)-mediated enhancement of the binding of the ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR) in intact cells. nitrobenzylmercaptopurine riboside 240-274 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 225-229 22837314-2 2012 A previous study from our laboratory established Cys222 in transmembrane (TM) 6 as the residue responsible for methyl methanethiosulfonate (a membrane-permeable sulfhydryl modifier)-mediated enhancement of the binding of the ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR) in intact cells. 4-nitrobenzylthioinosine 276-281 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 225-229 22837314-4 2012 We thus hypothesized that the inhibitory effects of the modifiers were due to the one or more of the six cysteine residues in the C-terminal half of ENT1, particularly one or both of those in the fifth intracellular loop (Cys414 and Cys416). Cysteine 105-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 149-153 22985987-1 2012 UNLABELLED: 3"-Fluoro-3"-deoxythymidine (FLT) has been proposed for positron emission tomography (PET)-based identification of tumor chemosensitivity that is mediated by the human equilibrative nucleoside transporter-1 (ENT1). alovudine 12-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-224 22985987-1 2012 UNLABELLED: 3"-Fluoro-3"-deoxythymidine (FLT) has been proposed for positron emission tomography (PET)-based identification of tumor chemosensitivity that is mediated by the human equilibrative nucleoside transporter-1 (ENT1). alovudine 41-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 180-218 22985987-1 2012 UNLABELLED: 3"-Fluoro-3"-deoxythymidine (FLT) has been proposed for positron emission tomography (PET)-based identification of tumor chemosensitivity that is mediated by the human equilibrative nucleoside transporter-1 (ENT1). alovudine 41-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-224 22985987-2 2012 ENT1 facilitates transport of FLT into cells and elevated levels of FLT are associated with both larger FLT-PET signals and increased response to nucleoside-based chemotherapies. Nucleosides 146-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 22702906-1 2012 Elacytarabine is a novel cytotoxic nucleoside analogue, independent of nucleoside transporters (e.g. human Equilibrative Nucleoside Transporter 1 [hENT1]) for cell uptake, and mechanisms of action similar to those of cytarabine. 5'-oleoyl cytarabine 0-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-152 22702906-1 2012 Elacytarabine is a novel cytotoxic nucleoside analogue, independent of nucleoside transporters (e.g. human Equilibrative Nucleoside Transporter 1 [hENT1]) for cell uptake, and mechanisms of action similar to those of cytarabine. Cytarabine 3-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-152 22970056-5 2012 We examined the molecular markers for GEM and Ara-C sensitivity in MTA-resistant cells and found increased gene expression of dCK and hENT1. Cytarabine 46-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-139 22705007-2 2012 Key determinants of gemcitabine cytotoxicity include the activities of the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), and ribonucleotide reductase subunit 1 (RRM1). gemcitabine 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-119 22705007-2 2012 Key determinants of gemcitabine cytotoxicity include the activities of the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), and ribonucleotide reductase subunit 1 (RRM1). gemcitabine 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 121-126 22705007-8 2012 Among patients who received gemcitabine, high levels of hENT1 and dCK were significantly associated with longer survival time (hazard ratios of 0.34 [P < .0001] and 0.57 [P = .012], respectively). gemcitabine 28-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-61 22705007-11 2012 CONCLUSIONS: High levels of hENT1 and dCK in PDAC predict longer survival times in patients treated with adjuvant gemcitabine. gemcitabine 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-33 21913012-0 2012 Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. gemcitabine 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-76 22580938-0 2012 Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection. gemcitabine 127-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 22580938-1 2012 OBJECTIVE: The aim of this study was to evaluate whether intratumoral human equilibrative nucleoside transporter 1 (hENT1) expression can predict the survival of advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection. gemcitabine 221-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-114 22580938-1 2012 OBJECTIVE: The aim of this study was to evaluate whether intratumoral human equilibrative nucleoside transporter 1 (hENT1) expression can predict the survival of advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection. gemcitabine 221-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-121 22622284-7 2012 Moreover, DZNeP enhanced the mRNA and protein expression of the nucleoside transporters hENT1/hCNT1, possibly because of the significant reduction of deoxynucleotide content (e.g., 25% reduction of deoxycytidine nucleotides in PANC-1), as detected by liquid chromatography/tandem mass spectrometry. 3-deazaneplanocin 10-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 22622284-7 2012 Moreover, DZNeP enhanced the mRNA and protein expression of the nucleoside transporters hENT1/hCNT1, possibly because of the significant reduction of deoxynucleotide content (e.g., 25% reduction of deoxycytidine nucleotides in PANC-1), as detected by liquid chromatography/tandem mass spectrometry. deoxynucleotide 150-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 22622284-7 2012 Moreover, DZNeP enhanced the mRNA and protein expression of the nucleoside transporters hENT1/hCNT1, possibly because of the significant reduction of deoxynucleotide content (e.g., 25% reduction of deoxycytidine nucleotides in PANC-1), as detected by liquid chromatography/tandem mass spectrometry. deoxycytidine nucleotides 198-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 22086444-0 2012 Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. gemcitabine 186-197 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-101 21913012-0 2012 Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. gemcitabine 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-83 21913012-2 2012 Human equilibrative nucleoside transporter-1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 21913012-2 2012 Human equilibrative nucleoside transporter-1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 21913012-3 2012 The aim of this study was to retrospectively determine the relationship between the outcome of pancreatic cancer after surgery followed by postoperative gemcitabine monotherapy and the expression of hENT1. gemcitabine 153-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 199-204 21913012-9 2012 CONCLUSIONS: A high expression of hENT1 in pancreatic cancer was found to be significantly associated with a longer survival in patients who received adjuvant gemcitabine monotherapy after curative resection, and hENT1 immunohistochemistry may well serve as a significant prognostic factor for these patients. gemcitabine 159-170 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-39 21898089-1 2012 BACKGROUND/PURPOSE: We aimed to determine the relationship between the intratumoral expression of human equilibrative nucleoside transporter (hENT1), the main gemcitabine transporter into cells, and the outcome of gemcitabine-based chemoradiotherapy (Gem-CRT) in patients with International Union Against Cancer (UICC) T3-T4 pancreatic adenocarcinoma. gemcitabine 159-170 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 21898089-1 2012 BACKGROUND/PURPOSE: We aimed to determine the relationship between the intratumoral expression of human equilibrative nucleoside transporter (hENT1), the main gemcitabine transporter into cells, and the outcome of gemcitabine-based chemoradiotherapy (Gem-CRT) in patients with International Union Against Cancer (UICC) T3-T4 pancreatic adenocarcinoma. gemcitabine 214-225 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 21898089-3 2012 RESULTS: The status of hENT1 expression (positive in 39 and negative in 16) was significantly associated with "clinical efficacy" (defined as more than 50% reduction of the serum carbohydrate antigen [CA] 19-9 level with stable disease [SD] or partial response [PR] according to the Response Evaluation Criteria in Solid Tumors [RECIST]) for Gem-CRT. Carbohydrates 179-191 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-28 21898089-7 2012 CONCLUSIONS: The hENT1 expression in pancreatic adenocarcinoma strongly influences the outcome of preoperative Gem-CRT treatment. gem-crt 111-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-22 22838949-4 2012 Clearance of 2 ,2 -difluorodeoxyuridine, a gemcitabine metabolite was significantly predicted by CDA, SLC29A1 and NT5C2 SNPs. gemcitabine 43-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-109 22838949-5 2012 This study reports an association of formation clearance of 2 ,2 -difluoro-2 -deoxycytidine triphosphate, an active form of gemcitabine with SNPs within uptake transporters SLC28A1, SLC28A3 and SLC29A1. 2 ,2 -difluoro-2 -deoxycytidine triphosphate 60-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 194-201 22838949-2 2012 MATERIALS & METHODS: SNPs within nine gemcitabine pathway genes, namely CDA, CMPK, DCK, DCTD, NT5C2, NT5C3, SLC28A1, SLC28A3 and SLC29A1 were analyzed for association with gemcitabine pharmacokinetics. gemcitabine 42-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-140 22838949-5 2012 This study reports an association of formation clearance of 2 ,2 -difluoro-2 -deoxycytidine triphosphate, an active form of gemcitabine with SNPs within uptake transporters SLC28A1, SLC28A3 and SLC29A1. gemcitabine 124-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 194-201 22644860-1 2012 The concentrative nucleoside transporter CNT1 and equilibrated nucleoside transporter ENT1 mediate the cellular uptake of naturally occurring pyrimidine and purine nucleosides and many structurally diverse anticancer and antiviral nucleoside analogs, thereby regulating drug responses or toxicity at the target site. pyrimidine 142-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 22838949-4 2012 Clearance of 2 ,2 -difluorodeoxyuridine, a gemcitabine metabolite was significantly predicted by CDA, SLC29A1 and NT5C2 SNPs. 2',2'-difluoro-2'-deoxyuridine 13-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-109 22644860-1 2012 The concentrative nucleoside transporter CNT1 and equilibrated nucleoside transporter ENT1 mediate the cellular uptake of naturally occurring pyrimidine and purine nucleosides and many structurally diverse anticancer and antiviral nucleoside analogs, thereby regulating drug responses or toxicity at the target site. purine 157-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 22644860-1 2012 The concentrative nucleoside transporter CNT1 and equilibrated nucleoside transporter ENT1 mediate the cellular uptake of naturally occurring pyrimidine and purine nucleosides and many structurally diverse anticancer and antiviral nucleoside analogs, thereby regulating drug responses or toxicity at the target site. Nucleosides 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 22644860-2 2012 The objectives of this study were to analyze interindividual variations in the cellular accumulation of gemcitabine and to examine the correlation between the uptake of gemcitabine and expression levels of CNT1 and ENT1 transporters. gemcitabine 169-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-219 22644860-3 2012 Gemcitabine was a substrate for both CNT1 and ENT1 with higher affinity to CNT1 than to ENT1. gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-50 22644860-3 2012 Gemcitabine was a substrate for both CNT1 and ENT1 with higher affinity to CNT1 than to ENT1. gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 22644860-5 2012 Among these, the CNT1- and ENT1-mediated uptake of gemcitabine was 14.3- and 16.5-folds, respectively. gemcitabine 51-62 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 22644860-8 2012 However, ENT1-mediated uptake of gemcitabine might compensate for the total uptake of gemcitabine; therefore, the variation in the apparent accumulation of gemcitabine was smaller than that of the individual transporters. gemcitabine 33-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-13 22644860-8 2012 However, ENT1-mediated uptake of gemcitabine might compensate for the total uptake of gemcitabine; therefore, the variation in the apparent accumulation of gemcitabine was smaller than that of the individual transporters. gemcitabine 86-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-13 22644860-8 2012 However, ENT1-mediated uptake of gemcitabine might compensate for the total uptake of gemcitabine; therefore, the variation in the apparent accumulation of gemcitabine was smaller than that of the individual transporters. gemcitabine 86-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-13 22137164-0 2012 Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. gemcitabine 111-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 22137164-0 2012 Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. gemcitabine 111-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 22137164-5 2012 Human equilibrative nucleoside transporter 1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 22137164-5 2012 Human equilibrative nucleoside transporter 1 (hENT1) is the major transporter responsible for gemcitabine uptake into cells. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 22137164-6 2012 hENT1 expression is associated with an increased survival for patients receiving gemcitabine after pancreatic cancer surgery, suggesting that hENT1 is predictive of response to gemcitabine. gemcitabine 81-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 22137164-6 2012 hENT1 expression is associated with an increased survival for patients receiving gemcitabine after pancreatic cancer surgery, suggesting that hENT1 is predictive of response to gemcitabine. gemcitabine 177-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 22137164-6 2012 hENT1 expression is associated with an increased survival for patients receiving gemcitabine after pancreatic cancer surgery, suggesting that hENT1 is predictive of response to gemcitabine. gemcitabine 177-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 22137164-14 2012 CONCLUSION: In this study we show the potential of hENT1 expression as a predictor of outcome in CC treated with gemcitabine. gemcitabine 113-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 22349506-1 2012 Human equilibrative nucleoside transporter 1 (hENT1) is an important determinant for nucleoside analog based chemotherapy success. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 22212648-2 2012 Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 22212648-2 2012 Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 22212648-2 2012 Equilibrative nucleoside transporter 1 (ENT1), encoded by SLC29A1 gene, is the main transporter that imports ribavirin into human hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-65 22409811-3 2012 In vitro studies showed that neuron-specific expression of human equilibrative nucleoside transporter 1 (hENT1) decreases extracellular adenosine levels and adenosine A1 receptor activity. Adenosine 136-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-103 22409811-3 2012 In vitro studies showed that neuron-specific expression of human equilibrative nucleoside transporter 1 (hENT1) decreases extracellular adenosine levels and adenosine A1 receptor activity. Adenosine 136-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-110 22314683-2 2012 Equilibrative nucleoside transporter type 1 (ENT1) regulates glutamate levels by regulating excitatory amino acid transporter expression and activity in the brain. Glutamic Acid 61-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-43 22314683-2 2012 Equilibrative nucleoside transporter type 1 (ENT1) regulates glutamate levels by regulating excitatory amino acid transporter expression and activity in the brain. Glutamic Acid 61-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-49 22314683-5 2012 We found decreased ENT1 expression in the STG in patients with schizophrenia, supporting the hypothesis of altered glutamate transport in this illness. Glutamic Acid 115-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-23 21678404-7 2012 ENT1-mediated adenosine uptake was also enhanced. Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 21678404-8 2012 When cells were incubated with dipyridamole to evaluate the potential contribution of ENT1 to EMT by blocking its transport activity, EMT was induced. Dipyridamole 31-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-90 21266914-5 2012 In vitro studies show that glucose per se increases the expression level of ENT-1 via mitogen-activating protein kinase-dependent pathways. Glucose 27-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 22173087-8 2012 Functional studies demonstrated that downregulation of SLC29A1, NT5C2, and RRM1 in NSCLC cell lines altered cell susceptibility to gemcitabine. gemcitabine 131-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-62 21266914-3 2012 In vascular smooth muscle cells, 95% of adenosine transport is mediated by ENT-1 and the rest by ENT-2. Adenosine 40-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 21266914-4 2012 In endothelial cells, 60%, 10%, and 30% of adenosine transport are mediated by ENT-1, ENT-2, and CNT-2, respectively. Adenosine 43-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-84 22232287-0 2012 ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. Ribavirin 8-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 22232287-2 2012 However, because the role of this transporter in the antiviral mechanism of the drug remains unclear, the present study aimed to elucidate the role of ENT1 in ribavirin antiviral action. Ribavirin 159-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-155 22232287-5 2012 Nitrobenzylmercaptopurine riboside (NBMPR) and micro-RNA targeted to ENT1 mRNA (miR-ENT1) were used to reduce the ribavirin uptake level in OR6 cells. Ribavirin 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-73 22232287-5 2012 Nitrobenzylmercaptopurine riboside (NBMPR) and micro-RNA targeted to ENT1 mRNA (miR-ENT1) were used to reduce the ribavirin uptake level in OR6 cells. Ribavirin 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-88 22232287-7 2012 It was found that the primary ribavirin transporter in OR6 cells was ENT1 and that inhibition of ENT1-mediated ribavirin uptake by NBMPR significantly attenuated the antiviral activity of the drug as well as its accumulation in OR6 cells. Ribavirin 30-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-73 22232287-7 2012 It was found that the primary ribavirin transporter in OR6 cells was ENT1 and that inhibition of ENT1-mediated ribavirin uptake by NBMPR significantly attenuated the antiviral activity of the drug as well as its accumulation in OR6 cells. Ribavirin 30-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-101 22232287-7 2012 It was found that the primary ribavirin transporter in OR6 cells was ENT1 and that inhibition of ENT1-mediated ribavirin uptake by NBMPR significantly attenuated the antiviral activity of the drug as well as its accumulation in OR6 cells. 4-nitrobenzylthioinosine 131-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-101 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 73-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 73-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 73-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 225-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 225-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-8 2012 The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. Ribavirin 225-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-127 22232287-9 2012 In conclusion, our results show that by facilitating its uptake and accumulation in OR6 cells, ENT1 plays a pivotal role in the antiviral effectiveness of ribavirin and therefore provides an important insight into the efficacy of the drug in anti-HCV therapy. Ribavirin 155-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 21266914-8 2012 It has been speculated that the increase in the activities of ENT-1 and CNT-2 may reduce the availability of adenosine to adenosine receptors, thereby weakening the vascular functions of adenosine. Adenosine 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-67 21266914-8 2012 It has been speculated that the increase in the activities of ENT-1 and CNT-2 may reduce the availability of adenosine to adenosine receptors, thereby weakening the vascular functions of adenosine. Adenosine 122-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-67 21266914-11 2012 ENTs are also sensitive to dihydropyridine-type calcium-channel blockers, particularly nimodipine, which can inhibit ENT-1 in the nanomolar range. Nimodipine 87-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-122 21266914-13 2012 The nonsteroidal anti-inflammatory drug sulindac sulfide is a competitive inhibitor of ENT-1. sulindac sulfide 40-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-92 22356238-3 2012 We assessed the ability of azacitidine, decitabine, and, for comparison, gemcitabine, to interact with human nucleoside transporters (hNTs) in Saccharomyces cerevisiae cells (hENT1/2, hCNT1/2/3) or Xenopus laevis oocytes (hENT3/4). Azacitidine 27-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-182 22356238-3 2012 We assessed the ability of azacitidine, decitabine, and, for comparison, gemcitabine, to interact with human nucleoside transporters (hNTs) in Saccharomyces cerevisiae cells (hENT1/2, hCNT1/2/3) or Xenopus laevis oocytes (hENT3/4). Decitabine 40-50 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-182 22427797-6 2012 Treatment with hydralazine reversed gemcitabine resistance and led to hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner. Hydralazine 15-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-75 22761898-6 2012 In contrast, ATP was a less potent inhibitor (IC(50) = 100 microM) in slices from mice expressing hENT1 in neurons. Adenosine Triphosphate 13-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-103 22427797-10 2012 CONCLUSIONS/SIGNIFICANCE: Our results demonstrate that acquired gemcitabine resistance is associated with DNA promoter methylation-independent hENT1 and dCK gene down-regulation and hyper-expression of G9A methyltransferase. gemcitabine 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-148 21965724-7 2011 However, combining gemcitabine with I3C further increased hENT1 expression. gemcitabine 19-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 21965724-9 2011 hENT1-specific inhibitor, nitrobenzylthioinosine, significantly abrogated I3C-induced gemcitabine cytotoxicity, further demonstrating its specificity. 4-nitrobenzylthioinosine 26-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 21965724-9 2011 hENT1-specific inhibitor, nitrobenzylthioinosine, significantly abrogated I3C-induced gemcitabine cytotoxicity, further demonstrating its specificity. gemcitabine 86-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 21965724-10 2011 This study demonstrates that up-regulation of hENT1 expression may be a novel mechanism involved in the additive effect of I3C and gemcitabine. gemcitabine 131-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 21791574-0 2011 Identification of cysteines involved in the effects of methanethiosulfonate reagents on human equilibrative nucleoside transporter 1. Cysteine 18-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-132 21791574-10 2011 The results of this study also indicate that the hENT1-C193S mutant may be useful as a MTSET/MTSES-insensitive transporter for future cysteine substitution studies to define the extracellular domains contributing to the binding of substrates and inhibitors to this critical membrane transporter. Cysteine 134-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-54 21791574-0 2011 Identification of cysteines involved in the effects of methanethiosulfonate reagents on human equilibrative nucleoside transporter 1. methanethiosulfonate reagents 55-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-132 21791574-1 2011 Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Cysteine 125-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 21791574-1 2011 Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Cysteine 125-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 21791574-1 2011 Inhibitor and substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be affected by cysteine-modifying reagents. Cysteine 125-133 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. nitrobenzylmercaptopurine riboside 46-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-25 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. nitrobenzylmercaptopurine riboside 46-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. 4-nitrobenzylthioinosine 82-87 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-25 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. 4-nitrobenzylthioinosine 82-87 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. Cysteine 184-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-25 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. Cysteine 184-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 21791574-2 2011 Given that selective ENT1 inhibitors, such as nitrobenzylmercaptopurine riboside (NBMPR), bind to the N-terminal half of the ENT1 protein, we hypothesized that one or more of the four cysteine residues in this region were contributing to the effects of the sulfhydryl modifiers. Sulfhydryl Compounds 257-267 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 21795683-12 2011 Site-directed mutagenesis identified Cys-414 in transmembrane helix 10 of hENT1 as the residue conferring nucleobase transport activity to the wild-type transporter. Cysteine 37-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-79 21982569-1 2011 INTRODUCTION: Recent studies in the human adenocarcinoma cell line A549 have identified cell growth-dependent equilibrative nucleoside transporter-1 (hENT1) as a modifier of 3"-fluoro-3"-deoxythymidine (FLT) uptake and retention. alovudine 174-201 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-155 21982569-1 2011 INTRODUCTION: Recent studies in the human adenocarcinoma cell line A549 have identified cell growth-dependent equilibrative nucleoside transporter-1 (hENT1) as a modifier of 3"-fluoro-3"-deoxythymidine (FLT) uptake and retention. alovudine 203-206 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-155 21795683-2 2011 Both transport purine and pyrimidine nucleosides and are distinguished functionally by a difference in sensitivity to inhibition by nanomolar concentrations of nitrobenzylmercaptopurine ribonucleoside (NBMPR), hENT1 being NBMPR-sensitive. purine 15-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 21730354-6 2011 The mRNA levels of the transporters ENT1 and ENT2 were higher in ara-G-sensitive than -resistant samples. 9-arabinofuranosylguanine 65-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-40 21795683-2 2011 Both transport purine and pyrimidine nucleosides and are distinguished functionally by a difference in sensitivity to inhibition by nanomolar concentrations of nitrobenzylmercaptopurine ribonucleoside (NBMPR), hENT1 being NBMPR-sensitive. Pyrimidine Nucleosides 26-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 21795683-2 2011 Both transport purine and pyrimidine nucleosides and are distinguished functionally by a difference in sensitivity to inhibition by nanomolar concentrations of nitrobenzylmercaptopurine ribonucleoside (NBMPR), hENT1 being NBMPR-sensitive. Nitrobenzylmercaptopurine Ribonucleoside 160-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 21795683-7 2011 In the present investigation, we have used the enhanced Xenopus oocyte expression vector pGEMHE to demonstrate that hENT1 additionally transports thymine and adenine and, to a lesser extent, uracil and guanine. Thymine 146-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-121 21795683-7 2011 In the present investigation, we have used the enhanced Xenopus oocyte expression vector pGEMHE to demonstrate that hENT1 additionally transports thymine and adenine and, to a lesser extent, uracil and guanine. Adenine 158-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-121 21795683-7 2011 In the present investigation, we have used the enhanced Xenopus oocyte expression vector pGEMHE to demonstrate that hENT1 additionally transports thymine and adenine and, to a lesser extent, uracil and guanine. Uracil 191-197 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-121 21795683-7 2011 In the present investigation, we have used the enhanced Xenopus oocyte expression vector pGEMHE to demonstrate that hENT1 additionally transports thymine and adenine and, to a lesser extent, uracil and guanine. Guanine 202-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-121 21795683-8 2011 Fluxes of hypoxanthine, thymine, and adenine by hENT1 were saturable and inhibited by NBMPR. Hypoxanthine 10-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 21795683-8 2011 Fluxes of hypoxanthine, thymine, and adenine by hENT1 were saturable and inhibited by NBMPR. Thymine 24-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 21795683-8 2011 Fluxes of hypoxanthine, thymine, and adenine by hENT1 were saturable and inhibited by NBMPR. Adenine 37-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 21795683-8 2011 Fluxes of hypoxanthine, thymine, and adenine by hENT1 were saturable and inhibited by NBMPR. 4-nitrobenzylthioinosine 86-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 21809900-2 2011 ENT1 is expressed ubiquitously in mammalian tissues and responsible for a significant portion of nucleoside analog drug uptake in humans. Nucleosides 97-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 21809900-6 2011 The large intracellular loop of ENT1, between transmembrane domains 6 and 7, has been suggested to be a site of regulation by phosphorylation, therefore we generated His/Ubiquitin tagged peptides of this region and used them for in vitro kinase assays to identify target serines. Serine 271-278 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-36 21809900-7 2011 Our data support a role for PKA and PKC in the phosphorylation of ENT1 within the intracellular loop and show that PKA can phosphorylate multiple sites within this loop while PKC specifically targets serines 279 and 286 and threonine 274. Serine 200-207 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-70 21809900-7 2011 Our data support a role for PKA and PKC in the phosphorylation of ENT1 within the intracellular loop and show that PKA can phosphorylate multiple sites within this loop while PKC specifically targets serines 279 and 286 and threonine 274. Threonine 224-233 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-70 21402067-3 2011 hENT1 is responsible for the uptake of nucleoside analog drugs used in treating viral infections and cancer, but despite its clinical importance, virtually nothing is known about the dynamics of the hENT1 life cycle including trafficking to the PM, endocytosis and degradation. Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 21644519-1 2011 The title compound, ent-1, the non-natural enantiomeric form of the lycorenine-type alkaloid (-)-clividine (1), has been prepared using the enantiomerically pure (ee >99.8%) cis-1,2-dihydrocatechol 3 as starting material. lycorenine 68-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 21644519-1 2011 The title compound, ent-1, the non-natural enantiomeric form of the lycorenine-type alkaloid (-)-clividine (1), has been prepared using the enantiomerically pure (ee >99.8%) cis-1,2-dihydrocatechol 3 as starting material. Alkaloids 84-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 21644519-1 2011 The title compound, ent-1, the non-natural enantiomeric form of the lycorenine-type alkaloid (-)-clividine (1), has been prepared using the enantiomerically pure (ee >99.8%) cis-1,2-dihydrocatechol 3 as starting material. clividine 93-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 21644519-1 2011 The title compound, ent-1, the non-natural enantiomeric form of the lycorenine-type alkaloid (-)-clividine (1), has been prepared using the enantiomerically pure (ee >99.8%) cis-1,2-dihydrocatechol 3 as starting material. cis-1,2-dihydrocatechol 177-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-25 21644519-2 2011 A key feature associated with the closing stages of the synthesis involved the diastereoselective addition of a nitrogen-centered radical onto a pendant cyclohexene to establish the cis-fused D-ring and the required stereochemistry at C11b in the final product ent-1. nitrogen-centered radical 112-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 261-266 21644519-2 2011 A key feature associated with the closing stages of the synthesis involved the diastereoselective addition of a nitrogen-centered radical onto a pendant cyclohexene to establish the cis-fused D-ring and the required stereochemistry at C11b in the final product ent-1. cyclohexene 153-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 261-266 21166756-0 2011 The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. gemcitabine 143-154 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-75 21166756-0 2011 The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. Cisplatin 155-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-75 21166756-1 2011 OBJECTIVE: To evaluate the expression of the human equilibrative nucleoside transporter 1 (hENT1) and excision repair cross complementing 1 (ERCC1) as possible prognostic factors for patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. gemcitabine 236-247 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-89 21166756-1 2011 OBJECTIVE: To evaluate the expression of the human equilibrative nucleoside transporter 1 (hENT1) and excision repair cross complementing 1 (ERCC1) as possible prognostic factors for patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. gemcitabine 236-247 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-96 21166756-1 2011 OBJECTIVE: To evaluate the expression of the human equilibrative nucleoside transporter 1 (hENT1) and excision repair cross complementing 1 (ERCC1) as possible prognostic factors for patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. Cisplatin 248-257 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-89 21166756-1 2011 OBJECTIVE: To evaluate the expression of the human equilibrative nucleoside transporter 1 (hENT1) and excision repair cross complementing 1 (ERCC1) as possible prognostic factors for patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. Cisplatin 248-257 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-96 21166756-2 2011 PATIENTS AND METHODS: The present study retrospectively evaluated the expression of hENT1 and ERCC1 by immunostaining in chemo-naive primary bladder tumour specimens from 40 patients with metastatic bladder cancer who received treatment with gemcitabine-cisplatin-based combination chemotherapy at Wakayama Medical University Hospital and affiliated hospitals from May 2002 to July 2009. gemcitabine 242-253 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 21166756-2 2011 PATIENTS AND METHODS: The present study retrospectively evaluated the expression of hENT1 and ERCC1 by immunostaining in chemo-naive primary bladder tumour specimens from 40 patients with metastatic bladder cancer who received treatment with gemcitabine-cisplatin-based combination chemotherapy at Wakayama Medical University Hospital and affiliated hospitals from May 2002 to July 2009. Cisplatin 254-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 21166756-9 2011 CONCLUSION: The data obtained in the present study show that high expression of hENT1 in tumour cells is associated with prolonged survival in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. gemcitabine 196-207 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 21166756-9 2011 CONCLUSION: The data obtained in the present study show that high expression of hENT1 in tumour cells is associated with prolonged survival in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy. Cisplatin 208-217 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 21264835-2 2011 Previous studies have suggested that in pancreatic cancer, human equilibrative nucleoside transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) expression may have prognostic value as well as predictive value with sensitivity to gemcitabine. gemcitabine 245-256 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-103 21264835-2 2011 Previous studies have suggested that in pancreatic cancer, human equilibrative nucleoside transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) expression may have prognostic value as well as predictive value with sensitivity to gemcitabine. gemcitabine 245-256 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-111 21264835-13 2011 CONCLUSIONS: Low expression of hENT-1 was associated with worse OS and PFS in patients with resected pancreatic adenocarcinoma independent of gemcitabine therapy. gemcitabine 142-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-37 21223299-3 2011 Interestingly, ethanol is known to increase adenosine levels by inhibiting an ethanol-sensitive adenosine transporter, equilibrative nucleoside transporter type 1 (ENT1). Ethanol 15-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-162 21395582-0 2011 Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenosine levels in physiological and hypoxic-ischemic conditions. Adenosine 86-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-58 21543469-6 2011 When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. Ribavirin 34-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 21543469-6 2011 When Huh7.5 cells were exposed to RBV, resistance developed through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduced. Ribavirin 76-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 21543469-7 2011 The uptake defect in RBV-resistant cells was specific to RBV, since transport of another ENT1 substrate, cytidine, was unaffected. Ribavirin 21-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-93 21539390-7 2011 This is the first reported dipyridamole-based ENT1 fluorescent probe, which adds a novel tool for probing ENT1, and possibly ENT2. Dipyridamole 27-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-50 21539390-7 2011 This is the first reported dipyridamole-based ENT1 fluorescent probe, which adds a novel tool for probing ENT1, and possibly ENT2. Dipyridamole 27-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 106-110 21310713-2 2011 Low concentrations of EdU (1 microM) are sufficient to allow detection of incorporation in cells expressing thymidine kinase and human equilibrative nucleoside transporter 1 (hENT1). 5-ethynyl-2'-deoxyuridine 22-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 135-173 21310713-2 2011 Low concentrations of EdU (1 microM) are sufficient to allow detection of incorporation in cells expressing thymidine kinase and human equilibrative nucleoside transporter 1 (hENT1). 5-ethynyl-2'-deoxyuridine 22-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-180 21382338-7 2011 No alterations of the deoxynucleotide pools were found, whereas a reduction in the expression of genes involved in nucleoside/nucleotide homeostasis (human equilibrative nucleoside transporter 1, thymidine phosphorylase) and mtDNA maintenance (DNA-polymerase gamma, mitochondrial transcription factor A) was observed. Nucleosides 115-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-194 21453390-0 2011 Neuronal ENT1 takes up synaptic adenosine even under hypoxia/ischemia. Adenosine 32-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-13 21539390-3 2011 In this study, we have developed a novel dipyridamole (DP)-based equilibrative nucleoside transporter 1 (ENT1) fluorescent probe. Dipyridamole 41-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-103 21539390-3 2011 In this study, we have developed a novel dipyridamole (DP)-based equilibrative nucleoside transporter 1 (ENT1) fluorescent probe. Dipyridamole 41-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-109 21539390-3 2011 In this study, we have developed a novel dipyridamole (DP)-based equilibrative nucleoside transporter 1 (ENT1) fluorescent probe. Dipyridamole 55-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-103 21539390-3 2011 In this study, we have developed a novel dipyridamole (DP)-based equilibrative nucleoside transporter 1 (ENT1) fluorescent probe. Dipyridamole 55-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 105-109 21539390-5 2011 The binding affinities of 8MDP-fluor at ENT1 and ENT2 are reflected by the uridine uptake inhibitory K(i) values of 52.1 nM and 285 nM, respectively. 8mdp-fluor 26-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 21539390-5 2011 The binding affinities of 8MDP-fluor at ENT1 and ENT2 are reflected by the uridine uptake inhibitory K(i) values of 52.1 nM and 285 nM, respectively. Uridine 75-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-44 21539390-6 2011 8MDP-fluor was successfully demonstrated to be a flow cytometric probe for ENT1 comparable to the nitrobenzylmercaptopurine riboside (NBMPR) analogue ENT1 fluorescent probe SAENTA-X8-fluorescein (SAENTA-fluor, 1). 8mdp-fluor 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-79 21515851-8 2011 Cells from GDM exhibited increased insulin receptor A isoform expression in addition to the reported NO-dependent inhibition of hENT1-adenosine transport and SLC29A1 reporter repression, and increased extracellular concentration of adenosine and NO synthase activity. Adenosine 134-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-133 21423062-1 2011 PURPOSE: We examined equilibrative nucleoside transporter-1 (ENT1) and thymidine kinase-1 (TK1) messenger ribonucleic acid (mRNA) expressions in cancer tissue samples to elucidate the mechanism of 3"-deoxy-3"-F-fluorothymidine (FLT) uptake by positron emission tomography (PET) scan in gastrointestinal cancer. 3"-deoxy-3"-f-fluorothymidine 197-226 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-59 21223299-3 2011 Interestingly, ethanol is known to increase adenosine levels by inhibiting an ethanol-sensitive adenosine transporter, equilibrative nucleoside transporter type 1 (ENT1). Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-162 21223299-3 2011 Interestingly, ethanol is known to increase adenosine levels by inhibiting an ethanol-sensitive adenosine transporter, equilibrative nucleoside transporter type 1 (ENT1). Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-168 21223299-3 2011 Interestingly, ethanol is known to increase adenosine levels by inhibiting an ethanol-sensitive adenosine transporter, equilibrative nucleoside transporter type 1 (ENT1). Ethanol 15-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-168 21455275-5 2011 Recombinant tandem histidine-affinity (HAT) and 3xFLAG tagged hENT1 was overexpressed in E. coli, affinity purified, and functionally characterized by nitrobenzylthioinosine (NBTI) binding. 4-nitrobenzylthioinosine 151-173 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-67 21455275-5 2011 Recombinant tandem histidine-affinity (HAT) and 3xFLAG tagged hENT1 was overexpressed in E. coli, affinity purified, and functionally characterized by nitrobenzylthioinosine (NBTI) binding. 4-nitrobenzylthioinosine 175-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-67 21291869-6 2011 The purpose of this study was to investigate the effects of dFdU on gemcitabine uptake and efflux via hENT1 and hENT2 in HeLa cells. 2',2'-difluoro-2'-deoxyuridine 60-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 21291869-6 2011 The purpose of this study was to investigate the effects of dFdU on gemcitabine uptake and efflux via hENT1 and hENT2 in HeLa cells. gemcitabine 68-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 21291869-7 2011 Our results suggest that dFdU is a substrate for both hENT1 and hENT2 as well as a competitive inhibitor of gemcitabine transport at concentrations >100-fold lower than those typically achieved in plasma (IC(50)=0.45 and 1.2muM for hENT1/2 and hENT2, respectively). 2',2'-difluoro-2'-deoxyuridine 25-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 21291869-7 2011 Our results suggest that dFdU is a substrate for both hENT1 and hENT2 as well as a competitive inhibitor of gemcitabine transport at concentrations >100-fold lower than those typically achieved in plasma (IC(50)=0.45 and 1.2muM for hENT1/2 and hENT2, respectively). 2',2'-difluoro-2'-deoxyuridine 25-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 235-242 21291869-7 2011 Our results suggest that dFdU is a substrate for both hENT1 and hENT2 as well as a competitive inhibitor of gemcitabine transport at concentrations >100-fold lower than those typically achieved in plasma (IC(50)=0.45 and 1.2muM for hENT1/2 and hENT2, respectively). gemcitabine 108-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 235-242 21284703-0 2011 Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. gemcitabine 93-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 21336182-2 2011 Preclinical data suggest that pemetrexed may synergistically interact with gemcitabine by enhancing the expression of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK), increasing the uptake and intracellular activation of gemcitabine. Pemetrexed 30-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 124-162 21336182-2 2011 Preclinical data suggest that pemetrexed may synergistically interact with gemcitabine by enhancing the expression of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK), increasing the uptake and intracellular activation of gemcitabine. Pemetrexed 30-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-169 21336182-2 2011 Preclinical data suggest that pemetrexed may synergistically interact with gemcitabine by enhancing the expression of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK), increasing the uptake and intracellular activation of gemcitabine. gemcitabine 75-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 124-162 21336182-2 2011 Preclinical data suggest that pemetrexed may synergistically interact with gemcitabine by enhancing the expression of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK), increasing the uptake and intracellular activation of gemcitabine. gemcitabine 75-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-169 21336182-2 2011 Preclinical data suggest that pemetrexed may synergistically interact with gemcitabine by enhancing the expression of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK), increasing the uptake and intracellular activation of gemcitabine. gemcitabine 257-268 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-169 21336182-7 2011 Quantitative real-time polymerase chain reaction analysis revealed a statistically significant (p < 0.001) biphasic increase in both hENT1 and dCK genes at 1 to 2 and 24 to 48 hours after pemetrexed administration. Pemetrexed 191-201 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-141 21336182-8 2011 CONCLUSIONS: This is the first evidence of dCK and hENT1 induction by pemetrexed in humans, suggesting that the pemetrexed gemcitabine combination should be optimized by the administration of gemcitabine 1 to 2 or 24 to 48 hours after pemetrexed. Pemetrexed 70-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 21336182-9 2011 These results support further studies to validate the role of dCK/hENT1 in vivo modulation for the optimization of gemcitabine-pemetrexed combination in patients with NSCLC. gemcitabine 115-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-71 21336182-9 2011 These results support further studies to validate the role of dCK/hENT1 in vivo modulation for the optimization of gemcitabine-pemetrexed combination in patients with NSCLC. Pemetrexed 127-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-71 21521023-5 2011 Inhibition of hENT1 reversed ara-C cytotoxicity. Cytarabine 29-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 21586890-0 2011 [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. gemcitabine 146-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-75 21205085-3 2011 The interacellular uptake of gemcitabine was greatly impaired in the chemoresistant cell lines due to dysfunction of ENT1 and ENT2. gemcitabine 29-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-121 21586890-0 2011 [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. gemcitabine 146-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 21586890-0 2011 [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. Cisplatin 158-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-75 21586890-0 2011 [The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy]. Cisplatin 158-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 21586890-10 2011 In our retrospective study, the predictive value of a high expression level of hENT1 was assessed in bladder cancer treated by gemcitabine combined combination chemotherapy. gemcitabine 127-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-84 20578980-0 2011 Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). gemcitabine 80-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 21283641-2 2011 In cultured cell and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known to regulate ethanol sensitivity and preference. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 21283641-2 2011 In cultured cell and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known to regulate ethanol sensitivity and preference. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 21283641-2 2011 In cultured cell and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known to regulate ethanol sensitivity and preference. Ethanol 153-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 21283641-2 2011 In cultured cell and animal studies, type 1 equilibrative nucleoside transporter (ENT1, slc29a1), which regulates adenosine levels, is known to regulate ethanol sensitivity and preference. Ethanol 153-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-95 21283641-4 2011 PRINCIPAL FINDINGS: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced extracellular adenosine levels. Ethanol 66-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 21283641-4 2011 PRINCIPAL FINDINGS: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced extracellular adenosine levels. Ethanol 66-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 172-176 21283641-4 2011 PRINCIPAL FINDINGS: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced extracellular adenosine levels. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 21283641-4 2011 PRINCIPAL FINDINGS: Our functional analysis showed that prolonged ethanol exposure increased adenosine uptake activity of mutant cells (ENT1-216Thr) compared to wild-type (ENT1-216Ile) transfected cells, which might result in reduced extracellular adenosine levels. Adenosine 248-257 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 21283641-8 2011 CONCLUSIONS: Together with the functional data, our findings suggest a potential contribution of a genetic variant of ENT1 to the development of alcoholism with increased risk of alcohol withdrawal-induced seizures in humans. Alcohols 145-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-122 20957282-1 2011 A concise asymmetric synthesis of (+)-swainsonine (ent-1) is described starting from 2, which was readily prepared from commercially available l-glutamic acid. Swainsonine 34-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 20957282-1 2011 A concise asymmetric synthesis of (+)-swainsonine (ent-1) is described starting from 2, which was readily prepared from commercially available l-glutamic acid. Glutamic Acid 143-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 20578980-0 2011 Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). gemcitabine 80-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 20578980-1 2011 BACKGROUND AND AIM: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. gemcitabine 205-216 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-135 20578980-1 2011 BACKGROUND AND AIM: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. gemcitabine 205-216 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-142 20578980-2 2011 The aim of this study was to retrospectively determine patients" outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. gemcitabine 149-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 104-109 20578980-9 2011 CONCLUSIONS: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC. gemcitabine 82-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 21443122-1 2010 BACKGROUND/AIMS: Human Equilibrative Nucleoside Transporters 1 (hENT1) gene is involving in mediating nucleosides and nucleoside analog drugs across the plasma membrane, and may affect the chemotherapeutical efficacy. Nucleosides 102-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 20956085-8 2011 Based on the observed sensitivity of pterin transport to nitrobenzylthioinosine (NBMPR), we examined the ability of ENT1 and ENT2, representative equilibrative nucleoside transporters, to transport sepiapterin (SP), BH(2) or BH(4) using HeLa cell and Xenopus oocyte expression systems. sepiapterin 198-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-120 20956085-10 2011 hENT1 could also transport the pterins but less efficiently. Pterins 31-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 22091436-3 2011 Human equilibrative nucleoside transporter 1 (hENT1) is recognized as a major transporter of GEM into cells. gemcitabine 93-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 22091436-3 2011 Human equilibrative nucleoside transporter 1 (hENT1) is recognized as a major transporter of GEM into cells. gemcitabine 93-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 22091436-4 2011 In addition, a factor that activates hENT1 is the inhibition of thymidylate synthase (TS), one of the 5-FU metabolic enzymes; TS inhibition mediates depleting intracellular nucleotide pools, resulting in the activation of the salvage pathway mediated through hENT1. Fluorouracil 102-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 24281217-4 2010 To exert its cytotoxic effects, gemcitabine must enter cells via nucleoside transporters, most notably human equilibrative nucleoside transporter 1 (hENT1). gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-147 24281217-4 2010 To exert its cytotoxic effects, gemcitabine must enter cells via nucleoside transporters, most notably human equilibrative nucleoside transporter 1 (hENT1). gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 149-154 24281217-5 2010 Increasingly strong evidence suggests hENT1 is a prognostic biomarker in gemcitabine-treated pancreatic cancer, and may well be a predictive biomarker of gemcitabine efficacy. gemcitabine 73-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 21443122-1 2010 BACKGROUND/AIMS: Human Equilibrative Nucleoside Transporters 1 (hENT1) gene is involving in mediating nucleosides and nucleoside analog drugs across the plasma membrane, and may affect the chemotherapeutical efficacy. Nucleosides 102-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 21443122-2 2010 We explored the relationship between hENT1 expression and 5-fluorouracil (5-FU) response in pancreatic cancer cell line. Fluorouracil 58-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 21443122-2 2010 We explored the relationship between hENT1 expression and 5-fluorouracil (5-FU) response in pancreatic cancer cell line. Fluorouracil 74-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 21443122-8 2010 However, when the cells were treated with 5-FU, cells viability and IC50 value of 5-FU was significantly reduced in the transfected cells, and cell cycle of pSilence-hENT1-Panc-1 was arrest in G0/G1. Fluorouracil 42-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 166-171 21443122-8 2010 However, when the cells were treated with 5-FU, cells viability and IC50 value of 5-FU was significantly reduced in the transfected cells, and cell cycle of pSilence-hENT1-Panc-1 was arrest in G0/G1. Fluorouracil 82-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 166-171 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. sahenta 54-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-229 20811706-3 2010 The aim of this study is to identify the most reliable chemoresistance marker to gemcitabine in BTC among the 4 molecules (hENT1, dCK, RRM1 and RRM2) involved in gemcitabine metabolism. gemcitabine 81-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 20811706-3 2010 The aim of this study is to identify the most reliable chemoresistance marker to gemcitabine in BTC among the 4 molecules (hENT1, dCK, RRM1 and RRM2) involved in gemcitabine metabolism. btc 96-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 20811706-3 2010 The aim of this study is to identify the most reliable chemoresistance marker to gemcitabine in BTC among the 4 molecules (hENT1, dCK, RRM1 and RRM2) involved in gemcitabine metabolism. gemcitabine 162-173 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 20728214-8 2010 hEPC-3d cells exhibit hENT1-like adenosine transport (NBTI-sensitive, Na(+)-independent), which is absent in hEPC-14d cells. 4-nitrobenzylthioinosine 54-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-27 20824050-6 2010 In cells with acquired gemcitabine resistance (up to 160 nM gemcitabine), the mRNA or protein expression of the gemcitabine transporters MRP5 and ENT1 was upregulated in several cell lines. gemcitabine 23-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-150 20824050-6 2010 In cells with acquired gemcitabine resistance (up to 160 nM gemcitabine), the mRNA or protein expression of the gemcitabine transporters MRP5 and ENT1 was upregulated in several cell lines. gemcitabine 60-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-150 20824050-7 2010 Combined treatment with 5-FU and gemcitabine caused a 5- to 40-fold increase in MRP5 and ENT1 expressions. Fluorouracil 24-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-93 20824050-7 2010 Combined treatment with 5-FU and gemcitabine caused a 5- to 40-fold increase in MRP5 and ENT1 expressions. gemcitabine 33-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-93 20718495-0 2010 Improved syntheses of 5"-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5"-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. 5"-s-(2-aminoethyl)-6-n-(4-nitrobenzyl)-5"-thioadenosine 22-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 205-210 20812847-1 2010 The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 82-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-42 20812847-1 2010 The equilibrative nucleoside transporter 1 (ENT1) is the main protein involved in ribavirin cellular uptake. Ribavirin 82-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 20812847-2 2010 Polymorphisms at the ENT1 gene may influence ribavirin activity as part of hepatitis C virus (HCV) therapy. Ribavirin 45-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-25 20812847-9 2010 In summary, a SNP rs760370A G at the ENT1 gene influences the chance of rapid virological response to pegIFN-ribavirin therapy in HIV-infected patients with chronic HCV infection due to HCV genotypes 1 or 4, most likely modulating intracellular ribavirin exposure within hepatocytes. pegifn 102-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-41 20812847-9 2010 In summary, a SNP rs760370A G at the ENT1 gene influences the chance of rapid virological response to pegIFN-ribavirin therapy in HIV-infected patients with chronic HCV infection due to HCV genotypes 1 or 4, most likely modulating intracellular ribavirin exposure within hepatocytes. Ribavirin 109-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-41 20812847-9 2010 In summary, a SNP rs760370A G at the ENT1 gene influences the chance of rapid virological response to pegIFN-ribavirin therapy in HIV-infected patients with chronic HCV infection due to HCV genotypes 1 or 4, most likely modulating intracellular ribavirin exposure within hepatocytes. Ribavirin 245-254 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-41 20728214-1 2010 Extracellular adenosine removal is via human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) in the endothelium, thus regulating adenosine-induced revascularization and angiogenesis. Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 20728214-1 2010 Extracellular adenosine removal is via human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) in the endothelium, thus regulating adenosine-induced revascularization and angiogenesis. Adenosine 143-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 86-91 20728214-8 2010 hEPC-3d cells exhibit hENT1-like adenosine transport (NBTI-sensitive, Na(+)-independent), which is absent in hEPC-14d cells. Adenosine 33-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-27 21054262-5 2010 Acute ethanol elevates extracellular adenosine levels by selectively inhibiting the type 1 equilibrative nucleoside transporter, ENT1. Ethanol 6-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 21054262-5 2010 Acute ethanol elevates extracellular adenosine levels by selectively inhibiting the type 1 equilibrative nucleoside transporter, ENT1. Adenosine 37-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 21054262-7 2010 Recently, we have shown that pharmacological inhibition or genetic deletion of ENT1 reduces the expression of excitatory amino acid transporter 2 (EAAT2), the primary regulator of extracellular glutamate, in astrocytes. Glutamic Acid 194-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-83 20720049-6 2010 RESULTS: (3)H-Thymidine transport was dominated by human equilibrative nucleoside transporter 1 (hENT1) under both growth conditions. Thymidine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-95 20720049-6 2010 RESULTS: (3)H-Thymidine transport was dominated by human equilibrative nucleoside transporter 1 (hENT1) under both growth conditions. Thymidine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 20720049-9 2010 Cell membrane levels of hENT1 increased in cells under exponential growth, and this increase was associated with a more rapid rate of uptake for both (3)H-thymidine and (3)H-FLT. h-thymidine 153-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 20720049-13 2010 Levels of hENT1, an important transporter of (3)H-FLT and (3)H-thymidine, increase as proliferating cells enter the cell cycle. h-thymidine 61-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Saenta 43-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-229 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Saenta 43-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 231-236 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. sahenta 54-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 231-236 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. fluorescein-5-yl isothiocyanate 67-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-229 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. fluorescein-5-yl isothiocyanate 67-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 231-236 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Fluorescein-5-isothiocyanate 100-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-229 20718495-2 2010 Conjugation of the pendant amino groups of SAENTA and SAHENTA with fluorescein-5-yl isothiocyanate (FITC) gave fluorescent probes that bound at nanomolar concentrations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant form in model expression systems and in native form in cancer cell lines. Fluorescein-5-isothiocyanate 100-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 231-236 20397706-2 2010 Although the conformations of 1 and ent-1 are restricted by the central cyclopropane ring, the 2-(4-chlorobenzylamino)ethyl side chain essential for the H(3) receptor binding may somewhat freely rotate. cyclopropane 72-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-41 20608756-5 2010 The aim of this study was to determine the factors, including genetic polymorphisms of CDA, DCK and solute carrier family 29A1 (SLC29A1 [hENT1]), that alter the pharmacokinetics of gemcitabine in Japanese cancer patients. gemcitabine 181-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-135 20608756-5 2010 The aim of this study was to determine the factors, including genetic polymorphisms of CDA, DCK and solute carrier family 29A1 (SLC29A1 [hENT1]), that alter the pharmacokinetics of gemcitabine in Japanese cancer patients. gemcitabine 181-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 137-142 20424118-5 2010 Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Dipyridamole 24-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-172 20424118-5 2010 Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Dilazep 41-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-166 20424118-5 2010 Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Dilazep 41-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-172 20424118-7 2010 Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity. ohsv 51-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 20424118-7 2010 Our results indicate that ENT1 antagonists augment oHSV replication in tumor cells by increasing cellular ribonucleoside activity. Ribonucleosides 106-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 20424118-0 2010 Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Dipyridamole 39-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-26 20424118-0 2010 Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Dilazep 56-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-26 20424118-5 2010 Two of these compounds, dipyridamole and dilazep, interfered with nucleotide metabolism by potently and directly inhibiting the equilibrative nucleoside transporter-1 (ENT1). Dipyridamole 24-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-166 20082300-2 2010 The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. gemcitabine 118-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 20082300-2 2010 The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. Cytarabine 131-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 20082300-2 2010 The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. gemcitabine 118-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 20082300-2 2010 The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. Cytarabine 131-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 20082300-2 2010 The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. fludarabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 19660438-10 2010 Our results highlight the importance of hENT1 and TK2 activities in response to gemcitabine. gemcitabine 80-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 20082300-2 2010 The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. fludarabine 147-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 20082300-3 2010 The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. gemcitabine 88-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-9 20032083-0 2010 Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPalpha in human umbilical vein endothelial cells from gestational diabetes. Nitric Oxide 0-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-28 20032083-1 2010 AIMS: Reduced expression of human equilibrative nucleoside transporter 1 (hENT1) results from nitric oxide (NO)-dependent reduced SLC29A1 transcriptional activity in human umbilical vein endothelial cells (HUVECs) from gestational diabetes. Nitric Oxide 94-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-72 20032083-1 2010 AIMS: Reduced expression of human equilibrative nucleoside transporter 1 (hENT1) results from nitric oxide (NO)-dependent reduced SLC29A1 transcriptional activity in human umbilical vein endothelial cells (HUVECs) from gestational diabetes. Nitric Oxide 94-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-79 20032083-1 2010 AIMS: Reduced expression of human equilibrative nucleoside transporter 1 (hENT1) results from nitric oxide (NO)-dependent reduced SLC29A1 transcriptional activity in human umbilical vein endothelial cells (HUVECs) from gestational diabetes. Nitric Oxide 94-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 130-137 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 99-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-47 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 99-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 171-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-47 20185188-5 2010 RESULTS: Equilibrative nucleoside transporter 1 (ENT1)-mediated uptake was exclusively involved in ribavirin uptake in HH268 and HH283 and was responsible for the largest ribavirin uptake fraction in HH291. Ribavirin 171-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 20185188-6 2010 The level of ENT1-mediated uptake in HH291 was higher than that in HH268 and HH283. hh268 67-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-17 20185188-6 2010 The level of ENT1-mediated uptake in HH291 was higher than that in HH268 and HH283. hh283 77-82 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-17 20185188-10 2010 CONCLUSIONS: ENT1, but not ENT2 or CNTs, is a major ribavirin uptake transporter in human hepatocytes. Ribavirin 52-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-17 20185188-11 2010 The different ENT1-mediated ribavirin uptake levels in different hepatocyte lines are associated with different expression levels of specific isoforms of ENT1 mRNAs. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-18 20185188-11 2010 The different ENT1-mediated ribavirin uptake levels in different hepatocyte lines are associated with different expression levels of specific isoforms of ENT1 mRNAs. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 20096989-0 2010 Kinetic study of anti-viral ribavirin uptake mediated by hCNT3 and hENT1 in Xenopus laevis oocytes. Ribavirin 28-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-72 20113503-3 2010 Although the uptake of purines through the human equilibrative nucleoside transporter (hENT1), the human facilitative nucleobase transporter (hFNT1) and the parasite-induced new permeation pathway (NPP) has been studied, no information appears to exist on the relative contribution of these three transporters to the uptake of adenosine and hypoxanthine. Purines 23-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-92 20113503-9 2010 Hypoxanthine and adenine appeared to enter erythrocytes mainly through the hFNT1 nucleobase transporter whereas adenosine entered predominantly through the hENT1 nucleoside transporter. Adenosine 112-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 20113503-13 2010 CONCLUSION: Collectively, the data obtained in this study clearly show that the endogenous host erythrocyte transporters hENT1 and hFNT1, rather than the NPP, are the major route of entry of purine into parasitized RBC. purine 191-197 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 121-126 20113503-14 2010 Inhibitors of hENT1 and hFNT1, as well as the NPP, should be considered in the development of anti-malarials targeted to purine transport. purine 121-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 19788890-1 2010 The abundance of human equilibrative nucleoside transporter 1 (hENT1) has recently been shown to be a predictive marker of benefit from gemcitabine therapy in patients with pancreatic cancer. gemcitabine 136-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-61 19788890-1 2010 The abundance of human equilibrative nucleoside transporter 1 (hENT1) has recently been shown to be a predictive marker of benefit from gemcitabine therapy in patients with pancreatic cancer. gemcitabine 136-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 63-68 19788890-2 2010 Since hENT1 is also important for the uptake of positron emission tomography (PET) tracer 3"-deoxy-3"-fluorothymidine (FLT) in various cultured human cell lines, this study was undertaken to determine if FLT uptake predicts gemcitabine uptake and/or toxicity in a panel of human pancreatic cancer cell lines (Capan-2, AsPC-1, BxPC-3, PL45, MIA PaCa-2, and PANC-1). alovudine 90-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-11 19788890-2 2010 Since hENT1 is also important for the uptake of positron emission tomography (PET) tracer 3"-deoxy-3"-fluorothymidine (FLT) in various cultured human cell lines, this study was undertaken to determine if FLT uptake predicts gemcitabine uptake and/or toxicity in a panel of human pancreatic cancer cell lines (Capan-2, AsPC-1, BxPC-3, PL45, MIA PaCa-2, and PANC-1). alovudine 119-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-11 19788890-2 2010 Since hENT1 is also important for the uptake of positron emission tomography (PET) tracer 3"-deoxy-3"-fluorothymidine (FLT) in various cultured human cell lines, this study was undertaken to determine if FLT uptake predicts gemcitabine uptake and/or toxicity in a panel of human pancreatic cancer cell lines (Capan-2, AsPC-1, BxPC-3, PL45, MIA PaCa-2, and PANC-1). gemcitabine 224-235 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-11 19788890-3 2010 Capan-2 cells displayed the lowest levels of (1) extracellular nitrobenzylmercaptopurine ribonucleoside (NBMPR) binding, which represents cell-surface hENT1, (2) FLT and gemcitabine uptake during short (1-45s) and prolonged (1h) periods, and (3) gemcitabine sensitivity. Nitrobenzylmercaptopurine Ribonucleoside 63-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-156 19788890-3 2010 Capan-2 cells displayed the lowest levels of (1) extracellular nitrobenzylmercaptopurine ribonucleoside (NBMPR) binding, which represents cell-surface hENT1, (2) FLT and gemcitabine uptake during short (1-45s) and prolonged (1h) periods, and (3) gemcitabine sensitivity. 4-nitrobenzylthioinosine 105-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 151-156 19788890-4 2010 Exposure to NBMPR (inhibits only hENT1) or dilazep (inhibits hENT1 and hENT2) reduced FLT and gemcitabine uptake and gemcitabine sensitivity, with dilazep having greater effects than NBMPR. 4-nitrobenzylthioinosine 12-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 19788890-4 2010 Exposure to NBMPR (inhibits only hENT1) or dilazep (inhibits hENT1 and hENT2) reduced FLT and gemcitabine uptake and gemcitabine sensitivity, with dilazep having greater effects than NBMPR. 4-nitrobenzylthioinosine 12-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-66 19788890-4 2010 Exposure to NBMPR (inhibits only hENT1) or dilazep (inhibits hENT1 and hENT2) reduced FLT and gemcitabine uptake and gemcitabine sensitivity, with dilazep having greater effects than NBMPR. Dilazep 43-50 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-66 19788890-4 2010 Exposure to NBMPR (inhibits only hENT1) or dilazep (inhibits hENT1 and hENT2) reduced FLT and gemcitabine uptake and gemcitabine sensitivity, with dilazep having greater effects than NBMPR. gemcitabine 94-105 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-66 19788890-5 2010 Gemcitabine permeation was almost completely mediated, primarily by hENT1 and to a lesser extent by hENT2, whereas FLT permeation included a substantial component of passive diffusion. gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 19861447-1 2009 PURPOSE: We showed in preclinical models that thymidylate synthase (TS) inhibition leads to redistribution of the nucleoside transporter, ENT1, to the cell membrane and hence increases tissue uptake of [(18)F]fluorothymidine (FLT). alovudine 209-224 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 20814156-2 2010 The uptake of uridine, an ENT1 substrate, showed saturation kinetics and was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), a specific ENT1 inhibitor, at both 23 degrees C and ICT. Uridine 14-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 20814156-2 2010 The uptake of uridine, an ENT1 substrate, showed saturation kinetics and was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), a specific ENT1 inhibitor, at both 23 degrees C and ICT. Uridine 14-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-146 20814156-2 2010 The uptake of uridine, an ENT1 substrate, showed saturation kinetics and was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), a specific ENT1 inhibitor, at both 23 degrees C and ICT. 4-nitrobenzylthioinosine 90-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 20814156-2 2010 The uptake of uridine, an ENT1 substrate, showed saturation kinetics and was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), a specific ENT1 inhibitor, at both 23 degrees C and ICT. 4-nitrobenzylthioinosine 90-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-146 20814156-2 2010 The uptake of uridine, an ENT1 substrate, showed saturation kinetics and was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), a specific ENT1 inhibitor, at both 23 degrees C and ICT. 4-nitrobenzylthioinosine 123-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-30 20814156-2 2010 The uptake of uridine, an ENT1 substrate, showed saturation kinetics and was inhibited by S-(4-nitrobenzyl)-6-thioinosine (NBMPR), a specific ENT1 inhibitor, at both 23 degrees C and ICT. 4-nitrobenzylthioinosine 123-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-146 20814156-3 2010 [3H]Uridine uptake was markedly trans-stimulated by preloading ROVs with unlabeled uridine or ribavirin, another ENT1 substrate, and the overshoot phenomenon was observed at ICT. Tritium 1-3 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-117 20814156-3 2010 [3H]Uridine uptake was markedly trans-stimulated by preloading ROVs with unlabeled uridine or ribavirin, another ENT1 substrate, and the overshoot phenomenon was observed at ICT. Uridine 4-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-117 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. [3h]uridine 31-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. 4-nitrobenzylthioinosine 102-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. Dipyridamole 109-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. Adenosine 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20814156-5 2010 The trans-stimulated uptake of [3H]uridine at ICT was inhibited by ENT1 inhibitors/substrates such as NBMPR, dipyridamole, adenosine, and ribavirin in a concentration-dependent manner. Ribavirin 138-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 20839414-1 2010 The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer. gemcitabine 85-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 20839414-1 2010 The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer. gemcitabine 85-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 19853583-6 2009 Taken together, these findings suggest that FLT3-ITD specifically induces ara-C resistance in leukemic cells by the repression of ENT1 expression, possibly through the upregulation of HIF-1alpha, while also partially accounting for the poor prognosis of AML with FLT3-ITD due to resistance to the standard chemotherapy protocols which include ara-C. Cytarabine 74-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 130-134 19853583-6 2009 Taken together, these findings suggest that FLT3-ITD specifically induces ara-C resistance in leukemic cells by the repression of ENT1 expression, possibly through the upregulation of HIF-1alpha, while also partially accounting for the poor prognosis of AML with FLT3-ITD due to resistance to the standard chemotherapy protocols which include ara-C. Cytarabine 343-348 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 130-134 20839414-1 2010 The human equilibrative nucleoside transporter 1 (hENT1) is the major means by which gemcitabine enters human cells; recent evidence exists that hENT1 is expressed in carcinoma of the ampulla of Vater and that it should be considered as a molecular prognostic marker for patients with resected ampullary cancer. gemcitabine 85-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-150 19853583-0 2009 FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Cytarabine 17-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-94 19853583-3 2009 Both of these cell lines were specifically resistant to the pyrimidine analogue cytosine arabinoside (ara-C), an essential agent for AML, accompanied by the downregulation of equilibrative nucleoside transporter 1 (ENT1), a transporter responsible for the cellular uptake of ara-C. Cytarabine 102-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-219 19853583-3 2009 Both of these cell lines were specifically resistant to the pyrimidine analogue cytosine arabinoside (ara-C), an essential agent for AML, accompanied by the downregulation of equilibrative nucleoside transporter 1 (ENT1), a transporter responsible for the cellular uptake of ara-C. Cytarabine 275-280 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-213 19853583-3 2009 Both of these cell lines were specifically resistant to the pyrimidine analogue cytosine arabinoside (ara-C), an essential agent for AML, accompanied by the downregulation of equilibrative nucleoside transporter 1 (ENT1), a transporter responsible for the cellular uptake of ara-C. Cytarabine 275-280 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-219 19861447-1 2009 PURPOSE: We showed in preclinical models that thymidylate synthase (TS) inhibition leads to redistribution of the nucleoside transporter, ENT1, to the cell membrane and hence increases tissue uptake of [(18)F]fluorothymidine (FLT). alovudine 226-229 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 19699178-1 2009 Human Equilibrative Nucleoside Transporter 1 (hENT1) is an integral membrane protein that transports nucleosides and analog drugs across cellular membranes. Nucleosides 101-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 19699178-1 2009 Human Equilibrative Nucleoside Transporter 1 (hENT1) is an integral membrane protein that transports nucleosides and analog drugs across cellular membranes. Nucleosides 101-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 19699178-5 2009 Quantification of GFP-hENT1 (mutant and wildtype) protein at the plasma membrane was conducted using nitrobenzylthioinosine (NBTI) binding. 4-nitrobenzylthioinosine 101-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-27 19699178-5 2009 Quantification of GFP-hENT1 (mutant and wildtype) protein at the plasma membrane was conducted using nitrobenzylthioinosine (NBTI) binding. 4-nitrobenzylthioinosine 125-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-27 19699178-6 2009 Functionality of the GFP-hENT1 mutants was determined by heterologous expression in Xenopus laevis oocytes followed by measurement of uridine uptake. Uridine 134-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-30 19428333-2 2009 After being transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara-C is phosphorylated to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. Cytarabine 101-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-91 19428333-2 2009 After being transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara-C is phosphorylated to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. Cytarabine 101-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 19428333-2 2009 After being transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara-C is phosphorylated to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. ara-ctp 148-155 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 19428333-2 2009 After being transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara-C is phosphorylated to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. Ara-C triphosphate 128-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-91 19428333-2 2009 After being transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara-C is phosphorylated to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. Ara-C triphosphate 128-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 19428333-2 2009 After being transported into leukemic cells by human equilibrative nucleoside transporter 1 (hENT1), ara-C is phosphorylated to ara-C triphosphate (ara-CTP), an active metabolite, and then incorporated into DNA, thereby inhibiting DNA synthesis. ara-ctp 148-155 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-91 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 123-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 19193655-9 2009 TGF-beta1 reduced hENT1-mediated adenosine transport, hENT1 protein abundance, hENT1 mRNA expression, and SLC29A1 gene promoter activity, but increased Sp1 binding to DNA. Adenosine 33-42 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 19193655-0 2009 TGF-beta1 inhibits expression and activity of hENT1 in a nitric oxide-dependent manner in human umbilical vein endothelium. Nitric Oxide 57-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 19193655-2 2009 hENT1-mediated adenosine transport and expression are reduced in gestational diabetes and hyperglycaemia, conditions associated with increased synthesis and release of nitric oxide (NO) and TGF-beta1 in this cell type. Adenosine 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 19193655-2 2009 hENT1-mediated adenosine transport and expression are reduced in gestational diabetes and hyperglycaemia, conditions associated with increased synthesis and release of nitric oxide (NO) and TGF-beta1 in this cell type. Nitric Oxide 168-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 19193655-5 2009 Total and hENT1-mediated adenosine transport was measured in the absence or presence of TGF-beta1, NG-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor), S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor), and/or KT-5823 (protein kinase G inhibitor) in control cells and cells expressing a truncated form of TGF-beta1 receptor type II (TTbetaRII). Adenosine 25-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-15 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 123-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-62 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-62 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-56 19244331-6 2009 Overexpression of equilibrative nucleoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in RBV-sensitive cell lines and restored the uptake defect in most RBV-resistant cell lines. Ribavirin 137-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-62 19244331-9 2009 Taken together, these results indicate that RBV uptake is restricted primarily to ENT1 in the cell lines examined. Ribavirin 44-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 82-86 19244331-10 2009 Interestingly, some RBV-resistant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activity of an alternative nucleoside transporter, ENT2. Ribavirin 20-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 19244331-10 2009 Interestingly, some RBV-resistant cell lines may compensate for reduced ENT1-mediated nucleoside uptake by increasing the activity of an alternative nucleoside transporter, ENT2. Nucleosides 86-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-76 19091561-0 2009 CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). s(6)-(4-nitrobenzyl)mercaptopurine riboside 36-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-157 19164463-0 2009 The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-54 19164463-0 2009 The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 19164463-0 2009 The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1-/- mouse erythrocytes. Ribavirin 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 19164463-2 2009 The human equilibrative nucleoside transporter (ENT) 1 transports ribavirin into erythrocytes where it is phosphorylated. Ribavirin 66-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-54 19164463-4 2009 Here, we examined the in vitro and ex vivo transport and metabolism of ribavirin by erythrocytes isolated from humans and Ent1-null mice. Ribavirin 71-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-126 19318496-0 2009 Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. gemcitabine 126-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 19318496-2 2009 Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2",2"-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. gemcitabine 158-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 19318496-2 2009 Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2",2"-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. gemcitabine 158-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 19318496-2 2009 Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2",2"-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. gemcitabine 190-201 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 19318496-2 2009 Human equilibrative nucleoside transporter 1 (hENT1) and human concentrative nucleoside transporter (hCNT) 1 and 3 are the major transporters responsible for 2",2"-difluoro-2-deoxycytidine (gemcitabine) uptake into cells. gemcitabine 190-201 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 19318496-3 2009 The aim of this study was to determine patients" outcome according to the expression of hENT1 and hCNT3 in tumoral cells after postoperative gemcitabine-based chemoradiation regimen. gemcitabine 141-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 19318496-7 2009 CONCLUSIONS: Pancreatic adenocarcinoma patients with a high expression of hENT1 and hCNT3 immunostaining have a significantly longer survival after adjuvant gemcitabine-based chemoradiation. gemcitabine 157-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-79 19185327-5 2009 A 3:2 molar ratio in favor of goniothalamin oxide (1) and ent-1 was observed from (R)- and (S)-4, respectively, when 3-chloroperbenzoic acid (mCPBA) was employed while an increase to 6:1 molar ratio was achieved with (S,S)-Jacobsen"s catalyst. 3-chloroperbenzoic acid 117-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 19185327-5 2009 A 3:2 molar ratio in favor of goniothalamin oxide (1) and ent-1 was observed from (R)- and (S)-4, respectively, when 3-chloroperbenzoic acid (mCPBA) was employed while an increase to 6:1 molar ratio was achieved with (S,S)-Jacobsen"s catalyst. 3-chloroperbenzoic acid 142-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 19222701-10 2009 Instead, hENT1 expression affects dynamic changes in endogenous adenosine levels, as revealed by altered behavioral responses to drugs that affect adenosine receptor signalling. Adenosine 64-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-14 19116148-0 2009 Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. Cytarabine 76-81 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 19116148-2 2009 DNA sequencing revealed that these cells expressed an equilibrative nucleoside transporter 1 (ENT1) with a single missense mutation resulting in glycine to arginine replacement (G24R). Glycine 145-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-92 19116148-2 2009 DNA sequencing revealed that these cells expressed an equilibrative nucleoside transporter 1 (ENT1) with a single missense mutation resulting in glycine to arginine replacement (G24R). Glycine 145-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-98 19116148-2 2009 DNA sequencing revealed that these cells expressed an equilibrative nucleoside transporter 1 (ENT1) with a single missense mutation resulting in glycine to arginine replacement (G24R). Arginine 156-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-92 19116148-2 2009 DNA sequencing revealed that these cells expressed an equilibrative nucleoside transporter 1 (ENT1) with a single missense mutation resulting in glycine to arginine replacement (G24R). Arginine 156-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-98 19116148-5 2009 An EGFP-tagged G24R ENT1 displayed plasma membrane localization even though it was unable to bind [3H]-NBMPR, an ENT1-specific inhibitor. Tritium 99-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-24 19116148-5 2009 An EGFP-tagged G24R ENT1 displayed plasma membrane localization even though it was unable to bind [3H]-NBMPR, an ENT1-specific inhibitor. 4-nitrobenzylthioinosine 103-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-24 19116148-6 2009 These results define G24 as critical amino acid for ENT1 nucleoside uptake and suggest that mutations in TM1 may provide a mechanism for Ara-C resistance in CCRF-CEM Ara-C/8C cells. Nucleosides 57-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-56 19091561-0 2009 CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). s(6)-(4-nitrobenzyl)mercaptopurine riboside 36-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 159-164 19091561-0 2009 CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). 4-nitrobenzylthioinosine 81-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-157 19091561-0 2009 CoMFA and CoMSIA 3D-QSAR studies on S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) analogs as inhibitors of human equilibrative nucleoside transporter 1 (hENT1). 4-nitrobenzylthioinosine 81-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 159-164 19214867-3 2009 The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. gemcitabine 28-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-139 18992248-0 2009 Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. gemcitabine 72-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 18992248-1 2009 BACKGROUND & AIMS: The human equilibrative nucleoside transporter (hENT1) protein transports gemcitabine into cells. Adenosine Monophosphate 12-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 18992248-1 2009 BACKGROUND & AIMS: The human equilibrative nucleoside transporter (hENT1) protein transports gemcitabine into cells. gemcitabine 97-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 18992248-9 2009 CONCLUSIONS: In this prospective randomized trial, hENT1 protein expression was associated with increased overall survival and disease-free survival in pancreatic cancer patients who received gemcitabine, but not in those who received 5-FU. gemcitabine 192-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 18992248-10 2009 These findings are supported by preclinical data; the gemcitabine transporter hENT1 is therefore a molecular and mechanistically relevant predictive marker of benefit from gemcitabine in patients with resected pancreatic cancer. gemcitabine 54-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-83 19214867-3 2009 The intracellular uptake of gemcitabine is dependent on nucleoside transporters, predominantly human equilibrative nucleoside transporter-1 (hENT-1), which is over-expressed in human pancreatic adenocarcinoma cells. gemcitabine 28-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-147 18669604-6 2008 [(3)H]FLT uptake in MCF-7, A549, U251, A498, MIA PaCa-2, and Capan-2 cells was inhibited at least 50% by the hENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR). Nitrobenzylmercaptopurine Ribonucleoside 125-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-114 18771661-3 2008 In this work, we investigated the action of the natural and synthetic enantiomers (R)-goniothalamin (1) and (S)-goniothalamin (ent-1) on cell viability, nitric oxide synthase (NOS) expression and activity, and the expression of selected proteins involved in apoptosis and autophagy in renal cancer cells. goniothalamin 108-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 127-132 18669604-6 2008 [(3)H]FLT uptake in MCF-7, A549, U251, A498, MIA PaCa-2, and Capan-2 cells was inhibited at least 50% by the hENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR). 4-nitrobenzylthioinosine 167-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-114 18728667-8 2008 ATP-TCA results for gemcitabine correlated to the tissue expression of human equilibrative nucleoside transporter-1 (hENT1). atp-tca 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-115 18728667-8 2008 ATP-TCA results for gemcitabine correlated to the tissue expression of human equilibrative nucleoside transporter-1 (hENT1). atp-tca 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-122 18728667-8 2008 ATP-TCA results for gemcitabine correlated to the tissue expression of human equilibrative nucleoside transporter-1 (hENT1). gemcitabine 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-115 18728667-8 2008 ATP-TCA results for gemcitabine correlated to the tissue expression of human equilibrative nucleoside transporter-1 (hENT1). gemcitabine 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-122 18728667-10 2008 Furthermore, time to relapse in gemcitabine-treated patients was related to hENT1 expression (P=0.0067). gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 18004569-6 2008 The inhibition of F-ara-ATP by imatinib is likely due to inhibition of nucleoside transporters hENT1 and hENT2. 2-fluoro-araATP 18-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-100 18635603-7 2008 Although ribavirin was predominately transported (89%) into the hepatocytes by hENT1, fialuridine (FIAU) was transported by both hENT1 (30%) and hCNTs (61%). fialuridine 86-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-134 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). Dipyridamole 165-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). Dipyridamole 165-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-51 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). Dilazep 179-186 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). Dilazep 179-186 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-51 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). draflazine 188-198 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). draflazine 188-198 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-51 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). soluflazine 200-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). soluflazine 200-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-51 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). 4-nitrobenzylthioinosine 216-221 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). 4-nitrobenzylthioinosine 216-221 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-51 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). Nitrobenzylmercaptopurine Ribonucleoside 223-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 18462193-1 2008 hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). Nitrobenzylmercaptopurine Ribonucleoside 223-263 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-51 18462193-2 2008 When a library of randomly mutated hENT1 cDNAs was screened using a yeast-based functional complementation assay for resistance to dilazep, a clone containing the W29G mutation was identified. Dilazep 131-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 18462193-6 2008 Trp29 mutations increased the IC50 values for hENT1 inhibition by dipyridamole, dilazep, NBMPR, soluflazine and draflazine. Dipyridamole 66-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18462193-6 2008 Trp29 mutations increased the IC50 values for hENT1 inhibition by dipyridamole, dilazep, NBMPR, soluflazine and draflazine. Dilazep 80-87 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18462193-6 2008 Trp29 mutations increased the IC50 values for hENT1 inhibition by dipyridamole, dilazep, NBMPR, soluflazine and draflazine. 4-nitrobenzylthioinosine 89-94 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18462193-6 2008 Trp29 mutations increased the IC50 values for hENT1 inhibition by dipyridamole, dilazep, NBMPR, soluflazine and draflazine. soluflazine 96-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18462193-6 2008 Trp29 mutations increased the IC50 values for hENT1 inhibition by dipyridamole, dilazep, NBMPR, soluflazine and draflazine. draflazine 112-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18004569-6 2008 The inhibition of F-ara-ATP by imatinib is likely due to inhibition of nucleoside transporters hENT1 and hENT2. Imatinib Mesylate 31-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-100 18703227-2 2008 Human equilibrative nucleoside transporters 1 (hENT1) and hENT2 are crucial to maintain physiological plasma levels of adenosine, thus modulating its several biological effects through adenosine receptor activation. Adenosine 119-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 18703227-8 2008 hPMEC from pre-eclampsia exhibit increased total transport (hENT1+hENT2), and maximal velocity (Vmax) for hENT2- (2-fold), but reduced Vmax for hENT1-mediated adenosine transport (75%), with no changes in apparent Km. Adenosine 159-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 144-149 18703227-11 2008 CGS-21680 (A2A agonist) did not alter hENTs expression or activity, but ZM-241385 (A2A antagonist) blocked pre-eclampsia effects and increased hENT1-mediated transport in normal pregnancies. ZM 241385 72-81 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 143-148 18589402-0 2008 Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. gemcitabine 100-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-82 18589402-0 2008 Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. gemcitabine 100-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 18589402-4 2008 Overexpression of hENT1 is associated with changes in cell cycle profile, in a variable manner depending on the particular cell type, thus suggesting a metabolic link between hENT1-mediated transport processes and the enzymatic machinery responsible for intracellular nucleoside metabolism. Nucleosides 268-278 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 18589402-4 2008 Overexpression of hENT1 is associated with changes in cell cycle profile, in a variable manner depending on the particular cell type, thus suggesting a metabolic link between hENT1-mediated transport processes and the enzymatic machinery responsible for intracellular nucleoside metabolism. Nucleosides 268-278 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-180 18589402-5 2008 When assayed in vivo in a human pancreatic adenocarcinoma xenograft, intratumoral Ad-hENT1 injection improved the therapeutic response to gemcitabine. gemcitabine 138-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-90 18589402-6 2008 In summary, hENT1 overexpression is associated with alterations in nucleoside enzymatic machinery and cell cycle progression in cultured cells and enhances gemcitabine action in vivo. Nucleosides 67-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 18589402-6 2008 In summary, hENT1 overexpression is associated with alterations in nucleoside enzymatic machinery and cell cycle progression in cultured cells and enhances gemcitabine action in vivo. gemcitabine 156-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 12-17 18668437-6 2008 The best-characterized members of the family, hENT1 and hENT2, possess similar broad permeant selectivities for purine and pyrimidine nucleosides, but hENT2 also efficiently transports nucleobases. nucleobases 185-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18490900-8 2008 In particular, expression levels of human equilibrative nucleoside transporter-1 and thymydilate synthase were significantly related to gemcitabine and 5-fluorouracil cytotoxicity. gemcitabine 136-147 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 18490900-8 2008 In particular, expression levels of human equilibrative nucleoside transporter-1 and thymydilate synthase were significantly related to gemcitabine and 5-fluorouracil cytotoxicity. Fluorouracil 152-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-80 18279955-4 2008 (3)H-ImmH transport assays demonstrated that the equilibrative nucleoside transporters (ENT1 and ENT2) facilitated the uptake of ImmH in human leukemia CCRF-CEM cells whereas (3)H-dGuo uptake was primarily dependent upon concentrative nucleoside transporters (CNTs). h-dguo 178-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-92 18668437-6 2008 The best-characterized members of the family, hENT1 and hENT2, possess similar broad permeant selectivities for purine and pyrimidine nucleosides, but hENT2 also efficiently transports nucleobases. purine 112-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18064606-0 2008 High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium. Glucose 5-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-30 18668437-6 2008 The best-characterized members of the family, hENT1 and hENT2, possess similar broad permeant selectivities for purine and pyrimidine nucleosides, but hENT2 also efficiently transports nucleobases. Pyrimidine Nucleosides 123-145 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 18489155-2 2008 An enantiodivergent strategy for the total chemical synthesis of both naturally occurring (+)-fomannosin (1) and its (-)-antipode (ent-1) from alpha-D-glucose has been developed and successfully implemented. fomannosin 90-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 131-136 18489155-2 2008 An enantiodivergent strategy for the total chemical synthesis of both naturally occurring (+)-fomannosin (1) and its (-)-antipode (ent-1) from alpha-D-glucose has been developed and successfully implemented. alpha-D-glucose 143-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 131-136 18519698-6 2008 This toxicity profile may relate to the function of 6BT as an inhibitor of the nucleoside transporter, ent1, which is thought to prevent it from entering many cell types. 6-benzylthioinosine 52-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-107 18064606-2 2008 Since NO represses SLC29A1 gene (hENT1) promoter activity we studied whether D-glucose-reduced hENT1-adenosine transport results from lower SLC29A1 expression in HUVEC primary cultures. Glucose 77-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-100 18064606-3 2008 HUVEC incubation (24 h) with high D-glucose (25 mM) reduced hENT1-adenosine transport and pGL3-hENT1(-1114) construct SLC29A1 reporter activity compared with normal D-glucose (5 mM). Glucose 34-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 18064606-1 2008 High D-glucose reduces human equilibrative nucleoside transporter 1 (hENT1)-mediated adenosine uptake involving endothelial nitric oxide synthase (eNOS), mitogen-activated protein (MAP) kinase kinases 1 and 2/MAP kinases p42/44 (MEK/ERKs), and protein kinase C (PKC) activation in human umbilical vein endothelium (HUVEC). Glucose 5-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 18064606-3 2008 HUVEC incubation (24 h) with high D-glucose (25 mM) reduced hENT1-adenosine transport and pGL3-hENT1(-1114) construct SLC29A1 reporter activity compared with normal D-glucose (5 mM). Glucose 34-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-100 18064606-3 2008 HUVEC incubation (24 h) with high D-glucose (25 mM) reduced hENT1-adenosine transport and pGL3-hENT1(-1114) construct SLC29A1 reporter activity compared with normal D-glucose (5 mM). Glucose 34-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-125 18064606-1 2008 High D-glucose reduces human equilibrative nucleoside transporter 1 (hENT1)-mediated adenosine uptake involving endothelial nitric oxide synthase (eNOS), mitogen-activated protein (MAP) kinase kinases 1 and 2/MAP kinases p42/44 (MEK/ERKs), and protein kinase C (PKC) activation in human umbilical vein endothelium (HUVEC). Glucose 5-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 18064606-3 2008 HUVEC incubation (24 h) with high D-glucose (25 mM) reduced hENT1-adenosine transport and pGL3-hENT1(-1114) construct SLC29A1 reporter activity compared with normal D-glucose (5 mM). Adenosine 66-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 18064606-1 2008 High D-glucose reduces human equilibrative nucleoside transporter 1 (hENT1)-mediated adenosine uptake involving endothelial nitric oxide synthase (eNOS), mitogen-activated protein (MAP) kinase kinases 1 and 2/MAP kinases p42/44 (MEK/ERKs), and protein kinase C (PKC) activation in human umbilical vein endothelium (HUVEC). Adenosine 85-94 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-67 18064606-4 2008 High D-glucose also reduced pGL3-hENT1(-1114) reporter activity compared with cells transfected with pGL3-hENT1(-795) construct. Glucose 5-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 18064606-1 2008 High D-glucose reduces human equilibrative nucleoside transporter 1 (hENT1)-mediated adenosine uptake involving endothelial nitric oxide synthase (eNOS), mitogen-activated protein (MAP) kinase kinases 1 and 2/MAP kinases p42/44 (MEK/ERKs), and protein kinase C (PKC) activation in human umbilical vein endothelium (HUVEC). Adenosine 85-94 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 18064606-8 2008 L-NAME, PD-98059, and calphostin C increased hENT1 expression without altering protein or mRNA stability. NG-Nitroarginine Methyl Ester 0-6 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 18452103-0 2008 High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. gemcitabine 179-190 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 18064606-8 2008 L-NAME, PD-98059, and calphostin C increased hENT1 expression without altering protein or mRNA stability. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 8-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 18064606-9 2008 High D-glucose increased Sp1 transcription factor protein abundance and binding to SLC29A1 promoter, phenomena blocked by L-NAME, PD-98059, and calphostin C. Sp1 overexpression reduced SLC29A1 promoter activity in normal D-glucose, an effect reversed by L-NAME and further reduced by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor) in high D-glucose. Glucose 5-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-90 18064606-9 2008 High D-glucose increased Sp1 transcription factor protein abundance and binding to SLC29A1 promoter, phenomena blocked by L-NAME, PD-98059, and calphostin C. Sp1 overexpression reduced SLC29A1 promoter activity in normal D-glucose, an effect reversed by L-NAME and further reduced by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor) in high D-glucose. Glucose 5-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 185-192 18064606-9 2008 High D-glucose increased Sp1 transcription factor protein abundance and binding to SLC29A1 promoter, phenomena blocked by L-NAME, PD-98059, and calphostin C. Sp1 overexpression reduced SLC29A1 promoter activity in normal D-glucose, an effect reversed by L-NAME and further reduced by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor) in high D-glucose. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 130-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-90 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Adenosine 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Adenosine 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-115 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Adenosine 29-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Glucose 57-66 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Glucose 57-66 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-115 18064606-10 2008 Thus, reduced hENT1-mediated adenosine transport in high D-glucose may result from increased Sp1 binding to SLC29A1 promoter down-regulating hENT1 expression. Glucose 57-66 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 18452103-0 2008 High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Vinorelbine 192-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 18452103-0 2008 High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study. Doxorubicin 218-233 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 18600540-4 2008 Here we report that imatinib treatment decreased ENT1-dependent activity and mRNA expression. Imatinib Mesylate 20-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-53 18600540-5 2008 Although, imatinib-resistant cells showed decreased levels of both ENT1 and ENT2 activity and expression, these cells remained sensitive to gemcitabine, suggesting that nucleoside analogs can be used as adjunctive therapy. Imatinib Mesylate 10-18 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 17883419-5 2007 Adenosine ENT1 uptake was the predominant transporter in both PBL(C) (55%) and PBL(LN) (46%). Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-14 18078872-4 2008 The aim of this study was to investigate whether IL-4 is able to modulate the expression and function of the human equilibrative NT1 (hENT1) in primary cultures of CLL cells and, consequently, to affect cytotoxicity induced by therapeutic nucleosides analogs. Nucleosides 239-250 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-139 17963371-2 2007 In this study, we report the first synthesis of enantiomeric lithocholic acid (ent-LCA, ent-1) and chenodeoxycholic acid (ent-CDCA, ent-2) via ent-testosterone (3). Lithocholic Acid 61-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 17963371-2 2007 In this study, we report the first synthesis of enantiomeric lithocholic acid (ent-LCA, ent-1) and chenodeoxycholic acid (ent-CDCA, ent-2) via ent-testosterone (3). Chenodeoxycholic Acid 126-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 17963371-2 2007 In this study, we report the first synthesis of enantiomeric lithocholic acid (ent-LCA, ent-1) and chenodeoxycholic acid (ent-CDCA, ent-2) via ent-testosterone (3). Testosterone 147-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 17963371-6 2007 Interestingly, ent-1 and ent-2 showed differential interactions with these proteins as compared to their corresponding natural bile acids. Bile Acids and Salts 127-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 15-20 18187485-2 2008 The human equilibrative nucleoside transporter 1 (hENT1) is a ubiquitous protein and is the major means by which gemcitabine enters human cells. gemcitabine 113-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 18187485-2 2008 The human equilibrative nucleoside transporter 1 (hENT1) is a ubiquitous protein and is the major means by which gemcitabine enters human cells. gemcitabine 113-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 18187485-3 2008 Moreover, recent reports indicate a significant correlation between immunohistochemical variations of hENT1 in tumor samples and survival after gemcitabine therapy in patients with solid tumors. gemcitabine 144-155 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 18289860-0 2008 Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. 4-nitrobenzylthioinosine 12-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-122 18289860-0 2008 Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. 4-nitrobenzylthioinosine 12-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 124-128 18289860-1 2008 Conformationally constrained analogue synthesis was undertaken to aid in pharmacophore mapping and 3D-QSAR analysis of nitrobenzylmercaptopurine riboside (NBMPR) congeners as equilibriative nucleoside transporter 1 (ENT1) inhibitors. nitrobenzylmercaptopurine riboside 119-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-214 18289860-1 2008 Conformationally constrained analogue synthesis was undertaken to aid in pharmacophore mapping and 3D-QSAR analysis of nitrobenzylmercaptopurine riboside (NBMPR) congeners as equilibriative nucleoside transporter 1 (ENT1) inhibitors. nitrobenzylmercaptopurine riboside 119-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 216-220 18289860-1 2008 Conformationally constrained analogue synthesis was undertaken to aid in pharmacophore mapping and 3D-QSAR analysis of nitrobenzylmercaptopurine riboside (NBMPR) congeners as equilibriative nucleoside transporter 1 (ENT1) inhibitors. 4-nitrobenzylthioinosine 155-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 175-214 18289860-1 2008 Conformationally constrained analogue synthesis was undertaken to aid in pharmacophore mapping and 3D-QSAR analysis of nitrobenzylmercaptopurine riboside (NBMPR) congeners as equilibriative nucleoside transporter 1 (ENT1) inhibitors. 4-nitrobenzylthioinosine 155-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 216-220 18289860-5 2008 7-NO(2)-1,2,3,4-Tetrahydroisoquino-2-yl purine riboside was identified as the analogue with the nitro group in the best orientation at the NBMPR binding site of ENT1. 7-no(2)-1,2,3,4-tetrahydroisoquino-2-yl purine riboside 0-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 161-165 18289860-5 2008 7-NO(2)-1,2,3,4-Tetrahydroisoquino-2-yl purine riboside was identified as the analogue with the nitro group in the best orientation at the NBMPR binding site of ENT1. nitro 96-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 161-165 18289860-7 2008 The flow cytometrically determined binding affinities indicated that the additional 5"-O,8-cyclo constraining was unfavorable for binding to the ENT1 transporter. 5"-o,8-cyclo 84-96 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 145-149 18344610-9 2008 mRNAs of nucleoside transporter (NT), ENT1, ENT2, CNT, and CNT3 were expressed in neutrophils; and their inhibitors, inosine, uridine, and s-(4-nitrobenzyl)-6-thioinosine, reduced the [Ca(2+)](i) rise induced by beta-NAD(+) and fMLP. Sulfur 4-5 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-42 18344610-9 2008 mRNAs of nucleoside transporter (NT), ENT1, ENT2, CNT, and CNT3 were expressed in neutrophils; and their inhibitors, inosine, uridine, and s-(4-nitrobenzyl)-6-thioinosine, reduced the [Ca(2+)](i) rise induced by beta-NAD(+) and fMLP. NAD 212-223 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-42 18383843-2 2008 The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose expression is up-regulated by thymidylate synthase inhibitors, such as 5-fluorouracil (5-FU). gemcitabine 41-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-96 18383843-2 2008 The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose expression is up-regulated by thymidylate synthase inhibitors, such as 5-fluorouracil (5-FU). gemcitabine 41-44 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-103 18383843-2 2008 The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose expression is up-regulated by thymidylate synthase inhibitors, such as 5-fluorouracil (5-FU). Fluorouracil 182-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-96 18383843-2 2008 The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose expression is up-regulated by thymidylate synthase inhibitors, such as 5-fluorouracil (5-FU). Fluorouracil 182-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-103 18383843-2 2008 The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose expression is up-regulated by thymidylate synthase inhibitors, such as 5-fluorouracil (5-FU). Fluorouracil 198-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-96 18383843-2 2008 The major mediator of cellular uptake of GEM is the human equilibrative nucleoside transporter 1 (hENT1) whose expression is up-regulated by thymidylate synthase inhibitors, such as 5-fluorouracil (5-FU). Fluorouracil 198-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-103 17881236-2 2007 S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) is a prototype inhibitor of the human equilibrative nucleoside transporter (hENT1), and is a high affinity ligand with a K(d) of 0.1-1.0 nM. (6)-(4-nitrobenzyl)mercaptopurine riboside 1-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-133 17881236-2 2007 S(6)-(4-nitrobenzyl)mercaptopurine riboside (NBMPR) is a prototype inhibitor of the human equilibrative nucleoside transporter (hENT1), and is a high affinity ligand with a K(d) of 0.1-1.0 nM. 4-nitrobenzylthioinosine 45-50 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-133 17881236-3 2007 We have synthesized and flow cytometrically evaluated the binding affinity of a series of novel C(2)-purine position substituted analogs of NBMPR at the hENT1. c(2)-purine 96-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-158 17881236-5 2007 Structure-activity relationships (SAR) indicate that increasing the steric bulk at the C(2)-purine position of NBMPR led to a decrease in binding affinity of these ligands at the hENT1. Carbon 87-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-184 17881236-5 2007 Structure-activity relationships (SAR) indicate that increasing the steric bulk at the C(2)-purine position of NBMPR led to a decrease in binding affinity of these ligands at the hENT1. (2)-purine 88-98 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-184 17881236-5 2007 Structure-activity relationships (SAR) indicate that increasing the steric bulk at the C(2)-purine position of NBMPR led to a decrease in binding affinity of these ligands at the hENT1. 4-nitrobenzylthioinosine 111-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-184 17921321-3 2007 hMVECs accumulated 2-[3H]chloroadenosine via the nitrobenzylmercaptopurine riboside-sensitive equilibrative nucleoside transporter 1 (ENT1) at a V(max) of 3.4 +/- 1 pmol.microl(-1).s(-1), with no contribution from the nitrobenzylmercaptopurine riboside-insensitive ENT2. 2-[3h]chloroadenosine 19-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-132 17921321-3 2007 hMVECs accumulated 2-[3H]chloroadenosine via the nitrobenzylmercaptopurine riboside-sensitive equilibrative nucleoside transporter 1 (ENT1) at a V(max) of 3.4 +/- 1 pmol.microl(-1).s(-1), with no contribution from the nitrobenzylmercaptopurine riboside-insensitive ENT2. 2-[3h]chloroadenosine 19-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-138 17921321-3 2007 hMVECs accumulated 2-[3H]chloroadenosine via the nitrobenzylmercaptopurine riboside-sensitive equilibrative nucleoside transporter 1 (ENT1) at a V(max) of 3.4 +/- 1 pmol.microl(-1).s(-1), with no contribution from the nitrobenzylmercaptopurine riboside-insensitive ENT2. nitrobenzylmercaptopurine riboside 49-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-132 17921321-3 2007 hMVECs accumulated 2-[3H]chloroadenosine via the nitrobenzylmercaptopurine riboside-sensitive equilibrative nucleoside transporter 1 (ENT1) at a V(max) of 3.4 +/- 1 pmol.microl(-1).s(-1), with no contribution from the nitrobenzylmercaptopurine riboside-insensitive ENT2. nitrobenzylmercaptopurine riboside 49-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-138 17921321-3 2007 hMVECs accumulated 2-[3H]chloroadenosine via the nitrobenzylmercaptopurine riboside-sensitive equilibrative nucleoside transporter 1 (ENT1) at a V(max) of 3.4 +/- 1 pmol.microl(-1).s(-1), with no contribution from the nitrobenzylmercaptopurine riboside-insensitive ENT2. nitrobenzylmercaptopurine riboside 218-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 94-132 17921321-3 2007 hMVECs accumulated 2-[3H]chloroadenosine via the nitrobenzylmercaptopurine riboside-sensitive equilibrative nucleoside transporter 1 (ENT1) at a V(max) of 3.4 +/- 1 pmol.microl(-1).s(-1), with no contribution from the nitrobenzylmercaptopurine riboside-insensitive ENT2. nitrobenzylmercaptopurine riboside 218-252 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-138 17921321-4 2007 Inhibition of 2-chloroadenosine uptake by ENT1 blockers produced monophasic inhibition curves, which are also compatible with minimal ENT2 expression. 2-Chloroadenosine 14-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 42-46 17636949-1 2007 Dipyridamole (Persantine) is a clinically used vasodilator with equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent than the prototype ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR). Dipyridamole 0-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-115 17887704-1 2007 The previously unknown stereoisomers 3, 4, ent-1, and ent-4 of the tris(pyrrolidinoindoline) alkaloids hodgkinsine (1) and hodgkinsine B (2) were prepared by stereocontrolled total synthesis. tris(pyrrolidinoindoline) alkaloids 67-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 17887704-1 2007 The previously unknown stereoisomers 3, 4, ent-1, and ent-4 of the tris(pyrrolidinoindoline) alkaloids hodgkinsine (1) and hodgkinsine B (2) were prepared by stereocontrolled total synthesis. hodgkinsine 103-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 17887704-1 2007 The previously unknown stereoisomers 3, 4, ent-1, and ent-4 of the tris(pyrrolidinoindoline) alkaloids hodgkinsine (1) and hodgkinsine B (2) were prepared by stereocontrolled total synthesis. hodgkinsine 123-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 17658213-0 2007 The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. gemcitabine 95-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-59 17658213-1 2007 We report here the development of a polyclonal antibody for human equilibrative nucleoside transporter 1 (hENT1) and assess the expression of hENT1 in non-small cell lung cancer (NSCLC) patients who were treated with gemcitabine-containing chemotherapy. gemcitabine 217-228 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-104 17658213-2 2007 hENT1 expression was analyzed by immunohistochemical staining in 24 NSCLC biopsy samples of formalin-fixed, paraffin-embedded tissues. Formaldehyde 92-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 17658213-2 2007 hENT1 expression was analyzed by immunohistochemical staining in 24 NSCLC biopsy samples of formalin-fixed, paraffin-embedded tissues. Paraffin 108-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 17658213-3 2007 The hENT1-positive staining in NSCLC samples was significantly associated with response to gemcitabine-containing chemotherapy. gemcitabine 91-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-9 17711502-4 2007 The chemosensitivity of TMK-1 cells expressing hENT1 and hENT2 to cytarabine and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) cytosine increased markedly in comparison to that of mock cells. Cytarabine 66-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 17711502-4 2007 The chemosensitivity of TMK-1 cells expressing hENT1 and hENT2 to cytarabine and 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) cytosine increased markedly in comparison to that of mock cells. 1-(3-C-ethynylribopentofuranosyl)cytosine 81-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 17636949-1 2007 Dipyridamole (Persantine) is a clinically used vasodilator with equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent than the prototype ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR). Dipyridamole 14-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-115 17636949-1 2007 Dipyridamole (Persantine) is a clinically used vasodilator with equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent than the prototype ENT1 inhibitor nitrobenzylmercaptopurine riboside (NBMPR). nitrobenzylmercaptopurine riboside 199-233 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-188 17636949-3 2007 A series of dipyridamole analogues were synthesized with systematic modification and evaluated as ENT1 inhibitors by flow cytometry. Dipyridamole 12-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-102 17512522-4 2007 Among the dihydropyridines tested, nimodipine proved to be the most potent inhibitor of hENT-1, with an IC(50) value of 60+/-31 muM, whereas nifedipine, nicardipine, nitrendipine, and felodipine exhibited 100-fold less effective inhibitory activity. Felodipine 184-194 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-94 17512522-3 2007 Therefore, we have studied the inhibitory effects of dihydropyridines on both human equilibrative nucleoside transporters, hENT-1 and hENT-2, which are the major transporters mediating nucleoside transport in most tissues. Dihydropyridines 53-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-129 17512522-9 2007 In addition, nimodipine and nifedipine inhibited the rate of NBTGR-induced dissociation of [(3)H]NBMPR from hENT-1 cell membrane. Nimodipine 13-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-114 17512522-4 2007 Among the dihydropyridines tested, nimodipine proved to be the most potent inhibitor of hENT-1, with an IC(50) value of 60+/-31 muM, whereas nifedipine, nicardipine, nitrendipine, and felodipine exhibited 100-fold less effective inhibitory activity. Dihydropyridines 10-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-94 17512522-4 2007 Among the dihydropyridines tested, nimodipine proved to be the most potent inhibitor of hENT-1, with an IC(50) value of 60+/-31 muM, whereas nifedipine, nicardipine, nitrendipine, and felodipine exhibited 100-fold less effective inhibitory activity. Nimodipine 35-45 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-94 17512522-9 2007 In addition, nimodipine and nifedipine inhibited the rate of NBTGR-induced dissociation of [(3)H]NBMPR from hENT-1 cell membrane. Nifedipine 28-38 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-114 17512522-10 2007 We conclude that dihydropyridines are non-competitive inhibitors of hENT-1 and hENT-2, probably working through reversible interactions with the allosteric sites. Dihydropyridines 17-33 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-74 17695509-0 2007 Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Fluorouracil 64-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17409283-6 2007 Equilibrium binding of [(3)H]nitrobenzylmercaptopurine ribonucleoside (NBMPR), a high-affinity inhibitor of hENT1, to brush-border membrane vesicles from cortex confirmed the presence of hENT1 on apical surfaces of proximal tubules. [(3)h]nitrobenzylmercaptopurine ribonucleoside 23-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-113 17409283-6 2007 Equilibrium binding of [(3)H]nitrobenzylmercaptopurine ribonucleoside (NBMPR), a high-affinity inhibitor of hENT1, to brush-border membrane vesicles from cortex confirmed the presence of hENT1 on apical surfaces of proximal tubules. [(3)h]nitrobenzylmercaptopurine ribonucleoside 23-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-192 17409283-6 2007 Equilibrium binding of [(3)H]nitrobenzylmercaptopurine ribonucleoside (NBMPR), a high-affinity inhibitor of hENT1, to brush-border membrane vesicles from cortex confirmed the presence of hENT1 on apical surfaces of proximal tubules. 4-nitrobenzylthioinosine 71-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 108-113 17409283-7 2007 Uptake of [(3)H]uridine by polarized renal proximal tubule cells exhibited a sodium-dependent component that was inhibited by thymidine and inosine as well as a sodium-independent component that was partially inhibited by NBMPR and completely inhibited by dilazep, indicating high levels of hENT1 and hCNT3 and low levels of hENT2 activities. [(3)h]uridine 10-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 291-296 17695509-4 2007 A [3H] gemcitabine cellular uptake assay was performed to examine the inhibition of hENT1 by nitrobenzylmercaptoprine ribonucleoside (NBMPR). nitrobenzylmercaptoprine ribonucleoside 93-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 17520485-7 2007 PK15 cells transfected with hENT1, which has Ser(254), was similar to mENT1b in its response to TBB. Serine 45-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-33 17695509-4 2007 A [3H] gemcitabine cellular uptake assay was performed to examine the inhibition of hENT1 by nitrobenzylmercaptoprine ribonucleoside (NBMPR). 4-nitrobenzylthioinosine 134-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-89 17695509-5 2007 RESULTS: The expression levels of hENT1 mRNA significantly correlated with the IC50 value of 5-FU in all seven lines and also correlated with gemcitabine resistance in six lines (except AsPC1). Fluorouracil 93-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-39 17695509-5 2007 RESULTS: The expression levels of hENT1 mRNA significantly correlated with the IC50 value of 5-FU in all seven lines and also correlated with gemcitabine resistance in six lines (except AsPC1). gemcitabine 142-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 34-39 17695509-7 2007 In the PSN1 cells, [3H] gemcitabine uptake via hENT1 was significantly inhibited by NBMPR, and 5-FU sensitivity was significantly increased when the cells were pretreated with NBMPR. Tritium 20-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 17695509-7 2007 In the PSN1 cells, [3H] gemcitabine uptake via hENT1 was significantly inhibited by NBMPR, and 5-FU sensitivity was significantly increased when the cells were pretreated with NBMPR. gemcitabine 24-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 17695509-7 2007 In the PSN1 cells, [3H] gemcitabine uptake via hENT1 was significantly inhibited by NBMPR, and 5-FU sensitivity was significantly increased when the cells were pretreated with NBMPR. 4-nitrobenzylthioinosine 84-89 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 17695509-8 2007 CONCLUSION: Our results suggest that hENT1 plays an important role in 5-FU resistance and that hENT1 mRNA levels might be a useful marker to predict 5-FU sensitivity in pancreatic cancer. Fluorouracil 70-74 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 17695509-8 2007 CONCLUSION: Our results suggest that hENT1 plays an important role in 5-FU resistance and that hENT1 mRNA levels might be a useful marker to predict 5-FU sensitivity in pancreatic cancer. Fluorouracil 149-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-100 17520485-7 2007 PK15 cells transfected with hENT1, which has Ser(254), was similar to mENT1b in its response to TBB. 4,5,6,7-tetrabromobenzotriazole 96-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 28-33 16965766-10 2006 This study demonstrates that although 5"-DFUR is substrate for both equilibrative nucleoside carriers, hENT1 function is essential for the full transcriptional response to 5"-DFUR treatment. doxifluridine 172-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Dipyridamole 139-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Dipyridamole 139-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Dilazep 153-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Dilazep 153-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Nitrobenzylmercaptopurine Ribonucleoside 162-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. Nitrobenzylmercaptopurine Ribonucleoside 162-202 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. 4-nitrobenzylthioinosine 204-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. 4-nitrobenzylthioinosine 204-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. draflazine 212-222 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. draflazine 212-222 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. soluflazine 228-239 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17379602-2 2007 Human equilibrative nucleoside transporter 1 (hENT1) is inhibited by nanomolar concentrations of structurally diverse compounds, including dipyridamole, dilazep, nitrobenzylmercaptopurine ribonucleoside (NBMPR), draflazine, and soluflazine. soluflazine 228-239 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. Nucleosides 257-267 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. Nucleosides 257-267 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 17121826-9 2007 Interestingly, mutant E206Q, which possesses the equivalent residue in ENT1, gained uridine transport activity. Uridine 84-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-75 17167068-7 2007 However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. Adenosine Diphosphate 9-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-78 17167068-7 2007 However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. Dipyridamole 113-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-78 17167068-7 2007 However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. 4-nitrobenzylthioinosine 130-134 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-78 17167068-7 2007 However, ADP responses were significantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI and were significantly inhibited by adenosine deaminase, indicating a role for extracellular adenosine. Adenosine 171-180 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-78 17926640-6 2007 HAART and HALS development are associated with the upregulation of the mRNA levels encoding hCNT2 and hENT1, and further enhancement of hCNT1, hCNT3 and hENT2 gene expression. hals 10-14 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 17346175-5 2007 In humans, purine uptake into many cell types is mediated by members of the Equilibrative Nucleoside Transporter (ENT) family, in particular hENT1 and hENT2. purine 11-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 17390066-0 2007 Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. gemcitabine 88-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 17390066-3 2007 Quantitative RT-PCR demonstrated that one of the nucleotide transporter genes; human equilibrative nucleoside transporter 1 (hENT1) was associated with the sensitivity to gemcitabine as represented by IC50, while the other genes for nucleotide transporter and metabolism were not. gemcitabine 171-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-123 17390066-3 2007 Quantitative RT-PCR demonstrated that one of the nucleotide transporter genes; human equilibrative nucleoside transporter 1 (hENT1) was associated with the sensitivity to gemcitabine as represented by IC50, while the other genes for nucleotide transporter and metabolism were not. gemcitabine 171-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-130 17390066-4 2007 We conclude that increased hENT1 expression is a most important determinant of gemcitabine sensitivity at least in an in vitro study. gemcitabine 79-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-32 17296311-2 2007 Gemcitabine enters the cell mostly via the human equilibrative nucleoside transporter-1 (hENT1), while drug metabolism occurs by phosphorylation by deoxycytidine kinase (dCK), 5"-nucleotidase (cN-II) and cytidine deaminase (CDA) are the main inactivating enzymes. gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 49-87 17296311-2 2007 Gemcitabine enters the cell mostly via the human equilibrative nucleoside transporter-1 (hENT1), while drug metabolism occurs by phosphorylation by deoxycytidine kinase (dCK), 5"-nucleotidase (cN-II) and cytidine deaminase (CDA) are the main inactivating enzymes. gemcitabine 0-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-94 17140564-4 2007 In Xenopus oocytes, influxes of ribavirin mediated by hCNT2 (concentrative nucleoside transporter 2), hCNT3 (concentrative nucleoside transporter 3), hENT1 (equilibrative nucleoside transporter 1) and hENT2 (equilibrative nucleoside transporter 2) were saturable, and apparent K(m) values were 18.0 microM, 14.2 microM, 3.46 mM and 3.71 mM, respectively. Ribavirin 32-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-155 17140564-7 2007 These results suggest that ribavirin is taken up by BeWo cells via both the high-affinity Na(+)-dependent transporter hCNT3 and the low-affinity Na(+)-independent transporters hENT1 and hENT2. Ribavirin 27-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 176-181 17224927-5 2007 Expression of hENT1 was increased in the development of gemcitabine resistance. gemcitabine 56-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 17224927-6 2007 As acquired resistance to gemcitabine seems to correlate with the balance of these four factors, we calculated the ratio of hENT1 x dCK/RRM1 x RRM2 gene expression in gemcitabine-resistant subclones. gemcitabine 26-37 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 124-129 17224927-6 2007 As acquired resistance to gemcitabine seems to correlate with the balance of these four factors, we calculated the ratio of hENT1 x dCK/RRM1 x RRM2 gene expression in gemcitabine-resistant subclones. gemcitabine 167-178 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 124-129 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. 5-Hydroxy-2-Methyl-4h-Pyran-4-Thione 136-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. 5-Hydroxy-2-Methyl-4h-Pyran-4-Thione 136-139 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. 1-Methyl-4-phenylpyridinium 184-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. 1-Methyl-4-phenylpyridinium 184-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. mangion-purified polysaccharide (Candida albicans) 213-217 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. mangion-purified polysaccharide (Candida albicans) 213-217 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. Uridine 246-253 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 17121826-4 2007 By constructing chimeras between human PMAT and ENT1, we showed that a chimera consisting of transmembrane domains (TM) 1-6 of PMAT and TM7-11 of hENT1 behaved like PMAT, transporting 1-methyl-4-phenylpyridinium (MPP+, an organic cation) but not uridine (a nucleoside), suggesting that TM1-6 contains critical domains responsible for substrate recognition. Uridine 246-253 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 17097625-7 2007 RESULTS: The mRNA expression of human equilibrative nucleoside transporter-1 (hENT-1), which is an uptake transporter of Ara-C, was initially decreased during the acquisition of resistance to Ara-C. Cytarabine 121-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-76 17097625-7 2007 RESULTS: The mRNA expression of human equilibrative nucleoside transporter-1 (hENT-1), which is an uptake transporter of Ara-C, was initially decreased during the acquisition of resistance to Ara-C. Cytarabine 121-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-84 17097625-7 2007 RESULTS: The mRNA expression of human equilibrative nucleoside transporter-1 (hENT-1), which is an uptake transporter of Ara-C, was initially decreased during the acquisition of resistance to Ara-C. Cytarabine 192-197 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-76 17097625-7 2007 RESULTS: The mRNA expression of human equilibrative nucleoside transporter-1 (hENT-1), which is an uptake transporter of Ara-C, was initially decreased during the acquisition of resistance to Ara-C. Cytarabine 192-197 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-84 17097625-9 2007 The cytotoxic effect of Ara-C on parental NALM-6 cells was ameliorated by hENT-1 inhibitors. Cytarabine 24-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-80 17097625-11 2007 CONCLUSIONS: Decreased hENT-1 expression and function is causatively responsible for the acquisition of Ara-C resistance and alterations in dCK and CDA contribute to the higher concentration range. Cytarabine 104-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-29 17706182-7 2007 The relative abilities of five human nucleoside transporters (hENT1/2, hCNT1/2/3 to bind the radiosensitizers were determined by quantifying their inhibition of uridine transport by recombinant transporters produced in yeast. Uridine 161-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-69 17706182-12 2007 Substitution of C-5 hydroxyl by fluorine in the ribose moiety greatly reduced interaction with hENT1/2 and hCNT1/2 and moderately reduced interaction with hCNT3 relative to thymidine and beta-AZR. c-5 hydroxyl 16-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-102 17706182-12 2007 Substitution of C-5 hydroxyl by fluorine in the ribose moiety greatly reduced interaction with hENT1/2 and hCNT1/2 and moderately reduced interaction with hCNT3 relative to thymidine and beta-AZR. Fluorine 32-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-102 17706182-12 2007 Substitution of C-5 hydroxyl by fluorine in the ribose moiety greatly reduced interaction with hENT1/2 and hCNT1/2 and moderately reduced interaction with hCNT3 relative to thymidine and beta-AZR. Ribose 48-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-102 16965766-0 2006 Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5"-DFUR in breast cancer MCF7 cells. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 16965766-0 2006 Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5"-DFUR in breast cancer MCF7 cells. doxifluridine 128-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-44 16965766-0 2006 Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5"-DFUR in breast cancer MCF7 cells. doxifluridine 128-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 16965766-6 2006 Although 5"-DFUR is a substrate for both plasma membrane equilibrative nucleoside carriers, hENT1 shows higher affinity for this molecule than hENT2. doxifluridine 9-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 92-97 16965766-7 2006 Inhibition of hENT1 function partially protected MCF7 cells from 5"-DFUR-induced cytotoxicity. doxifluridine 65-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-19 16965766-8 2006 Secondly, we have used a pharmacogenomic approach to determine how inhibition of hENT1 function contributes to the transcriptomic response associated to 5"-DFUR treatment. doxifluridine 153-160 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 16955524-1 2006 The total synthesis of the cyclic diterpene ent-tonantzitlolone (ent-1) is presented. cyclic diterpene ent-tonantzitlolone 27-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-70 17215872-5 2006 The well characterized hENTs (hENT1 and hENT2) are bidirectional facilitative diffusion transporters in plasma membranes; hENT3 and hENT4 are much less well known, although hENT3, found in lysosomal membranes, transports nucleosides and is pH dependent, whereas hENT4-PMAT is a H+-adenosine cotransporter as well as a monoamine-organic cation transporter. Nucleosides 221-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-35 17215872-5 2006 The well characterized hENTs (hENT1 and hENT2) are bidirectional facilitative diffusion transporters in plasma membranes; hENT3 and hENT4 are much less well known, although hENT3, found in lysosomal membranes, transports nucleosides and is pH dependent, whereas hENT4-PMAT is a H+-adenosine cotransporter as well as a monoamine-organic cation transporter. monoamine 318-327 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-35 17215872-7 2006 In renal epithelial cells, hCNT1, hCNT2, and hCNT3 at apical membranes, and hENT1 and hENT2 at basolateral membranes, apparently work in concert to mediate reabsorption of nucleosides from lumen to blood, driven by Na+ gradients. Nucleosides 172-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 17215872-9 2006 Mounting evidence suggests that hENT1 may have a presence at both apical and basolateral membranes of renal epithelia, and thus may participate in both selective secretory and reabsorptive fluxes of nucleosides. Nucleosides 199-210 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 16924660-2 2006 Adenosine uptake via the human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) has been proposed as a mechanism regulating adenosine plasma concentration, and therefore its vascular effects in human umbilical veins. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 16924660-2 2006 Adenosine uptake via the human equilibrative nucleoside transporters 1 (hENT1) and 2 (hENT2) has been proposed as a mechanism regulating adenosine plasma concentration, and therefore its vascular effects in human umbilical veins. Adenosine 137-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 16924660-3 2006 Thus, altered expression and/or activity of hENT1 or hENT2 could lead to abnormal physiological plasma adenosine level. Adenosine 103-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 16924660-6 2006 Insulin increased hENT2 protein abundance in normal or high D-glucose, but reduced hENT1 protein abundance in normal D-glucose. Glucose 117-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-88 16924660-7 2006 Insulin did not alter the reduced hENT1 protein abundance, but blocked the reduced hENT1 and hENT2 mRNA expression induced by high D-glucose. Glucose 131-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-88 16924660-8 2006 Insulin effect on hENT1 mRNA expression in normal D-glucose was blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) and mimicked by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). Glucose 50-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 16924660-8 2006 Insulin effect on hENT1 mRNA expression in normal D-glucose was blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) and mimicked by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). NG-Nitroarginine Methyl Ester 75-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 16924660-8 2006 Insulin effect on hENT1 mRNA expression in normal D-glucose was blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) and mimicked by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). NG-Nitroarginine Methyl Ester 111-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 16924660-8 2006 Insulin effect on hENT1 mRNA expression in normal D-glucose was blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) and mimicked by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). s-nitroso-n-acetyl-l,d-penicillamine 158-194 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 16924660-8 2006 Insulin effect on hENT1 mRNA expression in normal D-glucose was blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NO synthase inhibitor) and mimicked by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). snap 196-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 16873718-2 2006 Previous studies have implicated the equilibrative nucleoside transporter family member equilibrative nucleoside transporter-1 (ENT1) in the regulation of cardiac adenosine levels. Adenosine 163-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-126 17083135-3 2006 Recent in vivo reconstitution of this pathway in yeast by high-level expression of Herpes simplex virus thymidine kinase (HSV-TK) or combined expression of HSV-TK and human equilibrative nucleoside transporter (hENT1) has enabled analysis of BrdU incorporation in yeast. Bromodeoxyuridine 242-246 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 211-216 16873718-2 2006 Previous studies have implicated the equilibrative nucleoside transporter family member equilibrative nucleoside transporter-1 (ENT1) in the regulation of cardiac adenosine levels. Adenosine 163-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-132 16818276-9 2006 INTERPRETATION AND CONCLUSIONS: These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells. Nucleosides 79-89 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-218 16868547-2 2006 The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. gemcitabine 24-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 282-320 16868547-2 2006 The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. gemcitabine 24-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 322-327 16868547-2 2006 The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Pemetrexed 40-50 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 282-320 16868547-2 2006 The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Pemetrexed 40-50 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 322-327 16868547-2 2006 The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Pemetrexed 76-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 282-320 16868547-2 2006 The interaction between gemcitabine and pemetrexed was synergistic; indeed, pemetrexed favoured gemcitabine cytotoxicity by increasing cellular population in S-phase, reducing Akt phosphorylation as well as by inducing the expression of a major gemcitabine uptake system, the human equilibrative nucleoside transporter-1 (hENT1), and the key activating enzyme deoxycytidine kinase (dCK) in both cell lines. Pemetrexed 76-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 322-327 16688763-0 2006 Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. Nitric Oxide 0-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-47 16688763-0 2006 Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. Nitric Oxide 0-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-61 16688763-2 2006 Adenosine transport via human equilibrative nucleoside transporters 1 (hENT1) is reduced by NO by unknown mechanisms in HUVEC. Adenosine 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 16688763-3 2006 We examined whether gestational diabetes-reduced adenosine transport results from lower hENT1 gene (SLC29A1) expression. Adenosine 49-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 88-93 16688763-3 2006 We examined whether gestational diabetes-reduced adenosine transport results from lower hENT1 gene (SLC29A1) expression. Adenosine 49-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-107 16688763-4 2006 HUVEC from gestational diabetes exhibit reduced SLC29A1 promoter activity when transfected with pGL3-hENT1(-2154) compared with pGL3-hENT1(-1114) constructs, an effect blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NOS inhibitor), but unaltered by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). NG-Nitroarginine Methyl Ester 179-213 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-55 16868479-1 2006 OBJECTIVES: Gemcitabine is taken up by cells mainly via human equilibrative nucleoside transporter 1 (hENT1). gemcitabine 12-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 62-100 16868479-1 2006 OBJECTIVES: Gemcitabine is taken up by cells mainly via human equilibrative nucleoside transporter 1 (hENT1). gemcitabine 12-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 16868479-2 2006 Pretreatment of cancer cell lines with 5-fluorouracil (5-FU) leads to an increase in the expression of hENT1 and augments the effect of single-agent gemcitabine treatment in vitro. Fluorouracil 39-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 16868479-2 2006 Pretreatment of cancer cell lines with 5-fluorouracil (5-FU) leads to an increase in the expression of hENT1 and augments the effect of single-agent gemcitabine treatment in vitro. Fluorouracil 55-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 16868479-4 2006 METHODS: The expression level of hENT1 mRNA was examined using 6 types of human pancreatic cancer cell lines treated with 5-FU and MiaPaCa-2 xenograft tumors in BALB/c nu/nu mice treated with UFT. Fluorouracil 122-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 16868479-7 2006 RESULTS: MiaPaCa-2 cell line was one of the lines that showed the highest rate of 5-FU-induced increase in the hENT1 mRNA level. Fluorouracil 82-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-116 16688763-4 2006 HUVEC from gestational diabetes exhibit reduced SLC29A1 promoter activity when transfected with pGL3-hENT1(-2154) compared with pGL3-hENT1(-1114) constructs, an effect blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NOS inhibitor), but unaltered by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). NG-Nitroarginine Methyl Ester 179-213 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 16688763-4 2006 HUVEC from gestational diabetes exhibit reduced SLC29A1 promoter activity when transfected with pGL3-hENT1(-2154) compared with pGL3-hENT1(-1114) constructs, an effect blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NOS inhibitor), but unaltered by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). NG-Nitroarginine Methyl Ester 179-213 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-138 16688763-4 2006 HUVEC from gestational diabetes exhibit reduced SLC29A1 promoter activity when transfected with pGL3-hENT1(-2154) compared with pGL3-hENT1(-1114) constructs, an effect blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NOS inhibitor), but unaltered by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). NG-Nitroarginine Methyl Ester 215-221 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-55 16688763-4 2006 HUVEC from gestational diabetes exhibit reduced SLC29A1 promoter activity when transfected with pGL3-hENT1(-2154) compared with pGL3-hENT1(-1114) constructs, an effect blocked by N(G)-nitro-L-arginine methyl ester (L-NAME, NOS inhibitor), but unaltered by S-nitroso-N-acetyl-L,D-penicillamine (SNAP, NO donor). s-nitroso-n-acetyl-l,d-penicillamine 256-292 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-55 16688763-5 2006 In cells from gestational diabetes transfected with pGL3-hENT1(-2154), L-NAME increased, but SNAP did not alter promoter activity and hENT1 expression. NG-Nitroarginine Methyl Ester 71-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 16688763-8 2006 Thus, reduced adenosine transport may result from downregulation of SLC29A1 expression by NO in HUVEC from gestational diabetes. Adenosine 14-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-75 16818266-0 2006 Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samples. gemcitabine 50-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 15-20 16818276-0 2006 Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-58 16818276-0 2006 Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-65 16818276-9 2006 INTERPRETATION AND CONCLUSIONS: These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells. Nucleosides 149-159 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-218 16818276-9 2006 INTERPRETATION AND CONCLUSIONS: These results further support the concept that nucleoside transporters are implicated in the therapeutic response to nucleoside analogs, and suggest a particular and novel role for hENT1 in the genotoxic response to selected nucleoside analogs, such as gemcitabine, in MCL cells. gemcitabine 285-296 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 213-218 16617163-4 2006 In HeLa cells with recombinant human concentrative nucleoside transporter (hCNT) 1 or hCNT3 and pharmacologically blocked hENT1 and hENT2, transport of 10 microM[3H]TaraC and [3H]araC was not detected. Tritium 162-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-127 16617163-4 2006 In HeLa cells with recombinant human concentrative nucleoside transporter (hCNT) 1 or hCNT3 and pharmacologically blocked hENT1 and hENT2, transport of 10 microM[3H]TaraC and [3H]araC was not detected. Tritium 176-178 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 122-127 16617163-5 2006 The apparent affinities of recombinant transporters (produced in yeast) for a panel of cytosine-containing nucleosides yielded results that were consistent with the observed low-permeant activities of TaraC and araC for hENT1/2 and negligible permeant activities for hCNT1/2/3. Cytosine 87-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-227 16617163-5 2006 The apparent affinities of recombinant transporters (produced in yeast) for a panel of cytosine-containing nucleosides yielded results that were consistent with the observed low-permeant activities of TaraC and araC for hENT1/2 and negligible permeant activities for hCNT1/2/3. Nucleosides 107-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 220-227 16617163-6 2006 During prolonged drug exposures of CEM cells with hENT1 activity, araC was more cytotoxic than TaraC, whereas coexposures with nitrobenzylthioinosine (to pharmacologically block hENT1) yielded identical cytotoxicities for araC and TaraC. 4-nitrobenzylthioinosine 127-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 178-183 16617163-6 2006 During prolonged drug exposures of CEM cells with hENT1 activity, araC was more cytotoxic than TaraC, whereas coexposures with nitrobenzylthioinosine (to pharmacologically block hENT1) yielded identical cytotoxicities for araC and TaraC. Cytarabine 66-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 16595656-5 2006 Using confocal microscopy and different truncated and point mutants of hENT1-YFP (yellow fluorescent protein) expressed in Madin-Darby canine kidney cells, we identified amino acid residues Pro(71),Glu(72), and Asn(74) (the PEXN motif) of hENT1 as important in mitochondrial targeting of hENT1. Glutamic Acid 198-201 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 16595656-5 2006 Using confocal microscopy and different truncated and point mutants of hENT1-YFP (yellow fluorescent protein) expressed in Madin-Darby canine kidney cells, we identified amino acid residues Pro(71),Glu(72), and Asn(74) (the PEXN motif) of hENT1 as important in mitochondrial targeting of hENT1. Asparagine 211-214 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 16595656-0 2006 Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. fialuridine 185-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-104 16595656-9 2006 Sequence alignment of hENT1, mENT1, and rat ENT1 (rENT1) showed that the PEXN motif of hENT1 was substituted with a PAXS motif in both mENT1 and rENT1. paxs 116-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 87-92 16595656-0 2006 Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. fialuridine 185-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 106-111 16595656-1 2006 We have previously shown that the human equilibrative nucleoside transporter 1 (hENT1) is expressed and functional in the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of the nucleoside drug, fialuridine (FIAU) (Lai, Y., Tse, C. M., and Unadkat, J. D. (2004) J. Biol. fialuridine 230-241 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-78 16595656-1 2006 We have previously shown that the human equilibrative nucleoside transporter 1 (hENT1) is expressed and functional in the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of the nucleoside drug, fialuridine (FIAU) (Lai, Y., Tse, C. M., and Unadkat, J. D. (2004) J. Biol. fialuridine 230-241 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 16683783-1 2006 A short synthetic pathway has been developed for the synthesis of oseltamivir (1) or the enantiomer (ent-1). Oseltamivir 66-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 16595656-1 2006 We have previously shown that the human equilibrative nucleoside transporter 1 (hENT1) is expressed and functional in the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of the nucleoside drug, fialuridine (FIAU) (Lai, Y., Tse, C. M., and Unadkat, J. D. (2004) J. Biol. fialuridine 243-247 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-78 16595656-1 2006 We have previously shown that the human equilibrative nucleoside transporter 1 (hENT1) is expressed and functional in the mitochondrial membrane and that this expression enhances the mitochondrial toxicity of the nucleoside drug, fialuridine (FIAU) (Lai, Y., Tse, C. M., and Unadkat, J. D. (2004) J. Biol. fialuridine 243-247 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-85 16595656-5 2006 Using confocal microscopy and different truncated and point mutants of hENT1-YFP (yellow fluorescent protein) expressed in Madin-Darby canine kidney cells, we identified amino acid residues Pro(71),Glu(72), and Asn(74) (the PEXN motif) of hENT1 as important in mitochondrial targeting of hENT1. Proline 190-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 16858130-1 2006 Thirty-nine genetic variations, including thirty novel ones, were found in the human SLC29A1 gene, which encodes equilibrative nucleoside transporter 1, from 256 Japanese cancer patients administered gemcitabine. gemcitabine 200-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-92 16858130-1 2006 Thirty-nine genetic variations, including thirty novel ones, were found in the human SLC29A1 gene, which encodes equilibrative nucleoside transporter 1, from 256 Japanese cancer patients administered gemcitabine. gemcitabine 200-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-151 16234483-7 2006 The efficiency of Cl-F-ara-A transport by oocytes with recombinant transporters was hCNT3 > hENT2 > hENT1 > hCNT2; no transport was observed with hCNT1. Clofarabine 18-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 106-111 16609362-1 2006 The human equilibrative nucleoside transporter 1 gene (hENT1) is the primary nucleoside transporter for cytosine arabinoside (AraC), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. Cytarabine 104-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 16609362-1 2006 The human equilibrative nucleoside transporter 1 gene (hENT1) is the primary nucleoside transporter for cytosine arabinoside (AraC), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. Cytarabine 104-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-60 16609362-1 2006 The human equilibrative nucleoside transporter 1 gene (hENT1) is the primary nucleoside transporter for cytosine arabinoside (AraC), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. Cytarabine 126-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 16609362-1 2006 The human equilibrative nucleoside transporter 1 gene (hENT1) is the primary nucleoside transporter for cytosine arabinoside (AraC), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. Cytarabine 126-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-60 16609362-1 2006 The human equilibrative nucleoside transporter 1 gene (hENT1) is the primary nucleoside transporter for cytosine arabinoside (AraC), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. Deoxycytidine 135-148 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 16609362-1 2006 The human equilibrative nucleoside transporter 1 gene (hENT1) is the primary nucleoside transporter for cytosine arabinoside (AraC), a deoxycytidine analog used for treatment of acute leukemias and lymphomas. Deoxycytidine 135-148 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 55-60 16609362-10 2006 hENT1 promoter region haplotypes may influence gene expression and alter AraC chemosensitivity. Cytarabine 73-77 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 16585222-0 2006 Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. gemcitabine 130-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-70 16430205-3 2006 The ribosyl derivative (FuPmR) was used to demonstrate proof of principle in live cell imaging studies in 11 cultured human cancer cell lines with different hENT1 activities. ribosyl 4-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 157-162 16430205-4 2006 The autofluorescence emitted from FuPmR enabled direct visualization of its movement from the extracellular medium into the intracellular compartment of live cells, and this process was blocked by inhibitors of hENT1 (nitrobenzylmercaptopurine ribonucleoside, dipyridamole, and dilazep). Dipyridamole 260-272 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 211-216 16430205-4 2006 The autofluorescence emitted from FuPmR enabled direct visualization of its movement from the extracellular medium into the intracellular compartment of live cells, and this process was blocked by inhibitors of hENT1 (nitrobenzylmercaptopurine ribonucleoside, dipyridamole, and dilazep). Dilazep 278-285 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 211-216 16234483-4 2006 Cells producing hENT1 or hCNT3 exhibited the highest uptake of Cl-F-ara-A, whereas nucleoside transport-deficient cells and cells producing hCNT1 lacked uptake altogether. Clofarabine 63-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 16-21 16234483-5 2006 When Cl-F-ara-A transport rates by hENT1 were compared with those of Cl-dAdo and F-ara-A, Cl-dAdo had the highest efficiency of transport, although Cl-F-ara-A showed the greatest accumulation during 5-min exposures. Clofarabine 5-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 16234483-5 2006 When Cl-F-ara-A transport rates by hENT1 were compared with those of Cl-dAdo and F-ara-A, Cl-dAdo had the highest efficiency of transport, although Cl-F-ara-A showed the greatest accumulation during 5-min exposures. fludarabine 8-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 16234483-5 2006 When Cl-F-ara-A transport rates by hENT1 were compared with those of Cl-dAdo and F-ara-A, Cl-dAdo had the highest efficiency of transport, although Cl-F-ara-A showed the greatest accumulation during 5-min exposures. Cladribine 90-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 16234483-6 2006 In cytotoxicity studies with the CEM lines, Cl-F-ara-A was more cytotoxic to cells producing hENT1 than to the nucleoside transport-deficient cells. Clofarabine 44-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 16234483-8 2006 Affinity studies with recombinant transporters produced in yeast showed that hENT1, hENT2, and hCNT3 all had higher affinities for Cl-F-ara-A than for either Cl-dAdo or F-ara-A. Clofarabine 131-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 16234483-8 2006 Affinity studies with recombinant transporters produced in yeast showed that hENT1, hENT2, and hCNT3 all had higher affinities for Cl-F-ara-A than for either Cl-dAdo or F-ara-A. Cladribine 158-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 16234483-8 2006 Affinity studies with recombinant transporters produced in yeast showed that hENT1, hENT2, and hCNT3 all had higher affinities for Cl-F-ara-A than for either Cl-dAdo or F-ara-A. fludarabine 134-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 77-82 16333246-6 2005 Human equilibrative nucleoside transporter-1 (hENT1) mRNA expression and ara-C sensitivity were significantly correlated (rp=-0.46; P=0.001), with three-fold lower hENT1 mRNA levels in resistant patients (P=0.003). Cytarabine 73-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 16310172-0 2005 6-Benzylthioinosine analogues: promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es). 6-benzylthioinosine 0-19 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-123 16310172-8 2005 Previous studies have shown that some 6-benzylthioinosines are inhibitors of the mammalian nucleoside transporter ENT1 (es). 6-benzylthioinosine 38-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 16310172-9 2005 Therefore, we examined the efficacy of promising anti-toxoplasmic 6-benzylthioinosines as inhibitors of ENT1 (es) in an effort to elucidate the basis for the lack of uptake of anti-toxoplasmic 6-benzylthioinosines by uninfected host cells. 6-benzylthioinosine 66-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 104-108 16310172-9 2005 Therefore, we examined the efficacy of promising anti-toxoplasmic 6-benzylthioinosines as inhibitors of ENT1 (es) in an effort to elucidate the basis for the lack of uptake of anti-toxoplasmic 6-benzylthioinosines by uninfected host cells. Einsteinium 84-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 104-108 16333246-10 2005 In conclusion, decreased expression of hENT1, which transports ara-C across the cell membrane, appears to be a major factor in ara-C resistance in childhood AML. Cytarabine 63-68 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 16333246-6 2005 Human equilibrative nucleoside transporter-1 (hENT1) mRNA expression and ara-C sensitivity were significantly correlated (rp=-0.46; P=0.001), with three-fold lower hENT1 mRNA levels in resistant patients (P=0.003). Cytarabine 73-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 164-169 16333246-10 2005 In conclusion, decreased expression of hENT1, which transports ara-C across the cell membrane, appears to be a major factor in ara-C resistance in childhood AML. Cytarabine 127-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 16333246-7 2005 hENT1 mRNA expression also seemed to correlate inversely with the LC50 values of cladribine (rp=-0.30; P=0.04), decitabine (rp=-0.29; P=0.04) and gemcitabine (rp=-0.33; P=0.02). Cladribine 81-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 16333246-7 2005 hENT1 mRNA expression also seemed to correlate inversely with the LC50 values of cladribine (rp=-0.30; P=0.04), decitabine (rp=-0.29; P=0.04) and gemcitabine (rp=-0.33; P=0.02). Decitabine 112-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 16333246-7 2005 hENT1 mRNA expression also seemed to correlate inversely with the LC50 values of cladribine (rp=-0.30; P=0.04), decitabine (rp=-0.29; P=0.04) and gemcitabine (rp=-0.33; P=0.02). gemcitabine 146-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15923058-2 2005 In vitro studies of resistant human cell lines have confirmed that human equilibrative nucleoside transporter 1 (hENT1)-deficient cells display resistance to gemcitabine. gemcitabine 158-169 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 73-111 15905191-5 2005 Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside (NBMPR) caused a 33% to 45% reduction of TGN in ALL cells in vitro (P < .006), consistent with the gene expression findings. Nitrobenzylmercaptopurine Ribonucleoside 25-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-21 15905191-5 2005 Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside (NBMPR) caused a 33% to 45% reduction of TGN in ALL cells in vitro (P < .006), consistent with the gene expression findings. 4-nitrobenzylthioinosine 67-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 14-21 15923058-2 2005 In vitro studies of resistant human cell lines have confirmed that human equilibrative nucleoside transporter 1 (hENT1)-deficient cells display resistance to gemcitabine. gemcitabine 158-169 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-118 15933265-2 2005 Human umbilical vein endothelium (HUVEC) function in an environment with 3% to 5% O2 and exhibit efficient adenosine membrane transport via human equilibrative nucleoside transporters 1 (hENT1). Oxygen 82-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-192 16085043-1 2005 Human equilibrative, Na(+)-independent nucleoside transport is mediated by membrane proteins sensitive (system es, hENT1) or insensitive (system ei, hENT2) to nitrobenzylthioinosine (NBMPR). Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-120 15963471-5 2005 The present study studied the effects of three thiazolidinediones, troglitazone, pioglitazone and ciglitazone, on ENT1 in the human aortic smooth muscle cells (HASMCs). Troglitazone 67-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 15963471-5 2005 The present study studied the effects of three thiazolidinediones, troglitazone, pioglitazone and ciglitazone, on ENT1 in the human aortic smooth muscle cells (HASMCs). Pioglitazone 81-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 15963471-5 2005 The present study studied the effects of three thiazolidinediones, troglitazone, pioglitazone and ciglitazone, on ENT1 in the human aortic smooth muscle cells (HASMCs). ciglitazone 98-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 15963471-7 2005 The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1. Troglitazone 14-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-34 15963471-7 2005 The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1. Troglitazone 97-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 30-34 15963471-7 2005 The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1. Troglitazone 97-109 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-145 16085043-6 2005 D-Glucose reduced hENT1 and hENT2 mRNA expression, but only hENT1 protein abundance at the plasma membrane. Glucose 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 18-23 15963471-12 2005 From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1. Troglitazone 41-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-121 15963471-12 2005 From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1. Adenosine 93-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 117-121 15963471-13 2005 Pharmacologically, troglitazone is a novel inhibitor of ENT1. Troglitazone 19-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 56-60 15933265-8 2005 Thus, hypoxia-increased extracellular adenosine may result from reduced hENT1-adenosine transport in HUVEC. Adenosine 38-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 15933265-8 2005 Thus, hypoxia-increased extracellular adenosine may result from reduced hENT1-adenosine transport in HUVEC. Adenosine 78-87 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 15933265-2 2005 Human umbilical vein endothelium (HUVEC) function in an environment with 3% to 5% O2 and exhibit efficient adenosine membrane transport via human equilibrative nucleoside transporters 1 (hENT1). Adenosine 107-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 187-192 15933265-4 2005 Hypoxia (0 to 24 hours, 2% and 1% O2) reduced maximal hENT1-adenosine transport velocity (V(max)) and maximal nitrobenzylthionosine (NBMPR, a high-affinity hENT1 protein ligand) binding, but increased extracellular adenosine concentration. Oxygen 34-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 15933265-4 2005 Hypoxia (0 to 24 hours, 2% and 1% O2) reduced maximal hENT1-adenosine transport velocity (V(max)) and maximal nitrobenzylthionosine (NBMPR, a high-affinity hENT1 protein ligand) binding, but increased extracellular adenosine concentration. Oxygen 34-36 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 15933265-4 2005 Hypoxia (0 to 24 hours, 2% and 1% O2) reduced maximal hENT1-adenosine transport velocity (V(max)) and maximal nitrobenzylthionosine (NBMPR, a high-affinity hENT1 protein ligand) binding, but increased extracellular adenosine concentration. Adenosine 60-69 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 15933265-4 2005 Hypoxia (0 to 24 hours, 2% and 1% O2) reduced maximal hENT1-adenosine transport velocity (V(max)) and maximal nitrobenzylthionosine (NBMPR, a high-affinity hENT1 protein ligand) binding, but increased extracellular adenosine concentration. nitrobenzylthionosine 110-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 156-161 15695555-5 2005 Although RT-PCR demonstrated the presence of equilibrative nucleoside transporter-1 (ENT-1) and ENT-2 mRNA, functional studies revealed that adenosine transport in HASMCs was predominantly mediated by ENT-1 and inhibited by nitrobenzylmercaptopurine riboside (NBMPR, IC(50) = 0.69 +/- 0.05 nM). Adenosine 141-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 201-206 15795320-5 2005 Synergistic cytotoxicity was demonstrated, and pemetrexed significantly decreased the amount of phosphorylated Akt, enhanced apoptosis, and increased the expression of dCK in A549 and Calu-6 cells, as well as the expression of the human nucleoside equilibrative transporter 1 (hENT1) in all cell lines. Pemetrexed 47-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 277-282 15795320-7 2005 These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations. gemcitabine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 302-307 15795320-7 2005 These data demonstrated that 1) gemcitabine and pemetrexed synergistically interact against NSCLC cells through the suppression of Akt phosphorylation and induction of apoptosis; 2) the gene expression profile of critical genes may predict for drug chemosensitivity; and 3) pemetrexed enhances dCK and hENT1 expression, thus suggesting the role of gene-expression modulation for rational development of chemotherapy combinations. Pemetrexed 48-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 302-307 15695555-5 2005 Although RT-PCR demonstrated the presence of equilibrative nucleoside transporter-1 (ENT-1) and ENT-2 mRNA, functional studies revealed that adenosine transport in HASMCs was predominantly mediated by ENT-1 and inhibited by nitrobenzylmercaptopurine riboside (NBMPR, IC(50) = 0.69 +/- 0.05 nM). hasmcs 164-170 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 201-206 15695555-9 2005 Consistent with these observations, 25 mM d-glucose increased mRNA and protein expression of ENT-1. Glucose 42-51 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-98 15695555-10 2005 Treatment of serum-starved cells with the selective inhibitors of MAPK/ERK, PD-98059 (40 microM) and U-0126 (10 microM), abolished the effect of d-glucose on ENT-1. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 76-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 158-163 15695555-10 2005 Treatment of serum-starved cells with the selective inhibitors of MAPK/ERK, PD-98059 (40 microM) and U-0126 (10 microM), abolished the effect of d-glucose on ENT-1. U 0126 101-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 158-163 15695555-10 2005 Treatment of serum-starved cells with the selective inhibitors of MAPK/ERK, PD-98059 (40 microM) and U-0126 (10 microM), abolished the effect of d-glucose on ENT-1. Glucose 145-154 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 158-163 15695555-11 2005 We conclude that d-glucose upregulates the protein and message expression and functional activity of ENT-1 in HASMCs, possibly via MAPK/ERK-dependent pathways. Glucose 17-26 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 15695555-11 2005 We conclude that d-glucose upregulates the protein and message expression and functional activity of ENT-1 in HASMCs, possibly via MAPK/ERK-dependent pathways. hasmcs 110-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-106 15695555-12 2005 Pathologically, the increase in ENT-1 activity in diabetes may affect the availability of adenosine in the vicinity of adenosine receptors and, thus, alter vascular functions in diabetes. Adenosine 90-99 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-37 15644498-2 2005 In previous work, we demonstrated that mutation of residues 33 (Met versus Ile) of hENT1 and hENT2 altered sensitivity to dilazep and dipyridamole and that the hENT2 mutant (I33M) displayed a K(m) value for uridine that was lower than that of hENT2 and similar to that of hENT1 (J Biol Chem 277:395-401, 2002). Uridine 207-214 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-88 15529184-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. gemcitabine 152-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 15529184-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. gemcitabine 152-163 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15529184-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. Cytarabine 165-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 15529184-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. Cytarabine 165-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15529184-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. fludarabine 181-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 15529184-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is a member of the equilibrative nucleoside transporter family that mediates cellular entry of gemcitabine, cytarabine, and fludarabine. fludarabine 181-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15529184-3 2005 Since some nucleoside analogs have a role in treating patients with non-Hodgkin"s lymphoma (NHL), this study was undertaken to assess hENT1 abundance in NHL. Nucleosides 11-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 134-139 15529184-12 2005 Prospective studies to assess the value of hENT1 immunostaining in predicting resistance to nucleoside chemotherapy for NHL are warranted. Nucleosides 92-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 15644498-1 2005 Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. Nucleosides 20-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15644498-1 2005 Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. Dilazep 232-239 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-51 15644498-1 2005 Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. Dilazep 232-239 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15644498-1 2005 Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. Dipyridamole 244-256 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-51 15644498-1 2005 Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. Dipyridamole 244-256 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15644498-2 2005 In previous work, we demonstrated that mutation of residues 33 (Met versus Ile) of hENT1 and hENT2 altered sensitivity to dilazep and dipyridamole and that the hENT2 mutant (I33M) displayed a K(m) value for uridine that was lower than that of hENT2 and similar to that of hENT1 (J Biol Chem 277:395-401, 2002). Dilazep 122-129 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-88 15644498-2 2005 In previous work, we demonstrated that mutation of residues 33 (Met versus Ile) of hENT1 and hENT2 altered sensitivity to dilazep and dipyridamole and that the hENT2 mutant (I33M) displayed a K(m) value for uridine that was lower than that of hENT2 and similar to that of hENT1 (J Biol Chem 277:395-401, 2002). Dipyridamole 134-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 83-88 15649894-1 2005 The equilibrative nucleoside transporters, hENT1 and CeENT1 from humans and Caenorhabditis elegans, respectively, are inhibited by nanomolar concentrations of dipyridamole and share a common 11-transmembrane helix (TM) topology. Dipyridamole 159-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 15649894-2 2005 Random mutagenesis and screening by functional complementation in yeast for clones with reduced sensitivities to dipyridamole yielded mutations at Ile429 in TM 11 of CeENT1 and Met33 in TM 1 of hENT1. Dipyridamole 113-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 194-199 15649894-3 2005 Mutational analysis of the corresponding residues of both proteins suggested important roles for these residues in competitive inhibition of hENT1 and CeENT1 by dipyridamole. Dipyridamole 161-173 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 141-146 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Alanine 81-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Alanine 81-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 197-202 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Threonine 89-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Threonine 89-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 197-202 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Uridine 146-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15649894-6 2005 Functional analysis of the TM 1 and 11 mutants of hENT1 and CeENT1 revealed that Ala and Thr in the TM 1 and 11 positions, respectively, impaired uridine and adenosine transport and that Leu442 of hENT1 was involved in permeant selectivity. Adenosine 158-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15649894-8 2005 This study demonstrated that the corresponding residues in TMs 1 and 11 of hENT1, hENT2, and CeENT1 are important for dipyridamole interactions and nucleoside transport. Dipyridamole 118-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 15649894-8 2005 This study demonstrated that the corresponding residues in TMs 1 and 11 of hENT1, hENT2, and CeENT1 are important for dipyridamole interactions and nucleoside transport. Nucleosides 148-158 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-80 15486050-5 2005 The concentration dependence of inhibition of [(3)H]uridine transport in S. cerevisiae by TR exhibited lower K(i) values than BR: hCNT3 (5.4 versus 226 microM), hENT2 (16 versus 271 microM), hENT1 (57 versus 168 microM), and hCNT1 (221 versus 220 microM). [(3)h]uridine 46-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 191-196 15557207-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is an important modulator of the physiological action of adenosine. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 15557207-1 2005 The human equilibrative nucleoside transporter 1 (hENT1) is an important modulator of the physiological action of adenosine. Adenosine 114-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-55 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 46-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 46-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 241-246 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 210-219 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 142-147 15557207-2 2005 We identified amino acid residues involved in adenosine transport using a yeast-based assay to rapidly screen and identify randomly generated hENT1 mutants that exhibited decreased sensitivity to inhibition of adenosine transport by various hENT1 competitive inhibitors. Adenosine 210-219 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 241-246 15557207-6 2005 In contrast, compared with wild-type hENT1, the sensitivity to dipyridamole inhibition was significantly (p < 0.05) increased by only the Ser160Cys (approximately 2.6-fold) or the double mutant Met89Cys/Ser160Cys (approximately 4.7-fold) but not by the Met89Cys mutant. Dipyridamole 63-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 37-42 15557207-10 2005 In contrast, Ser160 and Met89 of hENT1, respectively, play a dominant role in conferring sensitivity to dipyridamole and adenosine/guanosine affinity. Dipyridamole 104-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 15557207-10 2005 In contrast, Ser160 and Met89 of hENT1, respectively, play a dominant role in conferring sensitivity to dipyridamole and adenosine/guanosine affinity. Adenosine 121-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 15557207-10 2005 In contrast, Ser160 and Met89 of hENT1, respectively, play a dominant role in conferring sensitivity to dipyridamole and adenosine/guanosine affinity. Guanosine 131-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 15557207-0 2005 Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Adenosine 102-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-77 15557207-0 2005 Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Guanosine 113-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-77 15557207-0 2005 Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. s6-(4-nitrobenzyl)-mercaptopurine riboside 124-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-77 15557207-0 2005 Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-mercaptopurine riboside, and dipyridamole. Dipyridamole 172-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-77 15634027-1 2005 4-nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. 4-nitrobenzylthioinosine 0-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-102 15634027-1 2005 4-nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. 4-nitrobenzylthioinosine 26-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-102 15486050-7 2005 Exposure to nitrobenzylmercaptopurine ribonucleoside conferred resistance to BR and TR cytotoxicity to hENT1-containing CEM cells, thereby demonstrating the importance of transport capacity for manifestation of cytoxicity. Nitrobenzylmercaptopurine Ribonucleoside 12-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 103-108 15632314-0 2004 Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. Cytarabine 102-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-91 15386342-12 2004 Since hCNT1, hENT1 and hENT2 recognize fluoropyrimidines as substrates, but with different affinities, this study anticipates high variability in drug uptake efficiency in solid tumors. fluoropyrimidines 39-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 13-18 15632314-0 2004 Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. Cytarabine 102-107 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-97 15632314-3 2004 The adenosine deaminase (ADA) gene was highly up-regulated in Ara-C-resistant cells, while equilibrative nucleoside transporter 1 (ENT1) and several cell-cycle-related genes were down-regulated. Cytarabine 62-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 131-135 15632314-4 2004 Of all these genes, ENT1 seemed the most likely to be relevant to Ara-C resistance. Cytarabine 66-71 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 20-24 15632314-5 2004 To investigate the role of ENT1 in Ara-C-resistant cells, we transfected the cells with the gene. Cytarabine 35-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 15632314-6 2004 ENT1-transfected Ara-C-resistant cells resembled wild-type CCRF-CEM cells more closely than untransfected Ara-C-resistant cells in terms of growth rate, Ara-C-uptake characteristics, and ADA expression levels. Cytarabine 17-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 15632314-6 2004 ENT1-transfected Ara-C-resistant cells resembled wild-type CCRF-CEM cells more closely than untransfected Ara-C-resistant cells in terms of growth rate, Ara-C-uptake characteristics, and ADA expression levels. Cytarabine 106-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 15632314-6 2004 ENT1-transfected Ara-C-resistant cells resembled wild-type CCRF-CEM cells more closely than untransfected Ara-C-resistant cells in terms of growth rate, Ara-C-uptake characteristics, and ADA expression levels. Cytarabine 106-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 15632314-7 2004 The down-regulation of the ENT1 gene is expected to result in nucleotide deficiency in addition to blockage of Ara-C influx. Cytarabine 111-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-31 15632314-8 2004 Accordingly, Ara-C-resistant cells showed low growth rates, which were restored by transfection with ENT1. Cytarabine 13-18 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-105 15481982-1 2004 4-Nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. 4-nitrobenzylthioinosine 0-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-102 15481982-1 2004 4-Nitrobenzylthioinosine (NBTI, 1) is a well-known inhibitor for the nucleoside transport protein ENT1. 4-nitrobenzylthioinosine 26-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 98-102 15205344-6 2004 Application of an inhibitor of SLC29A1, nitrobenzylmercaptopurine ribonucleoside, significantly reduced the potency of these two drugs, indicating that SLC29A1 plays a role in cellular uptake. Nitrobenzylmercaptopurine Ribonucleoside 40-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 152-159 15571274-1 2004 The uptake of nucleosides and nucleoside analogs into human leukemia K562 cells is facilitated by the equilibrative transporters ENT1 and ENT2. Nucleosides 14-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 15471562-2 2004 In this study we used quantitative RT-PCR to examine the expression levels of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK) genes in non-small cell lung cancer (NSCLC) cell lines in relation to sensitivity and resistance to gemcitabine. gemcitabine 262-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 84-122 15471562-2 2004 In this study we used quantitative RT-PCR to examine the expression levels of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK) genes in non-small cell lung cancer (NSCLC) cell lines in relation to sensitivity and resistance to gemcitabine. gemcitabine 262-273 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 124-129 15471562-3 2004 The basal expression levels of hENT1 were significantly correlated with the IC50 values for gemcitabine (r =-0.6769, P = 0.0005), whereas dCK expression levels were not. gemcitabine 92-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-36 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. gemcitabine 12-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-173 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. gemcitabine 12-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 209-214 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. gemcitabine 73-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-173 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. gemcitabine 73-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 209-214 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. Nitrobenzylmercaptopurine Ribonucleoside 102-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-173 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. 4-nitrobenzylthioinosine 144-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-173 15471562-4 2004 In a highly gemcitabine-sensitive cell line, NCI-H23, the sensitivity to gemcitabine was inhibited by nitrobenzylmercaptopurine ribonucleoside (NBMPR), an inhibitor of hENT1, without significant modulation of hENT1 expression. 4-nitrobenzylthioinosine 144-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 209-214 15471562-5 2004 These data suggest that hENT1 is associated with gemcitabine sensitivity in lung cancer. gemcitabine 49-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 15471562-7 2004 We conclude that increased hENT1 expression is a determinant of gemcitabine sensitivity, while decreased dCK expression is associated with acquired resistance to gemcitabine in NSCLC cells. gemcitabine 64-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-32 15471562-8 2004 Thus, hENT1 and dCK might be useful as predictive markers for efficacy of gemcitabine therapy in NSCLC. gemcitabine 74-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 6-11 15237994-4 2004 A second reformulation of the yatakemycin structure as 1, incorporating the alternatively substituted right-hand subunit as well as the initial thiomethyl ester reformulation, was confirmed by total synthesis of both (+)- and ent-(-)-1 in studies that also unambiguously established the absolute configuration of the natural product. yatakemycin 30-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 226-235 15371014-3 2004 These transporters resemble their human counterparts hENT1 and hENT2 in exhibiting similar broad permeant specificities for nucleosides, while differing in their permeant selectivities for nucleobases. Nucleosides 124-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15371014-3 2004 These transporters resemble their human counterparts hENT1 and hENT2 in exhibiting similar broad permeant specificities for nucleosides, while differing in their permeant selectivities for nucleobases. nucleobases 189-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Nucleosides 55-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-53 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Nucleosides 55-65 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-82 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Azacitidine 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-53 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. Azacitidine 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-82 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. inosine-glycodialdehyde 148-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-53 15205344-5 2004 We validated the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of nucleoside analogues, azacytidine and inosine-glycodialdehyde. inosine-glycodialdehyde 148-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 78-82 15205344-6 2004 Application of an inhibitor of SLC29A1, nitrobenzylmercaptopurine ribonucleoside, significantly reduced the potency of these two drugs, indicating that SLC29A1 plays a role in cellular uptake. Nitrobenzylmercaptopurine Ribonucleoside 40-80 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 31-38 15501974-0 2004 The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. gemcitabine 113-124 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 21-59 15501974-3 2004 In vitro studies have demonstrated that deficiency of human equilibrative nucleoside transporter 1 (hENT1), the most widely abundant and distributed nucleoside transporter in human cells, confers resistance to gemcitabine toxicity, but the distribution and abundance of nucleoside transporters in normal and malignant pancreatic tissue is unknown. gemcitabine 210-221 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 60-98 15501974-3 2004 In vitro studies have demonstrated that deficiency of human equilibrative nucleoside transporter 1 (hENT1), the most widely abundant and distributed nucleoside transporter in human cells, confers resistance to gemcitabine toxicity, but the distribution and abundance of nucleoside transporters in normal and malignant pancreatic tissue is unknown. gemcitabine 210-221 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 15501974-7 2004 Patients in whom all adenocarcinoma cells had detectable hENT1 had significantly longer median survivals from gemcitabine initiation than those for whom hENT1 was absent in a proportion (10 to 100%) of adenocarcinoma cells (median survival, 13 versus 4 months, P = 0.01). gemcitabine 110-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15501974-9 2004 CONCLUSIONS: Patients with pancreatic adenocarcinoma with uniformly detectable hENT1 immunostaining have a significantly longer survival after gemcitabine chemotherapy than tumors without detectable hENT1. gemcitabine 143-154 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 79-84 15501974-10 2004 Immunohistochemistry for hENT1 shows promise as a molecular predictive assay to appropriately select patients for palliative gemcitabine chemotherapy but requires formal validation in prospective, randomized trials. gemcitabine 125-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-30 15571274-1 2004 The uptake of nucleosides and nucleoside analogs into human leukemia K562 cells is facilitated by the equilibrative transporters ENT1 and ENT2. Nucleosides 14-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 15373484-3 2004 The versatility of the method is illustrated by the asymmetric syntheses of neurokinin substance P receptor antagonist L-733,061 (ent-1), (-)-deoxocassine (4), and an inhibitor of HIV proteases (5a). 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine 119-128 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 130-135 15157888-5 2004 hENT1 tk cells are healthy and efficiently incorporate exogenous thymidine and thymidine analogs. Thymidine 65-74 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15157888-5 2004 hENT1 tk cells are healthy and efficiently incorporate exogenous thymidine and thymidine analogs. Thymidine 79-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15132544-4 2004 The methodology was also applied to the synthesis of three further cis-solamin isomers 2, ent-1, and ent-2. cis-solamin 67-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-95 14759222-0 2004 Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. Inosine 68-75 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 203-208 14759222-0 2004 Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. 4-nitrobenzylthioinosine 88-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 203-208 14759222-0 2004 Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. s6-(4-nitrobenzyl)-mercaptopurine riboside 95-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 203-208 14759222-0 2004 Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1. Dilazep 143-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 203-208 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenine 66-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-34 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenine 66-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-175 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. ade2 88-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-34 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. ade2 88-92 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-175 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenine 134-141 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-34 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenosine 157-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 29-34 14759222-2 2004 In this assay, expression of hENT1 in a yeast strain deficient in adenine biosynthesis (ade2) permits yeast growth on a plate lacking adenine but containing adenosine, a hENT1 substrate. Adenosine 157-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-175 14759222-3 2004 This growth was prevented when inhibitors of hENT1 [e.g. NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside], dilazep or dipyridamole] were included in the media. 4-nitrobenzylthioinosine 57-62 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 14759222-3 2004 This growth was prevented when inhibitors of hENT1 [e.g. NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside], dilazep or dipyridamole] were included in the media. s6-(4-nitrobenzyl)-mercaptopurine riboside 64-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-50 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. nucleosides inosine 155-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. nucleosides inosine 155-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 132-137 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. Guanosine 179-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. Guanosine 179-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 132-137 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. 4-nitrobenzylthioinosine 227-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. 4-nitrobenzylthioinosine 227-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 132-137 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. Dilazep 237-244 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 14759222-12 2004 We have identified for the first time an amino acid residue (Leu92) of hENT1 that, when mutated, selectively alters the affinity of hENT1 to transport the nucleosides inosine and guanosine and its sensitivity to the inhibitors NBMPR and dilazep. Dilazep 237-244 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 132-137 15149181-1 2004 A bifunctional biotinylated photoaffinity label for the nitrobenzylmercaptopurine riboside (NBMPR)-sensitive (es) nucleoside transporter (ENT1) has been synthesized and evaluated. nitrobenzylmercaptopurine riboside 56-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 15149181-1 2004 A bifunctional biotinylated photoaffinity label for the nitrobenzylmercaptopurine riboside (NBMPR)-sensitive (es) nucleoside transporter (ENT1) has been synthesized and evaluated. 4-nitrobenzylthioinosine 92-97 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-142 14607828-7 2004 In agreement with these localization data, [14C]FIAU was efficiently transported into the mitochondria of cells expressing hENT1-YFP but not of cells expressing hCNT1-YFP. Carbon-14 44-47 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 14978234-3 2004 To define the relative and unified structural requirements of nucleoside analogs for interaction with hCNT1, hCNT2, and hENT1, we applied an array of structure-activity techniques. Nucleosides 62-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-125 14978234-10 2004 Addition of a hydroxyl group around the 2-position of purine (or 3-position of pyrimidine) may increase inhibition to hCNT2 transporter; addition of hydroxyl group around the 2,7-position of purine (or the 3,5-position of pyrimidine) would increase the inhibition to hENT1 transporter. purine 54-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 267-272 14978234-10 2004 Addition of a hydroxyl group around the 2-position of purine (or 3-position of pyrimidine) may increase inhibition to hCNT2 transporter; addition of hydroxyl group around the 2,7-position of purine (or the 3,5-position of pyrimidine) would increase the inhibition to hENT1 transporter. pyrimidine 79-89 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 267-272 14750831-1 2004 The chiral lactam 1 (or its enantiomer ent-1) was shown to be an effective (1)H NMR shift reagent for the ee determination of chiral lactams, quinolones, and oxazolidinones. Lactams 11-17 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 14607828-8 2004 The mitochondrial toxicity of FIAU to Madin-Darby canine kidney cells was enhanced by hENT1-YFP, even when hENT1 activity on the plasma membrane was selectively blocked by 10 nm nitrobenzylthioinosine. 4-nitrobenzylthioinosine 178-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 107-112 14750831-1 2004 The chiral lactam 1 (or its enantiomer ent-1) was shown to be an effective (1)H NMR shift reagent for the ee determination of chiral lactams, quinolones, and oxazolidinones. Lactams 133-140 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 14750831-1 2004 The chiral lactam 1 (or its enantiomer ent-1) was shown to be an effective (1)H NMR shift reagent for the ee determination of chiral lactams, quinolones, and oxazolidinones. Quinolones 142-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 306-310 14750831-1 2004 The chiral lactam 1 (or its enantiomer ent-1) was shown to be an effective (1)H NMR shift reagent for the ee determination of chiral lactams, quinolones, and oxazolidinones. Oxazolidinones 158-172 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-44 15037197-9 2004 Our results, using a yeast expression system, demonstrate that substituting glycine 154 of hENT1 with serine of hENT2 converts hENT1 to a transporter that exhibits partial characteristics of hENT2. Glycine 76-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-96 15037197-9 2004 Our results, using a yeast expression system, demonstrate that substituting glycine 154 of hENT1 with serine of hENT2 converts hENT1 to a transporter that exhibits partial characteristics of hENT2. Glycine 76-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 127-132 15037197-9 2004 Our results, using a yeast expression system, demonstrate that substituting glycine 154 of hENT1 with serine of hENT2 converts hENT1 to a transporter that exhibits partial characteristics of hENT2. Serine 102-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-96 15037197-9 2004 Our results, using a yeast expression system, demonstrate that substituting glycine 154 of hENT1 with serine of hENT2 converts hENT1 to a transporter that exhibits partial characteristics of hENT2. Serine 102-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 127-132 15037197-10 2004 For example, this conversion reduces sensitivity of hENT1 to the inhibitors NBMPR, DP, and DZ and reduces its transport affinity for the natural nucleosides cytidine and adenosine. Dipyridamole 83-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 15037197-10 2004 For example, this conversion reduces sensitivity of hENT1 to the inhibitors NBMPR, DP, and DZ and reduces its transport affinity for the natural nucleosides cytidine and adenosine. nucleosides cytidine 145-165 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 15037197-10 2004 For example, this conversion reduces sensitivity of hENT1 to the inhibitors NBMPR, DP, and DZ and reduces its transport affinity for the natural nucleosides cytidine and adenosine. Adenosine 170-179 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 15037197-11 2004 However, this conversion renders hENT1 less sensitive to inhibition by anti-HIV drugs azidothymidine, dideoxyinosine, and the nucleobase, hypoxanthine. Zidovudine 86-100 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 15037197-11 2004 However, this conversion renders hENT1 less sensitive to inhibition by anti-HIV drugs azidothymidine, dideoxyinosine, and the nucleobase, hypoxanthine. Didanosine 102-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 15037197-0 2004 Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Glycine 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15037197-0 2004 Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Nucleosides 33-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15037197-0 2004 Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. 4-nitrobenzylthioinosine 151-173 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15037197-0 2004 Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Dipyridamole 175-187 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15037197-0 2004 Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep. Dilazep 193-200 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 15037197-2 2004 hENT1 is ubiquitously expressed and plays an important role in the disposition and pharmacological activity of nucleoside drugs and nucleosides, such as adenosine. Nucleosides 111-121 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-2 2004 hENT1 is ubiquitously expressed and plays an important role in the disposition and pharmacological activity of nucleoside drugs and nucleosides, such as adenosine. Nucleosides 132-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-2 2004 hENT1 is ubiquitously expressed and plays an important role in the disposition and pharmacological activity of nucleoside drugs and nucleosides, such as adenosine. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-4 2004 hENT1 and hENT2 differ in their affinity for nucleoside substrates and in their sensitivity to inhibitors, such as nitrobenzylthioinosine (NBMPR). Nucleosides 45-55 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-4 2004 hENT1 and hENT2 differ in their affinity for nucleoside substrates and in their sensitivity to inhibitors, such as nitrobenzylthioinosine (NBMPR). 4-nitrobenzylthioinosine 115-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-4 2004 hENT1 and hENT2 differ in their affinity for nucleoside substrates and in their sensitivity to inhibitors, such as nitrobenzylthioinosine (NBMPR). 4-nitrobenzylthioinosine 139-144 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-5 2004 hENT1 has higher (or equal) affinity to hENT2 for all natural nucleosides except inosine. Nucleosides 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-5 2004 hENT1 has higher (or equal) affinity to hENT2 for all natural nucleosides except inosine. Inosine 81-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15037197-7 2004 This difference in inhibition potency is substantially dependent on the difference in amino acid at position 154 in hENT1 (glycine) and hENT2 (serine). Glycine 123-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 116-121 15037197-8 2004 Since NBMPR competitively inhibits nucleoside transporter activity, we hypothesized that G154 may also play a role in the transport of natural nucleosides and in the inhibition by other hENT1 inhibitors, dipyridamole (DP), and dilazep (DZ). 4-nitrobenzylthioinosine 6-11 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 186-191 15037197-8 2004 Since NBMPR competitively inhibits nucleoside transporter activity, we hypothesized that G154 may also play a role in the transport of natural nucleosides and in the inhibition by other hENT1 inhibitors, dipyridamole (DP), and dilazep (DZ). g154 89-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 186-191 12838422-4 2004 The best-characterised members of the family, hENT1 and hENT2, possess similar broad substrate specificities for purine and pyrimidine nucleosides, but hENT2 in addition efficiently transports nucleobases. purine 113-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 12838422-4 2004 The best-characterised members of the family, hENT1 and hENT2, possess similar broad substrate specificities for purine and pyrimidine nucleosides, but hENT2 in addition efficiently transports nucleobases. Pyrimidine Nucleosides 124-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 12838422-4 2004 The best-characterised members of the family, hENT1 and hENT2, possess similar broad substrate specificities for purine and pyrimidine nucleosides, but hENT2 in addition efficiently transports nucleobases. nucleobases 193-204 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 15043160-0 2004 Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in Saccharomyces cerevisiae. Uridine 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 36-81 15043160-1 2004 The sugar moiety of nucleosides has been shown to play a major role in permeant-transporter interaction with human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2). Sugars 4-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-160 15043160-1 2004 The sugar moiety of nucleosides has been shown to play a major role in permeant-transporter interaction with human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2). Sugars 4-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-167 15043160-1 2004 The sugar moiety of nucleosides has been shown to play a major role in permeant-transporter interaction with human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2). Nucleosides 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 115-160 15043160-1 2004 The sugar moiety of nucleosides has been shown to play a major role in permeant-transporter interaction with human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2). Nucleosides 20-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-167 15043160-2 2004 To better understand the structural requirements for interactions with hENT1 and hENT2, a series of uridine analogs with sugar modifications were subjected to an assay that tested their abilities to inhibit [3H]uridine transport mediated by recombinant hENT1 and hENT2 produced in Saccharomyces cerevisiae. 3h]uridine 208-218 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 253-258 15043160-3 2004 hENT1 displayed higher affinity for uridine than hENT2. Uridine 36-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 15043160-5 2004 The C(2")-OH at uridine was a structural determinant for uridine-hENT1, but not for uridine-hENT2, interactions. c(2")-oh 4-12 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-70 15043160-5 2004 The C(2")-OH at uridine was a structural determinant for uridine-hENT1, but not for uridine-hENT2, interactions. Uridine 16-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-70 15043160-5 2004 The C(2")-OH at uridine was a structural determinant for uridine-hENT1, but not for uridine-hENT2, interactions. Uridine 57-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-70 15043160-5 2004 The C(2")-OH at uridine was a structural determinant for uridine-hENT1, but not for uridine-hENT2, interactions. Uridine 57-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-70 15043160-6 2004 Both transporters were sensitive to modifications at C(5") and hENT2 displayed more tolerance to removal of C(5")-OH than hENT1; addition of an O-methyl group at C(5") greatly reduced interaction with either hENT1 or hENT2. c(5")-oh 108-116 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 208-213 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. Uridine 79-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. c(3")-oh 148-156 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. c(2")-oh 188-196 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. c(5")-oh 201-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. Uridine 213-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. c(3")-oh 268-276 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. c(5")-oh 301-309 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 15043160-7 2004 The changes in binding energies between transporter proteins and the different uridine analogs suggested that hENT1 formed strong interactions with C(3")-OH and moderate interactions with C(2")-OH and C(5")-OH of uridine, whereas hENT2 formed strong interactions with C(3")-OH, weak interactions with C(5")-OH, and no interaction with C(2")-OH. c(2")-oh 335-343 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 110-115 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 317-324 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 306-310 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 317-324 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 306-310 14612157-2 2003 There are five known, functionally characterized nucleoside transporters with varying substrate specificities for nucleosides: concentrative nucleoside transporters (CNT1-CNT3; Solute Carrier (SLC) 28A1-28A3), which mediate the intracellular flux of nucleosides, and equilibrative nucleoside transporters (ENT1-ENT2; SLC29A1-SLC29A2), which mediate bi-directional facilitated diffusion of nucleosides. Nucleosides 250-261 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 317-324 12820662-4 2003 Uptake studies demonstrated that the majority of adenosine transport was mediated by hENT1, which was localized to both apical and basolateral membranes, with a smaller hENT2-mediated component in basolateral membranes. Adenosine 49-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-90 12968351-3 2003 In contrast, replacement of positions 10 and 11 by the D-THF amino acid ent-1 gave rise to new and interesting channel properties. 3,7-dimethoxy-5,3',4'-trihydroxyflavone 55-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 12527552-11 2003 These data suggest that hENT1 and hENT2 on the basolateral membrane function with concentrative nucleoside transporters on the apical membrane to mediate active reabsorption of nucleosides within the kidney. Nucleosides 177-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 24-29 12724623-1 2003 The human equilibrative nucleoside transporter, ENT1, appears to play a critical role in the disposition of nucleosides and nucleoside analogs used clinically as anti-viral and anti-cancer drugs. Nucleosides 108-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 12724623-1 2003 The human equilibrative nucleoside transporter, ENT1, appears to play a critical role in the disposition of nucleosides and nucleoside analogs used clinically as anti-viral and anti-cancer drugs. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-52 14581375-1 2003 PURPOSE: Concentrative nucleoside transporter (CNT) 1, CNT3, equilibrative nucleoside transporter (ENT) 1, and, to a lesser extent, ENT2, appear to be the transporters responsible for 2",2"-difluorodeoxycytidine (gemcitabine; Gemzar) uptake into cells. gemcitabine 184-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-105 14581375-1 2003 PURPOSE: Concentrative nucleoside transporter (CNT) 1, CNT3, equilibrative nucleoside transporter (ENT) 1, and, to a lesser extent, ENT2, appear to be the transporters responsible for 2",2"-difluorodeoxycytidine (gemcitabine; Gemzar) uptake into cells. gemcitabine 213-224 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-105 14581375-1 2003 PURPOSE: Concentrative nucleoside transporter (CNT) 1, CNT3, equilibrative nucleoside transporter (ENT) 1, and, to a lesser extent, ENT2, appear to be the transporters responsible for 2",2"-difluorodeoxycytidine (gemcitabine; Gemzar) uptake into cells. gemcitabine 226-232 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-105 14581375-5 2003 RESULTS: All of the cell lines take up gemcitabine mostly via the hENT1 transporter, which is expressed at high levels. gemcitabine 39-50 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 66-71 14581375-9 2003 Despite high constitutive hENT1 activity, this increased sensitivity to gemcitabine. gemcitabine 72-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 12820662-5 2003 Whole-cell current measurements showed that application of extracellular nitrobenzylmercaptopurine ribonucleoside (NBMPR), a selective inhibitor of hENT1-mediated transport, had similar effects on whole-cell currents as the application of exogenous adenosine. Nitrobenzylmercaptopurine Ribonucleoside 73-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 148-153 12820662-5 2003 Whole-cell current measurements showed that application of extracellular nitrobenzylmercaptopurine ribonucleoside (NBMPR), a selective inhibitor of hENT1-mediated transport, had similar effects on whole-cell currents as the application of exogenous adenosine. 4-nitrobenzylthioinosine 115-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 148-153 12617917-1 2003 The syntheses of (+)-neamine 1, (-)-neamine ent-1 and their positional isomers 2, 3, ent-2 and ent-3 are reported as potential new scaffolds for novel aminoglycoside antibiotics. neamine 17-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 12617917-1 2003 The syntheses of (+)-neamine 1, (-)-neamine ent-1 and their positional isomers 2, 3, ent-2 and ent-3 are reported as potential new scaffolds for novel aminoglycoside antibiotics. neamine 32-43 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 12617917-1 2003 The syntheses of (+)-neamine 1, (-)-neamine ent-1 and their positional isomers 2, 3, ent-2 and ent-3 are reported as potential new scaffolds for novel aminoglycoside antibiotics. aminoglycoside antibiotics 151-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-49 12590919-1 2003 Protein glycosylation is important for nucleoside transport, and this has been demonstrated for the human equilibrative nucleoside transporter-1 (hENT1). Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 106-144 12590919-1 2003 Protein glycosylation is important for nucleoside transport, and this has been demonstrated for the human equilibrative nucleoside transporter-1 (hENT1). Nucleosides 39-49 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 12077112-3 2002 Consistent with the effects of these compounds on the nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter (ENT1), incubation with SB203580 or SB203580-iodo eliminated the binding of [3H]NBMPR to K562 cells or membranes isolated from human erythrocytes. 4-nitrobenzylthioinosine 54-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-137 12406912-9 2003 An oligonucleotide microarray screen (Affymetrix) comparing patients with MLL gene-rearranged ALL with those with nonrearranged ALL also showed a 1.9-fold lower dCK (P =.001) and a 2.7-fold higher hENT1 (P =.046) mRNA expression in patients with MLL gene-rearranged ALL. Oligonucleotides 3-18 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 197-202 12467044-3 2003 Both compounds 3 and 2" were converted into the optically pure norbornene aldehydes 1 and ent-1, respectively. norbornene aldehydes 63-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-95 12270166-1 2002 The title three compounds ent-1, 6, and ent-6 were synthesized by coupling the chiral sulfone 4 or ent-4 with the chiral piperidinaldehyde 5 or ent-5, which were readily prepared following the synthetic routes previously established by the novel total synthesis of natural himbacine 1. Sulfones 86-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 12270166-1 2002 The title three compounds ent-1, 6, and ent-6 were synthesized by coupling the chiral sulfone 4 or ent-4 with the chiral piperidinaldehyde 5 or ent-5, which were readily prepared following the synthetic routes previously established by the novel total synthesis of natural himbacine 1. piperidinaldehyde 121-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 12538831-2 2003 These compounds competed with the binding of nitrobenzylthioinosine (NBMPR) to K562 cells, consistent with inhibition of the NBMPR-sensitive equilibrative transporter (ENT1). 4-nitrobenzylthioinosine 45-67 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 168-172 12077112-3 2002 Consistent with the effects of these compounds on the nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter (ENT1), incubation with SB203580 or SB203580-iodo eliminated the binding of [3H]NBMPR to K562 cells or membranes isolated from human erythrocytes. 4-nitrobenzylthioinosine 78-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-137 12077112-3 2002 Consistent with the effects of these compounds on the nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter (ENT1), incubation with SB203580 or SB203580-iodo eliminated the binding of [3H]NBMPR to K562 cells or membranes isolated from human erythrocytes. SB 203580 156-164 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-137 12077112-3 2002 Consistent with the effects of these compounds on the nitrobenzylthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter (ENT1), incubation with SB203580 or SB203580-iodo eliminated the binding of [3H]NBMPR to K562 cells or membranes isolated from human erythrocytes. Tritium 209-211 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-137 12006583-7 2002 In contrast, recombinant hENT1 and rENT1 mediated negligible oocyte fluxes of hypoxanthine relative to hENT2 and rENT2. Hypoxanthine 78-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 25-30 12389626-4 2002 Because our prior studies showed that a deficiency in hENT1 confers high-level resistance to gemcitabine toxicity in vitro, we developed an immunohistochemical method to assess the hENT1 abundance of cells in tumor tissue. gemcitabine 93-104 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-59 12416024-11 2002 We also observed that p53 status influenced correlations between ENT1 transporter gene RNA levels and sensitivity to the drugs tiazafurin, AZQ and 3-deazauridine. tiazafurin 127-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-69 12416024-11 2002 We also observed that p53 status influenced correlations between ENT1 transporter gene RNA levels and sensitivity to the drugs tiazafurin, AZQ and 3-deazauridine. diaziquone 139-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-69 12416024-11 2002 We also observed that p53 status influenced correlations between ENT1 transporter gene RNA levels and sensitivity to the drugs tiazafurin, AZQ and 3-deazauridine. 3-Deazauridine 147-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 65-69 12416024-12 2002 One of three drugs identified by correlation of cytotoxicity patterns with ENT1 RNA levels, 3-deazauridine, inhibited uptake of the classic ENT1 substrate uridine, demonstrating a physical interaction between an identified drug and the transporter. 3-Deazauridine 92-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-79 12416024-12 2002 One of three drugs identified by correlation of cytotoxicity patterns with ENT1 RNA levels, 3-deazauridine, inhibited uptake of the classic ENT1 substrate uridine, demonstrating a physical interaction between an identified drug and the transporter. 3-Deazauridine 92-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 140-144 12416024-12 2002 One of three drugs identified by correlation of cytotoxicity patterns with ENT1 RNA levels, 3-deazauridine, inhibited uptake of the classic ENT1 substrate uridine, demonstrating a physical interaction between an identified drug and the transporter. Uridine 99-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 75-79 12416024-12 2002 One of three drugs identified by correlation of cytotoxicity patterns with ENT1 RNA levels, 3-deazauridine, inhibited uptake of the classic ENT1 substrate uridine, demonstrating a physical interaction between an identified drug and the transporter. Uridine 99-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 140-144 12008078-3 2002 These results suggest that expression of 5NT and reduced hENT1 in leukemic blasts at diagnosis are correlated with clinical outcome and may play a role in resistance mechanisms to ara-C in patients with AML. Cytarabine 180-185 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 12006583-2 2002 The human (h) and rat (r) equilibrative (Na(+)-independent) nucleoside transporters (ENTs) hENT1, rENT1, hENT2, and rENT2 belong to a family of integral membrane proteins with 11 transmembrane domains (TMs) and are distinguished functionally by differences in sensitivity to inhibition by nitrobenzylthioinosine and coronary vasoactive drugs. 4-nitrobenzylthioinosine 289-311 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 91-96 12006583-4 2002 In the present study, hENT1, rENT1, hENT2, and rENT2 were produced in Xenopus laevis oocytes and investigated for their ability to transport pyrimidine and purine nucleobases. pyrimidine 141-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 22-27 12389626-11 2002 We conclude that, because hENT1 deficiency has been previously related to nucleoside-drug resistance, immunohistochemical staining for hENT1 warrants evaluation as a predictive tool for guiding the appropriate use of gemcitabine in the treatment of HD. Nucleosides 74-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 12389626-11 2002 We conclude that, because hENT1 deficiency has been previously related to nucleoside-drug resistance, immunohistochemical staining for hENT1 warrants evaluation as a predictive tool for guiding the appropriate use of gemcitabine in the treatment of HD. gemcitabine 217-228 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 135-140 12069239-0 2002 Use of a small reporter molecule to determine cell-surface proteins by capillary electrophoresis and laser-induced fluorescence: use of 5-SAENTA-x8f for quantitation of the human equilibrative nucleoside transporter 1 protein. 5-saenta-x8f 136-148 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-217 12069239-1 2002 The human equilibrative nucleoside transporter 1 protein (hENT1) is a major mediator of cellular entry of nucleosides and anticancer nucleoside drugs; its assay is important in understanding and diagnosing chemotherapy resistance. Nucleosides 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 10-48 12069239-1 2002 The human equilibrative nucleoside transporter 1 protein (hENT1) is a major mediator of cellular entry of nucleosides and anticancer nucleoside drugs; its assay is important in understanding and diagnosing chemotherapy resistance. Nucleosides 106-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 12069239-1 2002 The human equilibrative nucleoside transporter 1 protein (hENT1) is a major mediator of cellular entry of nucleosides and anticancer nucleoside drugs; its assay is important in understanding and diagnosing chemotherapy resistance. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 12069239-3 2002 A cellular population is treated with 5"-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5"-thioadenosine-x8-fluorescein (5-SAENTA-x8f), which binds with high affinity and specificity to the hENT1 protein. 5"-s-(2-aminoethyl)-n6-(4-nitrobenzyl)-5"-thioadenosine-x8-fluorescein 38-108 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-184 12069239-3 2002 A cellular population is treated with 5"-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5"-thioadenosine-x8-fluorescein (5-SAENTA-x8f), which binds with high affinity and specificity to the hENT1 protein. 5-saenta-x8f 110-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 179-184 11906961-14 2002 Instead, 2-CADO, but not adenosine, is taken up into RA-FLSs via human equilibrative nucleoside transporter-1, where it is phosphorylated by adenosine kinase. 2-Chloroadenosine 9-15 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-109 12065074-3 2002 Displacement of the adenosine transporter antagonist [(3)H](S)-(nitrobenzyl)-6-thioinosine binding by DIFEQ in cultured U-937 cell preparations, expressing the human adenosine transporter protein (hENT1), showed a K(i) of 0.96+/-0.13 microM. [(3)h](s)-(nitrobenzyl)-6-thioinosine 53-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 197-202 11871901-2 2002 We designed (1S,2R)- and (1R,2R)-2-aminomethyl-1-(1H-imidazol-4-yl)cyclopropanes (1 and 2, respectively) and their enantiomers (ent-1 and ent-2) as conformationally restricted analogues of histamine. (1s,2r)- 12-20 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 128-133 11871901-7 2002 The four conformationally restricted target histamine analogues 1, 2, ent-1, and ent-2 were successfully synthesized from 7, 8, ent-7, and ent-8, respectively. Histamine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-75 12060121-2 2002 These factors include reduced influx of ara-C by the hENT1 transporter, reduced phosphorylation by deoxycytidine kinase (dCK), and increased degradation by high Km cytoplasmic 5"-nucleotidase (5NT) and/or cytidine deaminase (CDD). Cytarabine 40-45 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 53-58 12060121-10 2002 These results suggest that expression of DNA POL, 5NT and hENT1 at diagnosis may be resistance mechanisms to ara-C in AML patients. Cytarabine 109-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 58-63 12062437-2 2002 We show that acute stimulation of protein kinase C (PKC) causes a rapid increase in S-(4-nitrobenzyl)-6-thioinosine-sensitive (human equilibrative nucleoside transporter 1, hENT1) nucleoside uptake, in human cultured cells, which is not due to increased metabolism and which can be blocked by PKC inhibitors. 4-nitrobenzylthioinosine 84-115 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 133-171 12062437-2 2002 We show that acute stimulation of protein kinase C (PKC) causes a rapid increase in S-(4-nitrobenzyl)-6-thioinosine-sensitive (human equilibrative nucleoside transporter 1, hENT1) nucleoside uptake, in human cultured cells, which is not due to increased metabolism and which can be blocked by PKC inhibitors. 4-nitrobenzylthioinosine 84-115 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 173-178 12062437-4 2002 Down-regulation of PKC decreases hENT1-dependent uridine uptake. Uridine 49-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-38 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). Glucose 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). Glucose 15-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). Cibacron Blue F 3GA 108-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). Cibacron Blue F 3GA 108-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). Suramin 167-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). Suramin 167-174 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). galpha 176-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). galpha 176-182 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid 231-284 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11909821-5 2002 The effects of D-glucose and nucleotides on the number and activity of hENT1 and hENT1 mRNA were blocked by reactive blue 2 (nonspecific P2Y purinoceptor antagonist), suramin (Galpha(s) protein inhibitor), or hexokinase but not by pyridoxal phosphate-6-azophenyl-2",4"-disulfonic acid (nonselective P2 purinoceptor antagonist). pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid 231-284 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11909821-6 2002 Our findings demonstrate that inhibition of adenosine transport via hENT1 in endothelial cells cultured in 25 mmol/L D-glucose could be due to stimulation of P2Y2 purinoceptors by ATP, which is released from these cells in response to D-glucose. Adenosine 44-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 11909821-6 2002 Our findings demonstrate that inhibition of adenosine transport via hENT1 in endothelial cells cultured in 25 mmol/L D-glucose could be due to stimulation of P2Y2 purinoceptors by ATP, which is released from these cells in response to D-glucose. Glucose 117-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 11909821-6 2002 Our findings demonstrate that inhibition of adenosine transport via hENT1 in endothelial cells cultured in 25 mmol/L D-glucose could be due to stimulation of P2Y2 purinoceptors by ATP, which is released from these cells in response to D-glucose. Adenosine Triphosphate 180-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 11909821-6 2002 Our findings demonstrate that inhibition of adenosine transport via hENT1 in endothelial cells cultured in 25 mmol/L D-glucose could be due to stimulation of P2Y2 purinoceptors by ATP, which is released from these cells in response to D-glucose. Glucose 235-244 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 11801546-2 2002 We previously demonstrated that deficiency in hENT1, the most abundant and widely distributed plasma membrane nucleoside transporter in human cells, confers high-level resistance to gemcitabine toxicity in vitro, whereas the relationship between hENT1 activity and capecitabine toxicity is unknown. gemcitabine 182-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 11814344-9 2002 Based on these data, we conclude that when hENT1 is expressed in yeast, glycine 179 is critical not only to the ability of hENT1 to transport uridine but also as a determinant of hENT1 sensitivity to NBMPR. Glycine 72-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 11814344-9 2002 Based on these data, we conclude that when hENT1 is expressed in yeast, glycine 179 is critical not only to the ability of hENT1 to transport uridine but also as a determinant of hENT1 sensitivity to NBMPR. Glycine 72-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 11814344-9 2002 Based on these data, we conclude that when hENT1 is expressed in yeast, glycine 179 is critical not only to the ability of hENT1 to transport uridine but also as a determinant of hENT1 sensitivity to NBMPR. Uridine 142-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 11814344-9 2002 Based on these data, we conclude that when hENT1 is expressed in yeast, glycine 179 is critical not only to the ability of hENT1 to transport uridine but also as a determinant of hENT1 sensitivity to NBMPR. Uridine 142-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 11814344-9 2002 Based on these data, we conclude that when hENT1 is expressed in yeast, glycine 179 is critical not only to the ability of hENT1 to transport uridine but also as a determinant of hENT1 sensitivity to NBMPR. Uridine 142-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 123-128 11814344-11 2002 This is the first identification and characterization of a critical amino acid residue of hENT1 that is important in both nucleoside transporter function and sensitivity to inhibition by NBMPR. 4-nitrobenzylthioinosine 187-192 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 90-95 11689555-0 2002 Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. Dilazep 127-134 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-77 11689555-0 2002 Mutation of residue 33 of human equilibrative nucleoside transporters 1 and 2 alters sensitivity to inhibition of transport by dilazep and dipyridamole. Dipyridamole 139-151 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-77 11689555-1 2002 Human equilibrative nucleoside transporters (hENT) 1 and 2 differ in that hENT1 is inhibited by nanomolar concentrations of dipyridamole and dilazep, whereas hENT2 is 2 and 3 orders of magnitude less sensitive, respectively. Dipyridamole 124-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-79 11689555-1 2002 Human equilibrative nucleoside transporters (hENT) 1 and 2 differ in that hENT1 is inhibited by nanomolar concentrations of dipyridamole and dilazep, whereas hENT2 is 2 and 3 orders of magnitude less sensitive, respectively. Dilazep 141-148 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 74-79 12440703-1 2002 The human equilibrative nucleoside transporters I and 2 (hENT1, hENT2) share 50% amino acid identity and exhibit broad selectivities, accepting purine and pyrimidine nucleosides as permeants. purine 144-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 12440703-1 2002 The human equilibrative nucleoside transporters I and 2 (hENT1, hENT2) share 50% amino acid identity and exhibit broad selectivities, accepting purine and pyrimidine nucleosides as permeants. Pyrimidine Nucleosides 155-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 57-62 12440703-3 2002 Recent studies of hENT2 produced in recombinant form in functional expression systems have shown that it differs from hENT1 in that it transports nucleobases. nucleobases 146-157 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-123 12440703-4 2002 To further understand the structural requirements for permeant interaction with hENT2, we compared the relative abilities of uridine, cytidine, and their analogues to inhibit transport of [3H]uridine by recombinant hENT1 and hENT2 produced in yeast. Uridine 125-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-220 12440703-4 2002 To further understand the structural requirements for permeant interaction with hENT2, we compared the relative abilities of uridine, cytidine, and their analogues to inhibit transport of [3H]uridine by recombinant hENT1 and hENT2 produced in yeast. Cytidine 134-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-220 12440703-4 2002 To further understand the structural requirements for permeant interaction with hENT2, we compared the relative abilities of uridine, cytidine, and their analogues to inhibit transport of [3H]uridine by recombinant hENT1 and hENT2 produced in yeast. [3h]uridine 188-199 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-220 12440703-5 2002 hENT1 and hENT2 tolerated halogen modification at the 5 position of the base and the 2" and 5" positions of the ribose moieties of uridine whereas removal of the hydroxyl group at the 3" position of the ribose moiety of uridine eliminated interaction with both transporters. Halogens 26-33 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 12440703-5 2002 hENT1 and hENT2 tolerated halogen modification at the 5 position of the base and the 2" and 5" positions of the ribose moieties of uridine whereas removal of the hydroxyl group at the 3" position of the ribose moiety of uridine eliminated interaction with both transporters. Ribose 112-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 12440703-5 2002 hENT1 and hENT2 tolerated halogen modification at the 5 position of the base and the 2" and 5" positions of the ribose moieties of uridine whereas removal of the hydroxyl group at the 3" position of the ribose moiety of uridine eliminated interaction with both transporters. Uridine 131-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 12440703-5 2002 hENT1 and hENT2 tolerated halogen modification at the 5 position of the base and the 2" and 5" positions of the ribose moieties of uridine whereas removal of the hydroxyl group at the 3" position of the ribose moiety of uridine eliminated interaction with both transporters. Ribose 203-209 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 12440703-5 2002 hENT1 and hENT2 tolerated halogen modification at the 5 position of the base and the 2" and 5" positions of the ribose moieties of uridine whereas removal of the hydroxyl group at the 3" position of the ribose moiety of uridine eliminated interaction with both transporters. Uridine 220-227 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 11814344-0 2002 A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Glycine 9-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 11814344-0 2002 A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. Nucleosides 47-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 11814344-0 2002 A single glycine mutation in the equilibrative nucleoside transporter gene, hENT1, alters nucleoside transport activity and sensitivity to nitrobenzylthioinosine. 4-nitrobenzylthioinosine 139-161 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 76-81 11814344-1 2002 The human equilibrative nucleoside transporter, hENT1, which is sensitive to inhibition by nitrobenzylthioinosine (NBMPR), is expressed in a wide variety of tissues. 4-nitrobenzylthioinosine 91-113 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 11814344-1 2002 The human equilibrative nucleoside transporter, hENT1, which is sensitive to inhibition by nitrobenzylthioinosine (NBMPR), is expressed in a wide variety of tissues. 4-nitrobenzylthioinosine 115-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 48-53 11814344-2 2002 hENT1 is involved in the uptake of natural nucleosides, including regulation of the physiological effects of extracellular adenosine, and transports nucleoside drugs used in the treatment of cancer and viral diseases. Nucleosides 43-54 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 11814344-2 2002 hENT1 is involved in the uptake of natural nucleosides, including regulation of the physiological effects of extracellular adenosine, and transports nucleoside drugs used in the treatment of cancer and viral diseases. Adenosine 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 11814344-3 2002 Structure-function studies have revealed that transmembrane domains (TMD) 3 through 6 of hENT1 may be involved in binding of nucleosides. Nucleosides 125-136 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-94 11814344-7 2002 Similar point mutations at glycine 184 resulted in poor targeting of hENT1 to the plasma membrane and little or no detectable functional activity. Glycine 27-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-74 11814344-9 2002 Based on these data, we conclude that when hENT1 is expressed in yeast, glycine 179 is critical not only to the ability of hENT1 to transport uridine but also as a determinant of hENT1 sensitivity to NBMPR. Glycine 72-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 11689555-2 2002 When a yeast expression plasmid containing the hENT1 cDNA was randomly mutated and screened by phenotypic complementation in Saccharomyces cerevisiae to identify mutants with reduced sensitivity to dilazep, clones with a point mutation that converted Met33 to Ile (hENT1-M33I) were obtained. Dilazep 198-205 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 11689555-6 2002 These data established that mutation of residue 33 (Met versus Ile) of hENT1 and hENT2 altered the dilazep and dipyridamole sensitivities in both proteins, suggesting that a common region of inhibitor interaction has been identified. Dilazep 99-106 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11689555-6 2002 These data established that mutation of residue 33 (Met versus Ile) of hENT1 and hENT2 altered the dilazep and dipyridamole sensitivities in both proteins, suggesting that a common region of inhibitor interaction has been identified. Dipyridamole 111-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 71-76 11801546-2 2002 We previously demonstrated that deficiency in hENT1, the most abundant and widely distributed plasma membrane nucleoside transporter in human cells, confers high-level resistance to gemcitabine toxicity in vitro, whereas the relationship between hENT1 activity and capecitabine toxicity is unknown. Capecitabine 265-277 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 246-251 11801546-4 2002 The presence of NBMPR reduced the cytotoxic effects of 5"-deoxy-5-fluorouridine, indicating that hENT1 also enabled cellular uptake of this capecitabine metabolite by breast cancer cells. 4-nitrobenzylthioinosine 16-21 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 11801546-4 2002 The presence of NBMPR reduced the cytotoxic effects of 5"-deoxy-5-fluorouridine, indicating that hENT1 also enabled cellular uptake of this capecitabine metabolite by breast cancer cells. doxifluridine 55-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 11801546-4 2002 The presence of NBMPR reduced the cytotoxic effects of 5"-deoxy-5-fluorouridine, indicating that hENT1 also enabled cellular uptake of this capecitabine metabolite by breast cancer cells. Capecitabine 140-152 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 11801546-8 2002 We conclude that because hENT1 deficiency has previously been associated with nucleoside drug resistance, immunohistochemical staining of hENT1 warrants further study as a predictive tool for guiding the appropriate use of gemcitabine and capecitabine in the treatment of breast cancer. gemcitabine 223-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-143 11801546-8 2002 We conclude that because hENT1 deficiency has previously been associated with nucleoside drug resistance, immunohistochemical staining of hENT1 warrants further study as a predictive tool for guiding the appropriate use of gemcitabine and capecitabine in the treatment of breast cancer. Capecitabine 239-251 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 138-143 11585758-5 2001 Analysis of troxacitabine transportability by the five molecularly characterized human nucleoside transporters [human equilibrative nucleoside transporters 1 and 2, human concentrative nucleoside transporter (hCNT) 1, hCNT2, and hCNT3] revealed that short- and long-term uptake of 10-30 microM [(3)H]troxacitabine was low and unaffected by the presence of either nucleoside transport inhibitors or high concentrations of nonradioactive troxacitabine. troxacitabine 12-25 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 118-163 11584005-0 2001 Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. 4-nitrobenzylthioinosine 35-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 11584005-0 2001 Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. 4-nitrobenzylthioinosine 59-64 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 11584005-0 2001 Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs. Adenosine 144-153 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 11584005-1 2001 The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. Nucleosides 195-206 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 11584005-1 2001 The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. Adenosine 218-227 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 11584005-1 2001 The human equilibrative nucleoside transporter hENT1, the first identified member of the ENT family of integral membrane proteins, is the primary mechanism for the cellular uptake of physiologic nucleosides, including adenosine, and many anti-cancer nucleoside drugs. Nucleosides 24-34 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 11641443-1 2001 CEM-ARAC leukemia cells with resistance to cytarabine were shown to lack equilibrative transporter (hENT1) expression and activity. cem-arac 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 11085929-1 2000 Mammalian cells express at least two subtypes of equilibrative nucleoside transporters, i.e. ENT1 and ENT2, which can be distinguished functionally by their sensitivity and resistance respectively to inhibition by nitrobenzylthioinosine. 4-nitrobenzylthioinosine 214-236 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 93-97 11396612-4 2001 Whilst the name of the family reflects the properties of its prototypical member hENT1, an equilibrative transporter of nucleosides, some family members can also transport nucleobases and some are proton-dependent, concentrative transporters. Nucleosides 120-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11396612-4 2001 Whilst the name of the family reflects the properties of its prototypical member hENT1, an equilibrative transporter of nucleosides, some family members can also transport nucleobases and some are proton-dependent, concentrative transporters. nucleobases 172-183 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 81-86 11578233-1 2001 The cis-1,2-dihydrocatechol 3, which can be obtained in enantiomerically pure form by microbial dihydroxylation of bromobenzene, has been converted into the enantiomer, ent-1, of the cyclolysine-based marine natural product bengamide E (1). cis-1,2-dihydrocatechol 4-27 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 169-174 11578233-1 2001 The cis-1,2-dihydrocatechol 3, which can be obtained in enantiomerically pure form by microbial dihydroxylation of bromobenzene, has been converted into the enantiomer, ent-1, of the cyclolysine-based marine natural product bengamide E (1). bromobenzene 115-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 169-174 11578233-1 2001 The cis-1,2-dihydrocatechol 3, which can be obtained in enantiomerically pure form by microbial dihydroxylation of bromobenzene, has been converted into the enantiomer, ent-1, of the cyclolysine-based marine natural product bengamide E (1). cyclolysine 183-194 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 169-174 11578233-1 2001 The cis-1,2-dihydrocatechol 3, which can be obtained in enantiomerically pure form by microbial dihydroxylation of bromobenzene, has been converted into the enantiomer, ent-1, of the cyclolysine-based marine natural product bengamide E (1). bengamide E 224-235 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 169-174 11311901-6 2001 The apparent reciprocal distribution of hENT1 and hENT2 in human brain suggests that these nucleoside transporter proteins are produced in distinct regions of the CNS where they function in nucleoside salvage and/or regulation of exogenous adenosine. Nucleosides 91-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 11311901-6 2001 The apparent reciprocal distribution of hENT1 and hENT2 in human brain suggests that these nucleoside transporter proteins are produced in distinct regions of the CNS where they function in nucleoside salvage and/or regulation of exogenous adenosine. Adenosine 240-249 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 11139404-1 2001 The human and rat equilibrative nucleoside transporter proteins hENT1, rENT1, hENT2 and rENT2 belong to a family of integral membrane proteins with 11 potential transmembrane segments (TMs), and are distinguished functionally by differences in transport of nucleobases and sensitivity to inhibition by nitrobenzylthioinosine (NBMPR) and vasoactive drugs. nucleobases 257-268 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 11139404-1 2001 The human and rat equilibrative nucleoside transporter proteins hENT1, rENT1, hENT2 and rENT2 belong to a family of integral membrane proteins with 11 potential transmembrane segments (TMs), and are distinguished functionally by differences in transport of nucleobases and sensitivity to inhibition by nitrobenzylthioinosine (NBMPR) and vasoactive drugs. 4-nitrobenzylthioinosine 302-324 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 11139404-1 2001 The human and rat equilibrative nucleoside transporter proteins hENT1, rENT1, hENT2 and rENT2 belong to a family of integral membrane proteins with 11 potential transmembrane segments (TMs), and are distinguished functionally by differences in transport of nucleobases and sensitivity to inhibition by nitrobenzylthioinosine (NBMPR) and vasoactive drugs. 4-nitrobenzylthioinosine 326-331 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 64-69 11139404-2 2001 In the present study, we have produced recombinant hENT1, rENT1, hENT2 and rENT2 in Xenopus oocytes and investigated uridine transport following exposure to the impermeant thiol-reactive reagent p-chloromercuriphenyl sulphonate (PCMBS). Sulfhydryl Compounds 172-177 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-56 11085929-2 2000 The ENT1 transporters exhibit distinctive species differences in their sensitivities to inhibition by dipyridamole, dilazep and draflazine (human>mouse>rat). Dipyridamole 102-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-8 11085929-2 2000 The ENT1 transporters exhibit distinctive species differences in their sensitivities to inhibition by dipyridamole, dilazep and draflazine (human>mouse>rat). Dilazep 116-123 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-8 11085929-2 2000 The ENT1 transporters exhibit distinctive species differences in their sensitivities to inhibition by dipyridamole, dilazep and draflazine (human>mouse>rat). draflazine 128-138 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-8 10763851-9 2000 These draflazine analogues also varied in their differential affinities for mouse vs. human es/ENT1 transporters, and the degree of species discrimination was strongly dependent on the position of the aminocarbonyl group on the piperazine ring. draflazine 6-16 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 95-99 10722669-5 2000 With hENT1 being more sensitive, there is a 7000-fold and 71-fold difference in sensitivity to nitrobenzylthioinosine (NBMPR) (IC(50), 0.4 +/- 0.1 nM versus 2.8 +/- 0.3 microM) and dipyridamole (IC(50), 5.0 +/- 0.9 nM versus 356 +/- 13 nM), respectively. 4-nitrobenzylthioinosine 95-117 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 10722669-5 2000 With hENT1 being more sensitive, there is a 7000-fold and 71-fold difference in sensitivity to nitrobenzylthioinosine (NBMPR) (IC(50), 0.4 +/- 0.1 nM versus 2.8 +/- 0.3 microM) and dipyridamole (IC(50), 5.0 +/- 0.9 nM versus 356 +/- 13 nM), respectively. Dipyridamole 181-193 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 10722669-8 2000 7-, and 19.3-fold lower affinity than hENT1 for thymidine, adenosine, cytidine, and guanosine, respectively. Thymidine 48-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 10722669-8 2000 7-, and 19.3-fold lower affinity than hENT1 for thymidine, adenosine, cytidine, and guanosine, respectively. Adenosine 59-68 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 10722669-8 2000 7-, and 19.3-fold lower affinity than hENT1 for thymidine, adenosine, cytidine, and guanosine, respectively. Cytidine 70-78 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 10722669-8 2000 7-, and 19.3-fold lower affinity than hENT1 for thymidine, adenosine, cytidine, and guanosine, respectively. Guanosine 84-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 38-43 9804860-1 1998 The equilibrative nucleoside transporters (ENTs) are a newly recognized family of membrane proteins of which hENT1 is the nitrobenzylmercaptopurine ribonucleoside (NBMPR)-sensitive (es) and hENT2 the NBMPR-insensitive (ei) transporter of human cells. Nitrobenzylmercaptopurine Ribonucleoside 122-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-114 10547395-7 1999 Influxes of gemcitabine mediated by hCNT1, hENT1, and hENT2 were saturable and conformed to Michaelis-Menten kinetics with apparent K(m) values of 24, 160, and 740 microM, respectively. gemcitabine 12-23 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 43-48 10366666-3 1999 This uptake was decreased by 70-75% in the presence of 1 microM nitrobenzylthioinosine, a concentration that completely inhibits ENT1, and was completely blocked by the addition of 10 microM dipyridamole, a concentration that inhibits both ENT1 and ENT2. 4-nitrobenzylthioinosine 64-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 10366666-3 1999 This uptake was decreased by 70-75% in the presence of 1 microM nitrobenzylthioinosine, a concentration that completely inhibits ENT1, and was completely blocked by the addition of 10 microM dipyridamole, a concentration that inhibits both ENT1 and ENT2. 4-nitrobenzylthioinosine 64-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 240-244 10366666-3 1999 This uptake was decreased by 70-75% in the presence of 1 microM nitrobenzylthioinosine, a concentration that completely inhibits ENT1, and was completely blocked by the addition of 10 microM dipyridamole, a concentration that inhibits both ENT1 and ENT2. Dipyridamole 191-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 10366666-3 1999 This uptake was decreased by 70-75% in the presence of 1 microM nitrobenzylthioinosine, a concentration that completely inhibits ENT1, and was completely blocked by the addition of 10 microM dipyridamole, a concentration that inhibits both ENT1 and ENT2. Dipyridamole 191-203 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 240-244 10085223-5 1999 Dilazep and dipyridamole inhibited NBMPR binding to hENT1 with IC50 values of 130+/-10 and 380+/-20 nM respectively. Dilazep 0-7 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 10085223-5 1999 Dilazep and dipyridamole inhibited NBMPR binding to hENT1 with IC50 values of 130+/-10 and 380+/-20 nM respectively. Dipyridamole 12-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 10085223-5 1999 Dilazep and dipyridamole inhibited NBMPR binding to hENT1 with IC50 values of 130+/-10 and 380+/-20 nM respectively. 4-nitrobenzylthioinosine 35-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 52-57 10085223-6 1999 The role of N-linked glycosylation in the interaction of NBMPR with hENT1 was examined by the quantification of binding of [3H]NBMPR to yeast producing either wild-type hENT1 or a glycosylation-defective mutant (hENT1/N48Q) in which Asn-48 was converted into Gln. Nitrogen 12-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 10085223-6 1999 The role of N-linked glycosylation in the interaction of NBMPR with hENT1 was examined by the quantification of binding of [3H]NBMPR to yeast producing either wild-type hENT1 or a glycosylation-defective mutant (hENT1/N48Q) in which Asn-48 was converted into Gln. Nitrogen 12-13 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 10085223-6 1999 The role of N-linked glycosylation in the interaction of NBMPR with hENT1 was examined by the quantification of binding of [3H]NBMPR to yeast producing either wild-type hENT1 or a glycosylation-defective mutant (hENT1/N48Q) in which Asn-48 was converted into Gln. Tritium 124-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-73 10085223-6 1999 The role of N-linked glycosylation in the interaction of NBMPR with hENT1 was examined by the quantification of binding of [3H]NBMPR to yeast producing either wild-type hENT1 or a glycosylation-defective mutant (hENT1/N48Q) in which Asn-48 was converted into Gln. Tritium 124-126 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 10085223-8 1999 5+/-1.6 nM, indicating that the replacement of an Asn residue with Gln decreased the affinity of hENT1 for NBMPR. Asparagine 50-53 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 10085223-8 1999 5+/-1.6 nM, indicating that the replacement of an Asn residue with Gln decreased the affinity of hENT1 for NBMPR. Glutamine 67-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 10085223-8 1999 5+/-1.6 nM, indicating that the replacement of an Asn residue with Gln decreased the affinity of hENT1 for NBMPR. 4-nitrobenzylthioinosine 107-112 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 97-102 10085223-9 1999 The decreased affinity of hENT1/N48Q for NBMPR was due to an increased rate of dissociation (koff) and a decreased rate of association (kon) of specifically bound [3H]NBMPR because the values for hENT1-producing and hENT1/N48Q-producing yeast were respectively 0.14+/-0.02 and 0. Tritium 164-166 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 26-31 10085223-12 1999 These results indicated that the conservative conversion of an Asn residue into Gln at position 48 of hENT1 and/or the loss of N-linked glycosylation capability altered the binding characteristics of the transporter for NBMPR, dilazep and dipyridamole. Dilazep 227-234 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 10085223-12 1999 These results indicated that the conservative conversion of an Asn residue into Gln at position 48 of hENT1 and/or the loss of N-linked glycosylation capability altered the binding characteristics of the transporter for NBMPR, dilazep and dipyridamole. Dipyridamole 239-251 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 102-107 10206547-1 1999 Subreceptor selectivity tuning of N-(3-pyrrolidinyl)benzamides leading to the selective dopamine D3 ligand ent1h and the derivatives 1g and 1e/ent1e which preferably recognize human D2 or D4 receptors, respectively, is described. n-(3-pyrrolidinyl)benzamides 34-62 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 107-111 9804860-1 1998 The equilibrative nucleoside transporters (ENTs) are a newly recognized family of membrane proteins of which hENT1 is the nitrobenzylmercaptopurine ribonucleoside (NBMPR)-sensitive (es) and hENT2 the NBMPR-insensitive (ei) transporter of human cells. 4-nitrobenzylthioinosine 164-169 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-114 9804860-1 1998 The equilibrative nucleoside transporters (ENTs) are a newly recognized family of membrane proteins of which hENT1 is the nitrobenzylmercaptopurine ribonucleoside (NBMPR)-sensitive (es) and hENT2 the NBMPR-insensitive (ei) transporter of human cells. Einsteinium 182-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 109-114 9804860-9 1998 These results provided evidence for the presence of functional es and ei transporters in nuclear membranes and endoplasmic reticulum, suggesting that hENT1 and hENT2 may function in the translocation of nucleosides between the cytosol and the luminal compartments of one or both of these membrane types. Nucleosides 203-214 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 150-155 9756942-2 1998 These cells express at least three different nucleoside transport systems as follows: a nitrobenzylthioinosine-sensitive equilibrative transport system of the es-type, which appears to be associated with hENT1 expression, and two Na+-dependent transport systems that may correspond to N1 and to the recently characterized N5-type, which is nitrobenzylthioinosine-sensitive and guanosine-preferring. 4-nitrobenzylthioinosine 88-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 204-209 9756942-3 1998 B cell activators such as phorbol 12-myristate 13-acetate and lipopolysaccharide (LPS) up-regulate both concentrative transport systems but down-regulate the equilibrative es-type transporter, which correlates with lower hENT1 mRNA levels. Tetradecanoylphorbol Acetate 26-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 221-226 9705281-6 1998 Transplanting the amino-terminal half of hENT1 into rENT1 converted rENT1 into a dipyridamole/dilazep-sensitive transporter, whereas the amino-terminal half of rENT1 rendered hENT1 dipyridamole/dilazep-insensitive. Dipyridamole 81-93 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 41-46 9705281-6 1998 Transplanting the amino-terminal half of hENT1 into rENT1 converted rENT1 into a dipyridamole/dilazep-sensitive transporter, whereas the amino-terminal half of rENT1 rendered hENT1 dipyridamole/dilazep-insensitive. Dilazep 94-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 41-46 9705281-1 1998 We have recently isolated cDNAs from human placenta and rat jejunum encoding the prototypic human and rat equilibrative nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporters hENT1 and rENT1. 4-nitrobenzylthioinosine 120-142 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 185-190 9705281-1 1998 We have recently isolated cDNAs from human placenta and rat jejunum encoding the prototypic human and rat equilibrative nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporters hENT1 and rENT1. 4-nitrobenzylthioinosine 144-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 185-190 9353301-3 1997 When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site. Dipyridamole 125-137 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 9705281-3 1998 When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. purine 78-84 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 9705281-3 1998 When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. Pyrimidine Nucleosides 89-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 9705281-3 1998 When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. Adenosine 123-132 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 9705281-3 1998 When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. 4-nitrobenzylthioinosine 183-188 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 47-52 9705281-4 1998 hENT1 is also potently inhibited by coronary vasodilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is insensitive to inhibition by these compounds (dipyridamole IC50 values 190 nM (hENT1) and >/=10 microM (rENT1) at 10 microM uridine). Dipyridamole 64-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 9705281-4 1998 hENT1 is also potently inhibited by coronary vasodilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is insensitive to inhibition by these compounds (dipyridamole IC50 values 190 nM (hENT1) and >/=10 microM (rENT1) at 10 microM uridine). Dilazep 78-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 9705281-4 1998 hENT1 is also potently inhibited by coronary vasodilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is insensitive to inhibition by these compounds (dipyridamole IC50 values 190 nM (hENT1) and >/=10 microM (rENT1) at 10 microM uridine). draflazine 91-101 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 9705281-4 1998 hENT1 is also potently inhibited by coronary vasodilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is insensitive to inhibition by these compounds (dipyridamole IC50 values 190 nM (hENT1) and >/=10 microM (rENT1) at 10 microM uridine). Uridine 248-255 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 9396714-6 1997 Like hENT1, hENT2 mediates saturable transport of the pyrimidine nucleoside uridine (Km 0.2+/-0.03 mM) and also transports the purine nucleoside adenosine. pyrimidine nucleoside uridine 54-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 9396714-6 1997 Like hENT1, hENT2 mediates saturable transport of the pyrimidine nucleoside uridine (Km 0.2+/-0.03 mM) and also transports the purine nucleoside adenosine. purine nucleoside adenosine 127-154 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 5-10 9353301-3 1997 When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site. Dilazep 142-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 9353301-3 1997 When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site. Nucleosides 173-184 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 9353301-3 1997 When expressed in Xenopus oocytes, hENT1 mediated es-type transport activity and was inhibited by coronary vasoactive drugs (dipyridamole and dilazep) that may compete with nucleosides and NBMPR for binding to the substrate binding site. 4-nitrobenzylthioinosine 189-194 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 35-40 34435310-6 2021 Intestinal absorption, distribution throughout the body, and intracellular uptake of cladribine appear to be exclusively mediated by equilibrative and concentrative nucleoside transporters, specifically by ENT1, ENT2, ENT4, CNT2 (low affinity), and CNT3. Cladribine 85-95 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 206-210 34894346-4 2022 Intestinal absorption and distribution of cladribine throughout the body appear to be essentially mediated by equilibrative NTs (ENTs) and concentrative NTs (CNTs), specifically by ENT1, ENT2, ENT4, CNT2 (low affinity), and CNT3. Cladribine 42-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 181-185 34894346-6 2022 A key transporter for the intracellular uptake of cladribine into B and T-lymphocytes is ENT1 with ancillary contributions of ENT2 and CNT2. Cladribine 50-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 89-93 34784214-0 2021 Design, Synthesis, and Antifungal Activity of 16,17-Dihydroheronamide C and ent-Heronamide C. 16,17-Dihydroheronamide C (8) and ent-heronamide C (ent-1) were designed as probes for the mode-of-action analysis of heronamide C (1). ent-heronamide 76-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 34784214-0 2021 Design, Synthesis, and Antifungal Activity of 16,17-Dihydroheronamide C and ent-Heronamide C. 16,17-Dihydroheronamide C (8) and ent-heronamide C (ent-1) were designed as probes for the mode-of-action analysis of heronamide C (1). ent-Heronamide C 128-144 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 34784214-0 2021 Design, Synthesis, and Antifungal Activity of 16,17-Dihydroheronamide C and ent-Heronamide C. 16,17-Dihydroheronamide C (8) and ent-heronamide C (ent-1) were designed as probes for the mode-of-action analysis of heronamide C (1). heronamide C 212-224 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 146-151 34435310-7 2021 Renal excretion of cladribine appears to be most likely driven by breast cancer resistance protein, ENT1, and P-glycoprotein. Cladribine 19-29 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-104 34503974-0 2021 Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites. remdesivir 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 45-90 34503974-4 2021 In vitro transport experiments demonstrated that remdesivir was the most potent inhibitor of ENT-mediated (3H) uridine uptake (ENT1 IC50: 38.65 mM; ENT2 IC50: 76.72 mM), followed by EIDD-1931 (ENT1 IC50: 258.9 mM; ENT2 IC50: 467.3 mM), while molnupiravir was a modest inhibitor (ENT1 IC50: 701.0 mM; ENT2 IC50: 851.4 mM). remdesivir 49-59 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 127-131 34503974-4 2021 In vitro transport experiments demonstrated that remdesivir was the most potent inhibitor of ENT-mediated (3H) uridine uptake (ENT1 IC50: 38.65 mM; ENT2 IC50: 76.72 mM), followed by EIDD-1931 (ENT1 IC50: 258.9 mM; ENT2 IC50: 467.3 mM), while molnupiravir was a modest inhibitor (ENT1 IC50: 701.0 mM; ENT2 IC50: 851.4 mM). (3h) uridine 106-118 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 127-131 34503974-6 2021 Remdesivir accumulation decreased in the presence of NBMPR by 30% in ENT1 cells (p = 0.0248) and 27% in ENT2 cells (p = 0.0054). 4-nitrobenzylthioinosine 53-58 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 69-73 34503974-7 2021 EIDD-1931 accumulation decreased in the presence of NBMPR by 77% in ENT1 cells (p = 0.0463 ) and by 64% in ENT2 cells (p = 0.0132), supporting computational predictions that both are ENT substrates which may be important for efficacy against COVID-19. 4-nitrobenzylthioinosine 52-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 68-72 34503974-10 2021 Significance Statement Significance statement: This study identified remdesivir and EIDD-1931 as substrates of equilibrative nucleoside transporters 1 and 2. remdesivir 69-79 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 111-156 34388391-5 2021 Mechanistically, Pin1 drives the desmoplastic and immunosuppressive TME by acting on CAFs and induces lysosomal degradation of the PD-1 ligand PD-L1 and the gemcitabine transporter ENT1 in cancer cells, besides activating multiple cancer pathways. gemcitabine 157-168 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 181-185 34331561-10 2021 CONCLUSION: Four polymorphisms of the ABCC4, FPGS, SLC29A1, and MTHFR genes are likely to be potential predictive biomarkers for precision medicine in fluoropyrimidine-based treatments in the population of the Brazilian Amazon, which is constituted by a unique genetic background. 2-fluoropyrimidine 151-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-58 34682775-2 2021 Several proteins including human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), and ribonucleotide reductase subunit 1 (RRM1) are known to be involved in gemcitabine uptake and metabolism. gemcitabine 209-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-71 34682775-2 2021 Several proteins including human equilibrative nucleoside transporter-1 (hENT1), deoxycytidine kinase (DCK), cytidine deaminase (CDA), and ribonucleotide reductase subunit 1 (RRM1) are known to be involved in gemcitabine uptake and metabolism. gemcitabine 209-220 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 73-78 34283374-7 2021 RESULTS: Many studies have shown that ticagrelor can inhibit equilibrative nucleoside transporter 1 (ENT1). Ticagrelor 38-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 61-99 34283374-7 2021 RESULTS: Many studies have shown that ticagrelor can inhibit equilibrative nucleoside transporter 1 (ENT1). Ticagrelor 38-48 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 101-105 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Ticagrelor 62-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Adenosine 94-103 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Adenosine 118-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 34283374-9 2021 CONCLUSIONS: Based on the studies reviewed, it was found that ticagrelor essentially inhibits adenosine absorption of adenosine into cells through ENT1, which increases the concentration in the blood and subsequently increases the protection of the heart muscle by adenosine. Adenosine 265-274 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 34830914-0 2021 hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. gemcitabine 28-39 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-5 34830914-2 2021 Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. gemcitabine 65-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-38 34830914-2 2021 Equilibrative nucleoside transporter 1 (hENT1) predicts adjuvant gemcitabine treatment benefit over 5-FU. gemcitabine 65-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-45 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-169 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 62-73 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 186-190 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 230-241 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-169 34382915-3 2021 In the present study, we discovered that RNA-derived modified nucleosides are exported to extracellular space through equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2), with ENT1 showing higher preference for modified nucleosides than ENT2. Nucleosides 230-241 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 186-190 34382915-4 2021 Pharmacological inhibition or genetic deletion of ENT1 and ENT2 significantly attenuated export of modified nucleosides thereby resulting in their accumulation in cytosol. Nucleosides 108-119 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 50-54 34382915-5 2021 Using mutagenesis strategy, we identified an amino acid residue in ENT1 that is involved in the discrimination of unmodified and modified nucleosides. Nucleosides 138-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 67-71 34327872-1 2022 BACKGROUND: Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. gemcitabine 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-70 34275128-1 2021 BACKGROUND AND OBJECTIVES: Equilibrative nucleoside transporter (ENT) 1 is a widely-expressed drug transporter, handling nucleoside analogues as well as endogenous nucleosides. Nucleosides 121-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-71 34275128-1 2021 BACKGROUND AND OBJECTIVES: Equilibrative nucleoside transporter (ENT) 1 is a widely-expressed drug transporter, handling nucleoside analogues as well as endogenous nucleosides. Nucleosides 164-175 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 27-71 34275128-4 2021 METHODS: Inhibition of ENT1 activity was investigated in vitro through quantifying the decrease of (3H)-uridine uptake caused by TKIs in HAP1 ENT2-knockout cells, exhibiting selective ENT1 expression. 3h)-uridine 100-111 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 23-27 34275128-6 2021 Putative transport of the TKI lorlatinib by ENT1/ENT2 was analyzed by LC-MS/MS. lorlatinib 30-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 44-48 34275128-9 2021 Lorlatinib was notably a potent in vitro inhibitor of ENT1/ENT2 (IC50 values around 1.0-2.5 microM) and was predicted to inhibit these nucleoside transporters at relevant clinical concentrations, without, however, being a substrate for them. lorlatinib 0-10 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 54-58 34275128-10 2021 CONCLUSION: Our data unambiguously add ENT1 to the list of drug transporters inhibited by TKIs, especially by lorlatinib. lorlatinib 110-120 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 39-43 34275128-11 2021 This point likely merits attention in terms of possible drug-drug interactions, notably for nucleoside analogues, whose ENT1-mediated uptake into their target cells may be hampered by co-administrated TKIs such as lorlatinib. Nucleosides 92-102 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-124 34275128-11 2021 This point likely merits attention in terms of possible drug-drug interactions, notably for nucleoside analogues, whose ENT1-mediated uptake into their target cells may be hampered by co-administrated TKIs such as lorlatinib. lorlatinib 214-224 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 120-124 34327872-1 2022 BACKGROUND: Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. gemcitabine 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 34327872-1 2022 BACKGROUND: Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. gemcitabine 127-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 32-70 34327872-1 2022 BACKGROUND: Expression of human equilibrative nucleoside transporter-1 (hENT1) is reported to predict survival of gemcitabine (GEM)-treated patients. gemcitabine 127-130 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 72-77 34327872-9 2022 Multivariate analyses showed that adjuvant GEM was a significant predictor of the patients with low hENT1 expression using either 10D7G2 (Hazard ratio (HR) 2.39, p = .001) or SP120 (HR 1.84, p < .001). gemcitabine 43-46 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 100-105 35042768-0 2022 Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol. Dopamine 0-8 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 34667552-0 2021 Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1. rapadocin 48-57 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 119-123 34667552-1 2021 Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1). rapadocin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-208 34667552-1 2021 Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1). rapadocin 0-9 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 34667552-1 2021 Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1). Sirolimus 21-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-208 34667552-1 2021 Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1). Sirolimus 21-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 34667552-1 2021 Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1). polyketide-tetrapeptide 40-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 170-208 34667552-1 2021 Rapadocin is a novel rapamycin-inspired polyketide-tetrapeptide hybrid macrocycle that possesses highly potent and isoform-specific inhibitory activity against the human equilibrative nucleoside transporter 1 (hENT1). polyketide-tetrapeptide 40-63 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 210-215 34130695-3 2021 Focusing on the overexpression of human equilibrative nucleoside transporter 1 (ENT1) on the membrane of choriocarcinoma cells (JEG-3), cytarabine (Cy, a substrate of ENT1)-grafted liposomes (Cy-Lipo) were introduced for the targeted delivery of methotrexate (Cy-Lipo@MTX) for choriocarcinoma therapy in this study. Cytarabine 136-146 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 167-171 34130695-3 2021 Focusing on the overexpression of human equilibrative nucleoside transporter 1 (ENT1) on the membrane of choriocarcinoma cells (JEG-3), cytarabine (Cy, a substrate of ENT1)-grafted liposomes (Cy-Lipo) were introduced for the targeted delivery of methotrexate (Cy-Lipo@MTX) for choriocarcinoma therapy in this study. Cytarabine 148-150 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 167-171 34130695-3 2021 Focusing on the overexpression of human equilibrative nucleoside transporter 1 (ENT1) on the membrane of choriocarcinoma cells (JEG-3), cytarabine (Cy, a substrate of ENT1)-grafted liposomes (Cy-Lipo) were introduced for the targeted delivery of methotrexate (Cy-Lipo@MTX) for choriocarcinoma therapy in this study. Methotrexate 246-258 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 40-78 34130695-3 2021 Focusing on the overexpression of human equilibrative nucleoside transporter 1 (ENT1) on the membrane of choriocarcinoma cells (JEG-3), cytarabine (Cy, a substrate of ENT1)-grafted liposomes (Cy-Lipo) were introduced for the targeted delivery of methotrexate (Cy-Lipo@MTX) for choriocarcinoma therapy in this study. Methotrexate 246-258 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 80-84 34130695-3 2021 Focusing on the overexpression of human equilibrative nucleoside transporter 1 (ENT1) on the membrane of choriocarcinoma cells (JEG-3), cytarabine (Cy, a substrate of ENT1)-grafted liposomes (Cy-Lipo) were introduced for the targeted delivery of methotrexate (Cy-Lipo@MTX) for choriocarcinoma therapy in this study. Methotrexate 246-258 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 167-171 34130695-4 2021 ENT1 has a high affinity for Cy-Lipo and can mediate the endocytosis of the designed nanovehicles into JEG-3 cells. Cytarabine 29-31 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 0-4 33556172-6 2021 RESULTS: hENT1 and dCK, which play critical roles in the intracellular transport and activation of gemcitabine, respectively, were responsible for the high gemcitabine sensitivity of high-grade meningioma cells and were strongly expressed in high-grade meningiomas. gemcitabine 99-110 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-14 33556172-6 2021 RESULTS: hENT1 and dCK, which play critical roles in the intracellular transport and activation of gemcitabine, respectively, were responsible for the high gemcitabine sensitivity of high-grade meningioma cells and were strongly expressed in high-grade meningiomas. gemcitabine 156-167 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 9-14 33556172-9 2021 CONCLUSIONS: The present results suggest that hENT1 is a key molecular factor influencing the growth capacity and gemcitabine sensitivity of meningioma cells and also that hENT1, together with dCK, may be a viable prognostic marker for meningioma patients as well as a predictive marker of their responses to gemcitabine. gemcitabine 114-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 33556172-9 2021 CONCLUSIONS: The present results suggest that hENT1 is a key molecular factor influencing the growth capacity and gemcitabine sensitivity of meningioma cells and also that hENT1, together with dCK, may be a viable prognostic marker for meningioma patients as well as a predictive marker of their responses to gemcitabine. gemcitabine 309-320 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 46-51 33556172-9 2021 CONCLUSIONS: The present results suggest that hENT1 is a key molecular factor influencing the growth capacity and gemcitabine sensitivity of meningioma cells and also that hENT1, together with dCK, may be a viable prognostic marker for meningioma patients as well as a predictive marker of their responses to gemcitabine. gemcitabine 309-320 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 172-177 35505633-5 2022 A recent study identified that remdesivir and the active metabolite of molnupiravir, EIDD-1931, are substrates of equilibrative nucleoside transporters 1 and 2 (ENT1 and 2). remdesivir 31-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 161-171 35505633-5 2022 A recent study identified that remdesivir and the active metabolite of molnupiravir, EIDD-1931, are substrates of equilibrative nucleoside transporters 1 and 2 (ENT1 and 2). EIDD 2801 71-83 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 161-171 35456712-7 2022 Polymorphisms of SLC29A1, responsible for cytarabine uptake, demonstrated significant associations with survival and response in Asian populations. Cytarabine 42-52 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 17-24 35408815-5 2022 To test our hypothesis, fibroblasts from NPC1 patients were treated with dipyridamole, a clinically-approved drug with inhibitory activity towards ENT1. Dipyridamole 73-85 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 147-151 35408815-6 2022 Dipyridamole significantly reduced cholesterol accumulation in fibroblasts and rescued mitochondrial deficits; the mechanism elicited by dipyridamole relies on activation of the adenosine A2AR subtype subsequent to the increased levels of extracellular adenosine due to the inhibition of ENT1. Dipyridamole 137-149 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 288-292 35408815-6 2022 Dipyridamole significantly reduced cholesterol accumulation in fibroblasts and rescued mitochondrial deficits; the mechanism elicited by dipyridamole relies on activation of the adenosine A2AR subtype subsequent to the increased levels of extracellular adenosine due to the inhibition of ENT1. Adenosine 178-187 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 288-292 35408815-6 2022 Dipyridamole significantly reduced cholesterol accumulation in fibroblasts and rescued mitochondrial deficits; the mechanism elicited by dipyridamole relies on activation of the adenosine A2AR subtype subsequent to the increased levels of extracellular adenosine due to the inhibition of ENT1. Adenosine 253-262 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 288-292 35042768-0 2022 Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol. Adenosine 67-76 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 114-118 35042768-2 2022 A1Rs on other striatal neurons are activated by an adenosine tone that is limited by equilibrative nucleoside transporter 1 (ENT1) that is enriched on astrocytes and is ethanol-sensitive. Adenosine 51-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-123 35042768-2 2022 A1Rs on other striatal neurons are activated by an adenosine tone that is limited by equilibrative nucleoside transporter 1 (ENT1) that is enriched on astrocytes and is ethanol-sensitive. Adenosine 51-60 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 35042768-2 2022 A1Rs on other striatal neurons are activated by an adenosine tone that is limited by equilibrative nucleoside transporter 1 (ENT1) that is enriched on astrocytes and is ethanol-sensitive. Ethanol 169-176 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 85-123 35042768-2 2022 A1Rs on other striatal neurons are activated by an adenosine tone that is limited by equilibrative nucleoside transporter 1 (ENT1) that is enriched on astrocytes and is ethanol-sensitive. Ethanol 169-176 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 125-129 35042768-3 2022 We explored whether dopamine release in nucleus accumbens core is under tonic inhibition by A1Rs, and is regulated by astrocytic ENT1 and ethanol. Dopamine 20-28 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 129-133 35042768-6 2022 The ENT1 inhibitor NBTI reduced dopamine release and promoted A1R-mediated inhibition, and conversely, virally-mediated astrocytic overexpression of ENT1 enhanced dopamine release and relieved A1R-mediated inhibition. Dopamine 32-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 4-8 35042768-6 2022 The ENT1 inhibitor NBTI reduced dopamine release and promoted A1R-mediated inhibition, and conversely, virally-mediated astrocytic overexpression of ENT1 enhanced dopamine release and relieved A1R-mediated inhibition. Dopamine 32-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 149-153 35042768-6 2022 The ENT1 inhibitor NBTI reduced dopamine release and promoted A1R-mediated inhibition, and conversely, virally-mediated astrocytic overexpression of ENT1 enhanced dopamine release and relieved A1R-mediated inhibition. Dopamine 163-171 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 149-153 35042768-7 2022 By imaging the genetically encoded fluorescent adenosine sensor GRAB-Ado, we identified a striatal extracellular adenosine tone that was elevated by the ENT1 inhibitor and sensitive to gliotoxin fluorocitrate. Adenosine 47-56 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-157 35042768-7 2022 By imaging the genetically encoded fluorescent adenosine sensor GRAB-Ado, we identified a striatal extracellular adenosine tone that was elevated by the ENT1 inhibitor and sensitive to gliotoxin fluorocitrate. beta-apocarotenoid-14',13'-dioxygenase 69-72 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-157 35042768-7 2022 By imaging the genetically encoded fluorescent adenosine sensor GRAB-Ado, we identified a striatal extracellular adenosine tone that was elevated by the ENT1 inhibitor and sensitive to gliotoxin fluorocitrate. Adenosine 113-122 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 153-157 35042768-8 2022 Finally, we identified that ethanol (50 mM) promoted A1R-mediated inhibition of dopamine release, through diminishing adenosine uptake via ENT1. Ethanol 28-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 139-143 35042768-8 2022 Finally, we identified that ethanol (50 mM) promoted A1R-mediated inhibition of dopamine release, through diminishing adenosine uptake via ENT1. Dopamine 80-88 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 139-143 35042768-8 2022 Finally, we identified that ethanol (50 mM) promoted A1R-mediated inhibition of dopamine release, through diminishing adenosine uptake via ENT1. Adenosine 118-127 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 139-143 35042768-9 2022 Together, these data reveal that dopamine output dynamics are gated by a striatal adenosine tone, limiting amplitude but promoting contrast, regulated by ENT1, and promoted by ethanol. Dopamine 33-41 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 35042768-9 2022 Together, these data reveal that dopamine output dynamics are gated by a striatal adenosine tone, limiting amplitude but promoting contrast, regulated by ENT1, and promoted by ethanol. Adenosine 82-91 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 154-158 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Ethanol 118-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-57 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Ethanol 118-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Ethanol 118-125 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 174-178 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 19-57 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-63 35042768-12 2022 We reveal that the equilibrative nucleoside transporter 1 (ENT1) on astrocytes limits this tonic inhibition, and that ethanol promotes it by diminishing adenosine uptake via ENT1. Adenosine 153-162 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 174-178 35264969-3 2022 Our previous study has demonstrated that 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) is a novel inhibitor of ENTs, which is more selective to ENT2 than to ENT1. 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine 137-143 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-219 35264969-6 2022 The results of the (3H)uridine uptake study showed that the replacement of the naphthalene moiety with the benzene moiety could abolish the inhibitory effects on ENT1 and ENT2. Tritium 20-22 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-166 35264969-3 2022 Our previous study has demonstrated that 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) is a novel inhibitor of ENTs, which is more selective to ENT2 than to ENT1. 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine 41-135 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 215-219 35264969-6 2022 The results of the (3H)uridine uptake study showed that the replacement of the naphthalene moiety with the benzene moiety could abolish the inhibitory effects on ENT1 and ENT2. Uridine 23-30 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-166 35264969-6 2022 The results of the (3H)uridine uptake study showed that the replacement of the naphthalene moiety with the benzene moiety could abolish the inhibitory effects on ENT1 and ENT2. naphthalene 79-90 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-166 35264969-6 2022 The results of the (3H)uridine uptake study showed that the replacement of the naphthalene moiety with the benzene moiety could abolish the inhibitory effects on ENT1 and ENT2. Benzene 107-114 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 162-166 35264969-7 2022 The addition of chloride to the meta position of this benzene moiety could restore only the inhibitory effect on ENT1 but had no effect on ENT2. Chlorides 16-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-117 35264969-7 2022 The addition of chloride to the meta position of this benzene moiety could restore only the inhibitory effect on ENT1 but had no effect on ENT2. Benzene 54-61 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 113-117 35264969-8 2022 However, the addition of the methyl group to the meta position or the ethyl or oxymethyl group to the para position of this benzene moiety could regain the inhibitory activity on both ENT1 and ENT2. Benzene 124-131 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 184-188 35264969-9 2022 The presence of a halogen substitute, regardless of the position, in the fluorophenyl moiety next to the piperazine ring was essential for the inhibitory effects on ENT1 and ENT2. Piperazine 105-115 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 165-169 35264969-11 2022 Compound 3c reduced V max of (3H)uridine uptake in ENT1 and ENT2 without affecting K m. The inhibitory effect of compound 3c could not be washed out. (3h)uridine 29-40 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 51-55 35052828-5 2022 The outcomes of the study further showed promise in combining selenium and Gemcitabine when evaluated for apoptosis, proliferation, and ENT1 protein expression, specifically in BxPC-3 pancreatic cancer cells in vitro. Selenium 62-70 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 35204377-3 2022 Exosomes are vesicular cargos that transport multiple miRNAs, mRNAs and proteins from one cell to another cell and some of these factors can influence specific determinants of gemcitabine activity, such as the nucleoside transporter hENT1, or multidrug resistance proteins involved in the resistance to paclitaxel. gemcitabine 176-187 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 233-238 35204377-3 2022 Exosomes are vesicular cargos that transport multiple miRNAs, mRNAs and proteins from one cell to another cell and some of these factors can influence specific determinants of gemcitabine activity, such as the nucleoside transporter hENT1, or multidrug resistance proteins involved in the resistance to paclitaxel. Paclitaxel 303-313 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 233-238 35105678-0 2022 A Comment on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites". remdesivir 14-24 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 59-104 35105679-0 2022 Response to Comments on "Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites". remdesivir 25-35 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 70-115 35052828-5 2022 The outcomes of the study further showed promise in combining selenium and Gemcitabine when evaluated for apoptosis, proliferation, and ENT1 protein expression, specifically in BxPC-3 pancreatic cancer cells in vitro. gemcitabine 75-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 136-140 35221865-13 2022 Nucleoside transporters, such as ENT1, are vital in the uptake of synthetic nucleoside analogue drugs, used in cancer and viral chemotherapy. Nucleosides 76-86 solute carrier family 29 member 1 (Augustine blood group) Homo sapiens 33-37